AUDITED FINANCIAL STATEMENTS, SUPPLEMENTARY INFORMATION, AND REPORTS AND SCHEDULES REQUIRED BY THE UNIFORM GUIDANCE

Baylor College of Medicine Years Ended June 30, 2023 and 2022 With Reports of Independent Auditors

Ernst & Young LLP



Audited Financial Statements, Supplementary Information, and Reports and Schedules Required by the Uniform Guidance

Years Ended June 30, 2023 and 2022

Contents

Report of Independent Auditors	1
Audited Financial Statements	
Consolidated Balance Sheets	4
Consolidated Statements of Activities	5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	8
Supplementary Information	
Financial Responsibility Supplemental Schedule	52
Reports and Schedules Required by the Uniform Guidance	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	55
Report of Independent Auditors on Compliance for Each Major Federal Program and	
Report on Internal Control Over Compliance Required by the Uniform Guidance	57
and Texas Grant Management Standards	
Schedule of Expenditures of Federal Awards	
Schedule of Expenditures of State Awards	
Notes to Schedule of Expenditures of Federal Awards	
Schedule of Findings and Questioned Costs	116



Ernst & Young LLP 1401 McKinney Street Suite 2400 Houston, TX 77010 Tel: +1 713 750 1500 Fax: +1 713 750 1501 ey.com

Report of Independent Auditors

The Board of Trustees Baylor College of Medicine

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Baylor College of Medicine (the College), which comprise the consolidated statement of financial position as of June 30, 2023 and 2022, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Baylor College of Medicine at June 30, 2023 and 2022, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the College and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the College's ability to continue as a going concern for one year after the date that the financial statements are issued.



Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the College's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the College's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.



Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. We have not performed any procedures with respect to the audited consolidated financial statements subsequent to November 21, 2023. The accompanying Schedule of Expenditures of Federal Awards, and Schedule of Expenditures of State Awards as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards and State Awards of Texas Singular Audit Circular, and the Supplemental Schedule required by The United States Department of Education is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated November 21, 2023 on our consideration of Baylor College of Medicine's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Baylor College of Medicine's internal control over financial report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Baylor College of Medicine's internal control over financial reporting and compliance.

Ernst + Young LLP

November 21, 2023, except for our report on the Schedule of Expenditures of Federal and State Awards, for which the date is March 22, 2024

Consolidated Balance Sheets

	June 30)
		2023		2022
	(In Thousands)			ends)
Assets				
Cash and cash equivalents	\$	89,109	\$	49,548
Accounts receivable, net:				
Patient		30,393		29,690
Affiliates		152,278		147,309
Grants and contracts, and others		152,442		127,668
Pledges receivable		82,656		91,767
Notes receivable		16,585		15,708
Investments, including securities loaned of \$80,610				
and \$88,153 for 2023 and 2022, respectively		1,488,492		1,489,092
Equity investments in unconsolidated affiliates		278,352		301,099
Security lending collateral		84,259		92,630
Property and equipment, net		385,348		378,990
Leased right-of-use assets – operating		25,951		34,168
Other assets		29,851		23,386
Total assets	\$	2,815,716	\$	2,781,055
Liabilities and net assets				
Liabilities:				
Accounts payable and other liabilities	\$	245,074	\$	245,346
Short-term line of credit		107,500		50,500
Interest rate swap liability, net		37,172		48,476
Lease liability – operating		27,624		35,763
Self-insurance reserves		53,238		53,946
Deferred revenue		114,620		98,630
Bonds and notes payable		569,829		584,762
Assets held on behalf of others		49,081		48,752
Payable under security lending agreements		84,259		92,630
Total liabilities		1,288,397		1,258,805
Net assets:				
Without donor restrictions		408,443		437,250
With donor restrictions		1,118,876		1,085,000
Total net assets		1,527,319		1,522,250
Total liabilities and net assets	\$	2,815,716	\$	2,781,055

See accompanying notes.

Consolidated Statements of Activities

$\begin{tabular}{ c c c c c c c c c c } \hline Without & With & With & Donor & Don$
(In Thousands)(In Thousands)Uition and fees, net\$ 23,866 $-$ \$ 23,866\$ 24,684 $-$ \$ 24,684Medical services, net355,332 $-$ 355,332333,485 $-$ 333,485Affiliated hospital contracts1,298,579 $-$ 1,298,5791,181,041 $-$ 1,181,041Government grants and contracts: $-$ 406,757 $-$ 406,757 $-$ 386,709 $-$ 386,709Indirect111,108 $-$ 111,108101,384 $-$ 101,384Private grants and contracts: $-$ 91,558 $85,671$ $-$ 85,671Indirect13,225 $-$ 13,22510,589 $-$ 10,589Gifts and pledges2,611 $-$ 2,611 $3,479$ $-$ 3,479
Operating revenuesTuition and fees, net\$ 23,866 $-$ \$ 23,866\$ 24,684\$ - \$ 24,684Medical services, net355,332 $-$ 355,332333,485 $-$ 333,485Affiliated hospital contracts1,298,579 $-$ 1,298,5791,181,041 $-$ 1,181,041Government grants and contracts: $-$ 406,757 $-$ 406,757386,709 $-$ 386,709Indirect111,108 $-$ 111,108101,384 $-$ 101,384Private grants and contracts: $-$ 91,55885,671 $-$ 85,671Direct91,558 $-$ 91,55885,671 $-$ 85,671Indirect13,225 $-$ 13,22510,589 $-$ 10,589Gifts and pledges2,611 $-$ 2,6113,479 $-$ 3,479
Tuition and fees, net\$ 23,866\$ -\$ 23,866\$ 24,684\$ -\$ 24,684Medical services, net $355,332$ - $355,332$ $333,485$ - $333,485$ Affiliated hospital contracts $1,298,579$ - $1,298,579$ 1,181,041- $1,181,041$ Government grants and contracts: 0 - $406,757$ - $406,757$ $386,709$ - $386,709$ Indirect111,108-111,108101,384-101,384Private grants and contracts: 0 0 0 0 0 Direct91,558- $91,558$ $85,671$ - $85,671$ Indirect13,225- $13,225$ $10,589$ - $10,589$ Gifts and pledges $2,611$ - $2,611$ $3,479$ - $3,479$
Medical services, net 355,332 - 355,332 333,485 - 333,485 Affiliated hospital contracts 1,298,579 - 1,298,579 1,181,041 - 1,181,041 Government grants and contracts: Direct 406,757 - 406,757 386,709 - 386,709 Indirect 111,108 - 111,108 101,384 - 101,384 Private grants and contracts: - 91,558 - 91,558 85,671 - 85,671 Direct 91,558 - 91,558 - 91,558 85,671 - 85,671 Gifts and pledges 2,611 - 2,611 3,479 - 3,479
Affiliated hospital contracts 1,298,579 - 1,298,579 1,181,041 - 1,181,041 Government grants and contracts: Direct 406,757 - 406,757 386,709 - 386,709 Indirect 111,108 - 111,108 101,384 - 101,384 Private grants and contracts: - 91,558 - 91,558 85,671 - 85,671 Indirect 13,225 - 13,225 10,589 - 10,589 Gifts and pledges 2,611 - 2,611 3,479 - 3,479
Government grants and contracts: 406,757 - 406,757 386,709 - 386,709 Indirect 111,108 - 111,108 101,384 - 101,384 Private grants and contracts: - 91,558 - 91,558 85,671 - 85,671 Indirect 13,225 - 13,225 10,589 - 10,589 Gifts and pledges 2,611 - 2,611 3,479 - 3,479
Direct 406,757 - 406,757 386,709 - 386,709 Indirect 111,108 - 111,108 101,384 - 101,384 Private grants and contracts: - 91,558 - 91,558 85,671 - 85,671 Indirect 13,225 - 13,225 10,589 - 10,589 Gifts and pledges 2,611 - 2,611 3,479 - 3,479
Indirect111,108-111,108101,384-101,384Private grants and contracts:Direct91,558-91,55885,671-85,671Indirect13,225-13,22510,589-10,589Gifts and pledges2,611-2,6113,479-3,479
Private grants and contracts: 91,558 - 91,558 85,671 - 85,671 Direct 13,225 - 13,225 10,589 - 10,589 Gifts and pledges 2,611 - 2,611 3,479 - 3,479
Direct91,558-91,55885,671-85,671Indirect13,225-13,22510,589-10,589Gifts and pledges2,611-2,6113,479-3,479
Indirect13,225-13,22510,589-10,589Gifts and pledges2,611-2,6113,479-3,479
Gifts and pledges 2,611 - 2,611 3,479 - 3,479
State appropriations 32,439 - 32,439 41,772 - 41,772
Investment income, net of expenses 65,954 – 65,954 57,592 – 57,592
Equity in loss of unconsolidated
affiliates – operating (24,135) – (24,135) – (19,805) – (19,805)
Equipment acquired through grants and
contracts 14,427 – 14,427 10,481 – 10,481
Net assets released from restrictions $36,182 - 36,182 - 31,442 - 31,442$
Other 96,357 – 96,357 104,265 – 104,265
Total operating revenues 2,524,260 - 2,352,789 - 2,352,789
Operating expenses
Salaries, wages, and benefits 1,985,560 – 1,985,560 1,846,165 – 1,846,165
Services, supplies, and other $497,274 - 497,274 437,352 - 437,352$
Depreciation 57,366 - 57,366 - 58,060 - 58,060
Interest 25,840 - 25,840 - 25,859 - 25,859
Total operating expenses 2,566,040 – 2,566,040 – 2,367,436 – 2,367,436
Operating expenses in excess of revenues $(41,780)$ $ (41,647)$ $ (14,647)$
Nonoperating activities
Gifts and pledges36844,65145,019125113,780113,905
Investment income (loss), net of
distribution and expenses 3 25,407 25,410 (74,202) (139,219) (213,421)
Unrealized gain on interest rate swaps 11,304 – 11,304 36,783 – 36,783
Net assets released from restrictions – (36,182) – (31,442) (31,442)
Equity in gain (loss) of unconsolidated
affiliates – nonoperating 1,388 – 1,388 (620) – (620)
Other nonoperating activities (90) – (90) (1,397) (1,397)
Change in net assets from nonoperating
activities 12,973 33,876 46,849 (39,311) (56,881) (96,192)
Change in net assets (28,807) 33,876 5,069 (53,958) (56,881) (110,839)
Net assets, beginning of year 437,250 1,085,000 1,522,250 491,208 1,141,881 1,633,089
Net assets, end of year \$ 408,443 \$1,118,876 \$1,527,319 \$ 437,250 \$1,085,000 \$1,522,250

See accompanying notes.

Consolidated Statements of Cash Flows

		Year Ended Ju 2023	ne 30 2022
		(In Thousan	ds)
Operating activities	¢		(110.020)
Change in net assets	\$	5,069 \$	(110,839)
Adjustments to reconcile change in net assets to net cash used in			
operating activities:		50.026	50 100
Depreciation and loss on disposal of property and equipment and other		58,936	59,188
Loss on extinguishment of debt		-	408
Equity in losses of unconsolidated affiliates, net		22,746	20,373
Equipment acquired through grants and contracts		(14,427)	(10,481)
Reinvested income		(4,277)	(3,399)
Change in interest rate swap liability		(11,304)	(36,783)
Net realized and unrealized (gains) losses on investments		(96,380)	152,863
Decrease in bond premium/discount and original issue costs		(548)	(552)
Change in pledges receivable		9,111	(49,683)
Change in accounts receivable		(30,446)	(45,504)
Gifts and pledges with donor restrictions and other		(13,988)	2,422
Change in other assets		(6,465)	(4,606)
Change in assets held on behalf of others		329	(4,353)
Change in accounts payable and other liabilities		(494)	20,572
Change in deferred revenue		15,990	(38,763)
Net cash used in operating activities		(66,148)	(49,137)
Net cash used in operating activities		(00,148)	(49,137)
Investing activities			
Purchases of investments		(200,672)	(85,760)
Proceeds from sales of investments		396,920	124,724
Purchases of property and equipment		(50,809)	(37,719)
Investment income		4,277	3,399
Issuances of notes receivable		(3,152)	(3,222)
Repayment of notes receivable		2,275	4,903
Net cash provided by investing activities		148,839	6,325
Financing activities			
Proceeds from line of credit, net		57,000	50,500
Repayment of bonds payable		(14,385)	(82,545)
Issuance costs on bonds		_	(544)
Proceeds from issuance of bonds and notes payable		_	75,000
Gifts and pledges with donor restrictions and other		13,988	(2,422)
Cash flows from financing leases		(464)	(464)
Net cash provided by financing activities		56,139	
Net cash provided by financing activities		50,139	39,525
Net change in cash, cash equivalents, restricted cash, and restricted			
cash equivalents		138,830	(3,287)
Cash, cash equivalents, restricted cash, and restricted cash equivalents			
at beginning of year		114,015	117,302
Cash, cash equivalents, restricted cash, and restricted cash equivalents			,
at end of year	\$	252,845 \$	114,015
5		-) +	1

Consolidated Statements of Cash Flows (continued)

	Year End 2023	ed Ju	ne 30 2022
	(In Th	ousan	ds)
Reconciliation of cash, cash equivalents, restricted cash, and restricted cash equivalents	Υ.		,
Cash and cash equivalents	\$ 89,109	\$	49,548
Restricted cash and cash equivalents included in investments	163,736		64,467
Cash, cash equivalents, restricted cash, and restricted cash equivalents	\$ 252,845	\$	114,015
Supplemental disclosures			
Net interest paid on bonds	\$ 28,723	\$	25,218
Right-of-use assets obtained in exchange for lease liabilities	\$ 2,867	\$	3,597
Noncash investing and financing activities			
Increase (decrease) in security lending collateral	\$ 8,371	\$	(16,081)
Increase (decrease) in payable under security lending agreement	\$ 8,371	\$	(16,081)

See accompanying notes.

Notes to Consolidated Financial Statements

June 30, 2023

1. Organization

Baylor College of Medicine (the College or Baylor) is one of the leading health science universities and biomedical research institutions in the United States. Founded in 1900, Baylor owns and operates educational, research, and patient care facilities. The College is an institution comprising four separate colleges, including a medical school, a graduate school of biomedical sciences, a health professions school, and a national school of tropical medicine. Baylor trains more than 3,500 medical, graduate, nurse anesthesia, physician assistant, orthotics and prosthetics, and genetics counseling students, as well as residents and postdoctoral fellows, each year. The College ranks among the nation's top biomedical research institutions and the country's top medical schools. Finally, the College provides extensive patient care services through its wholly owned Baylor Medicine Clinic and through faculty physician service agreements primarily with eight independently owned and operated affiliated hospitals, including Baylor St. Luke's Medical Center; see description below.

Baylor's main campus is located in the Texas Medical Center, a 700-acre complex of approximately 50 independent institutions and state instrumentalities in Houston, Texas. The College is the only private medical school in the southwestern United States.

Effective January 1, 2014, St. Luke's Health System Corporation (n/k/a CHI St. Luke's Health), a Texas nonprofit corporation exempt from federal income tax under Section 501(a) of the Internal Revenue Code of 1986, as amended (the Code), as an organization described in Section 501(c)(3) of the Code, conveyed to the College a 35% membership interest in St. Luke's Medical Center (n/k/a CHI St. Luke's Health Baylor College of Medicine Medical Center), a Texas nonprofit corporation exempt from federal income tax under Section 501(a) of the Code, as an organization described in Section 501(c)(3) of the Code. CHI St. Luke's Health retained a 65% membership interest in CHI St. Luke's Health Baylor College of Medicine Medical Center (BSLMC), which owns and operates a quaternary care hospital in the Texas Medical Center; other land and improvements in and near the Texas Medical Center; and ambulatory clinics located in the Texas Medical Center area, Tanglewood, and Pearland. As consideration, the College contributed to BSLMC cash, certain real property, and improvements, including a portion of the real property generally known as the McNair Campus; the hospital/clinic building located on the McNair Campus (except for a portion of the top five floors to be used for the College's clinical operations and a conference center on the first floor); and, effective February 16, 2015, the ambulatory surgery center located in the Lee and Joe Jamail Specialty Care Center. BSLMC sold the O'Quinn Medical Tower in 2016. The College and CHI St. Luke's Health share governance of BSLMC: each member appoints, and has the unilateral ability to remove, six voting board members and one

Notes to Consolidated Financial Statements (continued)

1. Organization (continued)

nonvoting board member. Doing business under the name Baylor St. Luke's Medical Center, the hospital serves as the home of most of the College's medical doctors dedicated to caring for private adult inpatients.

Effective February 2, 2015, the College formed a joint venture with H.U. Group (HUG, formerly Miraca Holdings, Inc.), a company based in Tokyo, Japan, and traded on the Tokyo Stock Exchange. HUG is dedicated to in vitro diagnostic, clinical laboratory testing, and other health-care-related businesses through its subsidiaries, such as Fujirebio Inc., one of the major Japanese domestic in vitro diagnostic reagent manufacturers, and SRL, Inc., the largest clinical laboratory testing company in Japan. Under the agreement, the College contributed its clinical genetics diagnostic laboratories business (including leases, equipment, receivables, other contracts, and certain employees) into a subsidiary company and conveyed a 60% membership interest in the subsidiary to a HUG affiliate for \$135.9 million in cash. The College retained a 40% membership interest. The College and the HUG affiliate share governance of the joint venture, called Baylor Miraca Genetics Laboratories, LLC (Baylor Genetics), a Texas limited liability company, and the College retained certain approval rights over aspects of Baylor Genetics that relate to the College's mission.

2. Summary of Significant Accounting Policies

Basis of Accounting and Reporting

The accompanying consolidated financial statements of Baylor have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The accompanying consolidated financial statements include the accounts of all entities in which Baylor has a significant financial interest and over which Baylor has control. All intercompany accounts and transactions have been eliminated upon consolidated financial statements. The Foundation) is consolidated in the College's consolidated financial statements. The Foundation is a Texas nonprofit corporation organized exclusively to aid, support, and maintain the College through contributions received from third-party donors. Baylor's membership interests in BSLMC and Baylor Genetics are included in the College's consolidated financial statements as equity method investments.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Based on the existence or absence of donor-imposed restrictions, Baylor classifies resources into two categories: net assets without donor restrictions and net assets with donor restrictions.

Net assets without donor restrictions are free of donor-imposed restrictions. All revenues, gains, and losses that are not restricted by donors are included in this classification. All expenditures are reported in the without donor restrictions category since the use of restricted gifts and pledges in accordance with donors' stipulations results in the release of the restriction. Net assets without donor restrictions may be designated for specific purposes by the College's Board of Trustees.

Net assets with donor restrictions are subject to donor-imposed restrictions. Some donor-imposed restrictions expire with the passage of time or can be satisfied by action of the College. Other donor-imposed restrictions are perpetual in nature. These net assets may include unconditional pledges, interests in trusts held by others, accumulated appreciation on donor-restricted endowments that have not yet been appropriated by the Board of Trustees for distribution, and donor-restricted endowments (at historical value). Generally, the donors of these assets permit the College to use a portion of the income earned on related investments for specific purposes.

Expirations of donor-imposed restrictions on net assets (i.e., the passage of time, along with the annual board approval of the endowment spending rate and/or fulfilling donor-imposed stipulations) are reported as net assets released from restrictions between the applicable classes of net assets on the consolidated statements of activities. Net assets with donor-imposed restrictions related to the purchase or construction of property and equipment are released when the property or equipment is placed in service, unless donor stipulations limit the use of the assets for a period of time or for a particular purpose.

Net assets with donor restrictions as of June 30, 2023 and 2022 are principally restricted for research, education, and facilities for these purposes.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses during the reporting period, as well as the disclosure of contingent assets and liabilities. Actual results ultimately could differ from management's estimates and assumptions.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Cash Equivalents

Cash and cash equivalents are liquid assets with minimal interest rate risk and original maturities of three months or less when purchased. Such assets, reported at fair value, primarily consist of depository account balances, money market funds, and short-term U.S. treasury securities.

Restricted cash and cash equivalents represent amounts set aside for long-term investments or posted as collateral as required by interest rate swap agreements. These amounts are included in investments, including securities loaned and interest rate swap liability, net on the consolidated balance sheets.

Patient Receivables

Patient receivables are reported at the amount that reflects the consideration to which the College expects to be entitled in exchange for providing physician health care services. Patient receivables include discounts for contractual, implicit price concession and charity adjustments and are recorded on an accrual basis at net realizable value on the consolidated balance sheets. The estimates of implicit price concessions for patient receivables are based primarily on the College's historical collection and write-off experience (see Note 4).

Affiliate Receivables

Affiliate receivables consist of amounts owed by various affiliated hospitals to which the College provides medical, professional, and supervisory staff to deliver patient care, teaching, and staff leadership services. These receivables are recorded on an accrual basis at net realizable value on the consolidated balance sheets.

Grants and Contracts, and Other Receivable

Grants and contracts, and other receivable primarily represent unreimbursed grant and contract expenditures from the federal government, principally the National Institutes of Health, and other nonfederal sources for payment for research provided by the College. These amounts are recorded on an accrual basis at net realizable value on the consolidated balance sheets.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Pledges Receivable

Unconditional promises to give that are expected to be collected within one year are recorded at net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at fair value, which is measured as the present value of their future cash flows. The discounts on those amounts are computed using risk-adjusted interest rates applicable to the years in which the promises are received. Amortization of the discounts is included in gifts and pledges revenue.

An allowance is made for uncollectible pledges receivable based upon the College's analysis of past collection experience and other judgmental factors.

Investments

The College's investments in marketable equity and fixed-income securities are recorded at fair value. Non-marketable securities are securities for which no public market exists; substantially all of these securities are accounted for at fair value using the practical expedient of net asset value per share or the equivalent. These non-marketable securities include investments in private equity limited liability corporations or partnerships. Other investments are stated at cost or fair value at the date of the acquisition or donation.

Realized gains and losses arising from the sale or other disposition of investments have been accounted for as changes in net assets without donor restrictions unless restrictions have been imposed by the donor. Certain investments are pooled with each fund subscribing to or disposing of units on the basis of the market value per unit, which is computed monthly. Realized gains and losses arising from the sale of securities are determined on an average cost basis.

The College's intent is to maintain a long-term investment portfolio to support research, education, and other activities. Accordingly, the total investment return is reported on the consolidated statements of activities in two categories. The investment return allocated to operating activities is determined by a formula, which involves allocating 5% of a trailing 28-quarter average market value of the endowment assets. Management believes this return is approximately equal to the real return the College expects to earn on its investments over the long term. The Board of Trustees may, in its discretion, designate additional funds to be used for operating purposes. The unallocated investment return, included in nonoperating activities on the consolidated statements of activities, represents the difference between the total investment return and the amount allocated to operating activities, net of investment costs.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Securities Lending

The College participates in securities lending transactions, whereby a portion of its investments are loaned through its agent under respective borrowing agreements to various parties. In return, the parties provide collateral for the securities loaned, usually on a short-term basis. The collateral consists of eligible securities that meet credit quality criteria and diversification limits in accordance with noncash collateral guidelines selected by the College. The College's claim on the collateral is limited to the market value of the loaned securities. Market values of the securities on loan and the collateral are monitored each business day by the agent to ensure the collateral is maintained at levels of at least 100% of the fair value of the securities on loan. Upon termination of a borrowing agreement or as deemed necessary by the agent, the agent is to deliver identical collateral or a portion of it to satisfy the College's obligations with the borrower. The collateral and the obligation of the College to return the collateral is reported as an asset and a liability, respectively, on the consolidated balance sheets at the fair value of the underlying securities. The fees received for these transactions are recorded as investment income.

Property and Equipment

Purchased property, plant, and equipment are recorded at cost, including, where appropriate, capitalized interest and software costs. Donated assets are recorded at fair value at the date of donation. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method to allocate the cost of various classes of assets over their estimated useful lives. Property, plant, and equipment are removed from the accounting records at the time of disposal.

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment charge is recognized when the fair value of the asset or group of assets is less than the carrying value.

Deferred Revenue

Deferred revenue consists of amounts received from grant and contract sponsors, affiliated hospitals, and others for which the College has not yet fulfilled its obligations. These amounts will be recognized in future periods to support the College's medical, education, and research missions once the obligations have been satisfied.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Assets Held on Behalf of Others

The College holds assets received from others and agrees to use those assets on behalf of or transfer the assets, return on investment of the assets, or both to a specified beneficiary. For the years ended June 30, 2023 and 2022, pooled investments in the amount of \$38.4 million and \$38.1 million, respectively, were held on behalf of the state of Texas (see Note 6). The College also held funds associated with a cooperative agreement with the federal government in the amount of \$10.6 million for the years ended June 30, 2023 and 2022. These funds are appropriated for the use of a federal government facility.

Fair Value Measurements

Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, *Fair Value Measurement*, defines fair value, requires expanded disclosures about fair value measurements, and establishes a three-level hierarchy for fair value measurements based on the observable inputs to the valuation of an asset or a liability at the measurement date. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (exit price) in an orderly transaction between market participants at the measurement date. ASC 820 prioritizes the inputs to the valuation techniques used to measure fair value by giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements).

Furthermore, ASC 820 applies to certain investment funds that do not have readily determinable fair values, including private investments, hedge funds, real estate, and other funds. ASC 820 allows for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value using net asset value per share or its equivalent. See Note 12 for further discussion of fair value measurements.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Debt Portfolio Financial Instruments

Long-term debt is reported at carrying value. The College employs derivatives in the form of fixed payor swaps, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable rate debt. Derivative financial instruments are reported at fair value with any resulting gain or loss recognized as a nonoperating item on the consolidated statements of activities. Periodic net cash settlement amounts with counterparties are accounted for as adjustments to interest expense on the related debt.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates, as well as risk of credit loss in the event of nonperformance by the counterparty. Baylor deals only with high-quality counterparties that meet rating criteria for financial stability and creditworthiness. Additionally, certain agreements require the posting of collateral when amounts subject to credit risk under the contracts exceed specified levels. Collateral levels are tied to the College's credit rating. The College records its interest rate swap liability net of collateral posted.

Operating Results

Operating results are broadly defined as changes in net assets without donor restrictions from operating activities and are reported as operating expenses in excess of revenues on the consolidated statements of activities. Net assets without donor restrictions are also affected by nonoperating activities, which include gains on formation of joint ventures; equity in earnings or losses that are not integral to operations; investment income/loss and other, net of distributions; change in the fair value of interest rate swap agreements; gifts and pledges for plant facilities; and certain other nonrecurring items.

Charity Care

The College is committed to providing assistance to financially indigent patients in the community who require care and services at reduced or no cost, as determined by its affiliated hospitals. Records are maintained to identify and monitor the level of charity care the College provides. These records include the amount of charges forgone and estimated costs for services and supplies furnished under its charity care policy. Costs incurred are estimated based on a Medicare cost factor applied to total gross charges for indigent patients after reducing costs for any payments received. The level of charity care provided, based on estimated costs, during fiscal years 2023 and 2022 was \$31.3 million and \$31.1 million, respectively.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Endowment Investments and Income Distribution

The College's investments are managed to achieve the maximum long-term return. Operating investment income distribution and other consists of amounts distributed from the College's endowment funds and from income on operating investments. The amount distributed from the endowment funds to support current operations is determined by the Board of Trustees and is based on a 5% distribution rate applied to a trailing 28-quarter average market value of the endowment portfolio. The Board of Trustees may, in its discretion, designate additional funds to be used for operating purposes. The primary objective of the 5% endowment distribution methodology is to reduce the impact of capital market fluctuations on operational programs. Nonoperating investment income (loss) consists of dividends, interest, and realized and unrealized gains and losses on endowed investments, net of distribution to operations and investment expenses.

Leases

The College recognizes right-of-use (ROU) assets and related lease liabilities in accordance with Accounting Standards Update (ASU) No. 2016-02, *Leases (Topic 842)*.

The College leases various equipment and facilities, including office space. Operating and financing leases with an initial term greater than 12 months are recognized as ROU assets and lease liabilities on the consolidated balance sheets. Financing ROU assets and liabilities are reported as part of property and equipment, net and accounts payable and other liabilities, respectively. ROU assets and related liabilities are recognized on the commencement date on the consolidated balance sheets based on future lease payments, and discounted based on the applicable risk-free interest rate, as permitted under the standard for nonpublic business entities.

Lease payments under certain agreements may escalate over the lease term either by a fixed percentage or a fixed dollar amount. Certain leases may provide for variable lease payments in the form of payments based on index-based (e.g., the U.S. Consumer Price Index) adjustments to lease payments. Baylor's lease terms may include options to extend or terminate the lease. Such options are included in the measurement of the ROU asset and liability, provided the existence of reasonable assurance that the College will exercise the option. The College has no leases that contain residual value guarantees provided by the College as a lessee.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Income Taxes

The College is a tax-exempt organization as described in Section 501(c)(3) of the Code and is generally exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. Baylor is, however, subject to federal and state income tax on unrelated business income and files unrelated business income tax and other information returns as required by government authorities. Management annually reviews its tax positions and has determined that there are no material uncertain tax positions that require recognition on the accompanying consolidated balance sheets as of June 30, 2023 or 2022. As of and for the year ended June 30, 2023, the College has followed regulations and made reasonable estimates of the provision for income taxes; the compensation excise tax; and the effects, if any, on existing deferred tax balances based on accounting guidance included in ASC 740, *Income Taxes*.

COVID-19

In March 2020, the World Health Organization designated COVID-19 as a global pandemic. Clinical patient volumes, research activities, and related revenue of these services were most significantly impacted beginning in mid-March 2020 as various policies were implemented by federal, state, and local governments in response to the COVID-19 pandemic, including stay-at-home orders, business closures, social distancing, and suspension of elective and nonemergent procedures. The College's Education and Public Services missions were less impacted financially from the pandemic. During this time, the College experienced supply chain disruptions, including significant price increases in medical supplies, particularly personal protective equipment. The pandemic also created significant volatility in the U.S. and global financial markets, which impacted the College's investment portfolio.

In response to the pandemic, federal and state governments passed legislation and took other administrative actions to provide assistance to organizations impacted by the pandemic. Sources of relief included the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act), which was enacted on March 27, 2020. During the 2022 fiscal year, the College received provider relief funds under the CARES Act in the amount of \$6.6 million. The total amount of provider relief funds recognized for the 2022 fiscal year was \$17.8 million. No provider relief funds were received or recognized as revenue during the 2023 fiscal year.

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

The College took additional measures to improve its liquidity during the pandemic. As permitted under the CARES Act Section 2302, the College deferred a total of \$34.1 million of the employer's portion of payroll taxes beginning March 2020 through December 2020. Of this balance, \$18.4 million was recorded in accounts payable and other liabilities as of June 30, 2022 and paid as of December 31, 2022.

Section 2301 of the CARES Act established the Employee Retention Credit (ERC), a refundable tax credit to encourage eligible organizations whose operations were impacted by COVID-19 to retain employees on their payroll. The College was eligible to receive the ERC due to the partial suspension of its operations as required by government orders during March 22, 2020 through September 30, 2020. The College recognized \$6.8 million and \$16.0 million within other revenue during the fiscal years ended June 30, 2023 and 2022, respectively, all of which was received.

Reclassifications

Certain reclassifications have been made to the fiscal year 2022 consolidated financial statements to conform with classifications used in fiscal year 2023. Receivables have been reclassified among the affiliates and grants, contracts, and others lines on the consolidated balance sheets. All other reclassifications had no significant effect on total assets, total liabilities, or operating results.

Subsequent Events

The College evaluated events and transactions occurring subsequent to June 30, 2023 through November 21, 2023, the date the accompanying consolidated financial statements were issued. During this period, there were no subsequent events that required recognition in the accompanying consolidated financial statements, nor were there any additional nonrecognized subsequent events that require disclosure.

Notes to Consolidated Financial Statements (continued)

3. Equity Investments in Unconsolidated Affiliates

The College has a 35% membership interest in BSLMC, which operates as a tax-exempt entity described in Section 501(c)(3) of the Code. The College's investment in BSLMC, which is accounted for under the equity method, was \$225.7 million and \$249.7 million at June 30, 2023 and 2022, respectively. The College recorded a loss from its investment in BSLMC in the amount of \$24.1 million and \$19.8 million for the fiscal years 2023 and 2022, respectively. The difference between the carrying value of the College's investment in BSLMC and its interest in BSLMC's net asset value is \$63.4 million of total distributions received in prior years, \$26.9 million recorded by the College to report its initial investment at fair value, and changes to BSLMC's net assets in excess of net income (loss). A summary of BSLMC's reported total assets, liabilities, and net assets at June 30 is as follows (in thousands):

	 2023	2022
Total assets	\$ 1,265,450	\$ 1,156,012
Total liabilities	\$ 509,486	\$,
Total net assets	755,964	823,844
Total liabilities and net assets	\$ 1,265,450	\$ 1,156,012

A summary of BSLMC's reported revenues, expenses, and net income (loss) for the years ended June 30 is as follows (in thousands):

	2023	2022
Revenue	\$ 1,151,242	\$ 1,062,509
Expenses	(1,220,379)	(1,120,133)
Operating loss	(69,137)	(57,624)
Nonoperating income	334	747
Deficit of revenues over expenses	\$ (68,803) \$	\$ (56,877)

Notes to Consolidated Financial Statements (continued)

3. Equity Investments in Unconsolidated Affiliates (continued)

The College has a 40% membership interest in Baylor Genetics, which operates as a Texas limited liability company. The College's investment in Baylor Genetics, which is accounted for under the equity method, was \$50.8 million and \$49.4 million at June 30, 2023 and 2022, respectively. The College recorded earnings of \$1.4 million and a loss of \$0.6 million from its investment in Baylor Genetics in fiscal years 2023 and 2022, respectively. The difference in the carrying value of the College's investment in Baylor Genetics and its interest in Baylor Genetics shareholder's deficit is \$16.0 million of members' net capital contributions recorded in Baylor Genetics shareholder's deficit, \$70.6 million recorded by the College to report its initial investment in Baylor Genetics at fair value, and the College's additional contribution of \$2.3 million. A summary of Baylor Genetics' reported total assets, liabilities, and shareholder's deficit at June 30 is as follows (in thousands):

	 2023	2022
Total assets	\$ 35,248 \$	23,824
Total liabilities Total shareholder's deficit	\$ 52,269 \$ (16,841)	42,458 (18,634)
Total liabilities and shareholder's deficit	\$ 35,428 \$	23,824

A summary of Baylor Genetics' reported revenues, expenses, and net income (loss) for the years ended June 30 is as follows (in thousands):

	 2023	2022
Revenues	\$ 79,315 \$	64,783
Expenses	 (75,844)	(66,334)
Net income (loss)	\$ 3,471 \$	(1,551)

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition

Revenue is recognized when control of the promised services is transferred to the customers (students, patients, affiliated hospitals, and governmental entities) in an amount that reflects the consideration the College is entitled to receive in exchange for those services.

The timing of revenue recognition, billings, and cash collections results in accounts receivable and deferred revenue on the consolidated balance sheets. Receivables are recognized only to the extent that it is probable that the College will collect substantially all of the consideration to which the College is entitled in exchange for the services that will be transferred to the customer.

Tuition and Fees, Net

The performance obligation for tuition and fees, net relates to the training or educating of undergraduate medical, research graduate, and health profession students. Revenue is recognized ratably as services are rendered during the academic semester using the input method based on time elapsed over the academic semester.

The transaction price is the price of tuition net of scholarships, applicable discounts, and refunds.

The College's academic year is consistent with its fiscal year in which students are billed at the beginning of each semester within the fiscal period and payment is due before the semester ends, also within the fiscal period. The College does not receive advance payments from students prior to the start of the fiscal period. No accounts receivable or deferred liabilities related to tuition and fees were recorded within the accompanying consolidated balance sheets as of June 30, 2023 or 2022.

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Medical Services, Net

Medical services, net consist of physician health care services in health care facilities, which include inpatient, outpatient, and ambulatory care facilities; physician practices; and other sites. Performance obligations include individual medical services provided to patients in both an inpatient and outpatient setting. Inpatient services are satisfied over time from patient admission to the point when services are no longer required, which is generally at the time of discharge. The inpatient medical services are recognized utilizing the input method of measuring progress, which is based on actual charges incurred. Outpatient services are satisfied at a point in time and revenue is recognized when control of services is transferred. The College believes this method provides a fair depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. These services are considered to be a single performance obligation.

Because all of its performance obligations relate to contracts with a duration of less than one year, the College has elected to apply the optional exemption provided in Topic 606, *Revenue From Contracts With Customers*, and, therefore, is not required to disclose the aggregate amount of transaction price allocated to medical services performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The College uses a portfolio approach to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. The portfolios consist of major payor classes. Based on the historical collection trends and other analyses, the College believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

The College determines the transaction price of medical services revenue, which involves significant estimates and judgment, based on standard charges for goods and services provided, reduced by explicit and implicit price concessions, including contractual adjustments provided to commercial insurance carriers, health care maintenance organizations, and preferred provider organizations; discounts provided to uninsured and underinsured patients in accordance with policy; and/or implicit price concessions based on the historical collection experience of patient accounts. The majority of what historically was classified as provision for doubtful accounts is now treated as an implicit price concession factored into net medical service revenues.

In addition, the College determines the transaction price associated with services provided to patients who have third-party payor coverage with Medicare and Medicaid based on reimbursement terms per contractual agreements, discount policies, and historical experience.

Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. The College believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no such regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medicaid programs. Changes in the Medicare and Medicaid programs could have a material adverse or positive impact on prospective medical services revenues.

Management has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the payors. The composition of medical service revenue, by payor, was as follows (in thousands):

	 2023	2022
Managed care	\$ 175,344 \$	168,905
Medicare	118,333	110,041
Medicaid	40,920	31,333
Self-pay	11,156	11,960
Other	9,579	11,246
	\$ 355,332 \$	333,485

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

The composition of patient receivables (net of contractual allowance and implicit price concession) by payor at June 30 was as follows:

	Patient Re	eceivables
	2023	2022
Managed care	64.3%	67.0%
Medicare	17.1	17.5
Medicaid	15.1	12.1
Self-pay	1.9	1.8
Other	1.6	1.6
	100.0%	100.0%

Affiliated Hospital Contracts

The College has affiliation agreements with hospitals, including, but not limited to, Texas Children's, Harris Health (formerly Harris County Hospital District), Baylor St. Luke's Medical Center, Michael E. DeBakey Veterans Affairs Medical Center, The Methodist Hospital, The Menninger Clinic, MD Anderson Cancer Center, Christus Children's, and The Institute for Rehabilitation and Research. Under the terms of these agreements, the College conducts administrative, research, and educational activities on behalf of these hospitals.

The College provides residents to the affiliated institutions; the residents in turn, provide patient care services as part of their medical training. The College satisfies this performance obligation over time as the hospitals receive the benefit of professional services. Affiliated hospital contract revenue is recognized as time elapses for actual personnel and operating costs incurred less collections that are received by the College from patient payors.

Amounts are billed periodically in accordance with agreed-upon contractual terms. The timing of revenue recognition, billings, and cash collections results in billed and unbilled receivables and customer advances and deposits on the consolidated balance sheets. These assets and liabilities are reported on the consolidated balance sheets on a contract-by-contract basis at the end of each reporting period. Affiliate receivables in the amount of \$152.3 million and \$147.3 million were recorded as of June 30, 2023 and 2022, respectively. Affiliate deferred revenue in the amount of \$23.7 million and \$18.6 million is included within deferred revenue on the accompanying consolidated balance sheets as of June 30, 2023 and 2022, respectively.

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Following were the affiliates that accounted for greater than 10% of total affiliated contract revenue for the years ended June 30:

	2023	2022
Harris Health	17.5%	17.9%
BSLMC	20.8	19.1
Texas Children's	50.5	50.5

Following were the affiliates that accounted for greater than 10% of total affiliated contract receivables as of June 30:

	2023	2022
Harris Health	24.1%	19.0%
BSLMC	22.2	29.1
Texas Children's	39.8	37.9

Other

Other revenue primarily consists of several other exchange contracts, including academic program fees from the College's affiliates, royalties on certain licenses of intellectual property and the Baylor College of Medicine brand, and various other types of income. Depending on the program, revenue is recognized at a point in time or over time as obligations are met.

State Appropriations

The College received funding in the form of appropriations from the State of Texas Higher Education Coordinating Board (the Coordinating Board) for the purpose of training or educating Texas resident undergraduate medical students and graduate medical residents in the amount of \$32.4 million and \$41.8 million in 2023 and 2022, respectively. The College expended \$257.8 million and \$233.1 million for fiscal years 2023 and 2022, respectively, to train and educate undergraduate medical students and graduate medical residents. Expenditures used to satisfy these appropriations are reflected on the schedule of functional expenses (see Note 13) as instruction expenditures and certain amounts related to the instruction of graduate medical residents that are included in affiliated hospital programs expenditures.

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Effective September 1, 2021, the Coordinating Board approved the transfer of a portion of the College's undergraduate medical funding to the Texas Health and Human Services Commission. The intergovernmental transfer allows the College to participate and receive federal funding under the Texas Incentives Physicians and Professional Services (TIPPS), a directed payment program approved by the Centers for Medicare & Medicaid Services (CMS) for physician practice groups that provide health care services to patients enrolled in Medicaid managed care programs. CMS approved TIPPS for state fiscal years 2023 and 2022. The College recognized \$11.4 million and \$5.8 million of TIPPS payments as medical services, net, for services provided at Baylor clinics, during the fiscal years ended June 30, 2023 and 2022, respectively.

During the 2022 fiscal year, the College executed agreements with the Harris Health System and Christus Children's, to provide services that are eligible under TIPPS to patients of these affiliated hospitals. Through these arrangements, the College pays the affiliated hospitals a share of TIPPS payments received and recognizes its share of the payments. The College recognized \$26.0 million and \$11.3 million of TIPPS payments as affiliated hospital contracts under these arrangements during the fiscal years ended June 30, 2023 and 2022, respectively.

Government and Private Grants and Contracts

Government and private grants and contracts represent revenue from grants and contracts with federal, state, and local governments; private foundations; and corporate sponsors primarily for research and education activities conducted by the College. Direct recoveries are recognized when allowable direct expenditures for salaries and supplies are incurred under the terms of each sponsor's agreement. Indirect recoveries represent reimbursement of the costs of facilities and administrative (F&A) overhead associated with government and private grants and contracts. Indirect recoveries are recognized as revenue as the corresponding allowable direct grant and contract expenses are incurred under the terms of each sponsor's agreement. Baylor's federal F&A costs recovery rate for on-campus research was 60.0% in both fiscal years 2023 and 2022. Baylor's federal F&A costs recovery rate for off-campus research was 26.0% in both fiscal years 2023 and 2023 and 2022.

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Gifts and Pledges

As pledges are made to the College, the intent of the donor, circumstances regarding the pledge, and any action taken by the College in response to the pledge are considered in determining whether the pledge is an unconditional promise to give or a conditional promise. Unconditional promises to give (pledges) are recognized as revenue without donor restrictions when the donor's commitment is received. Gifts and pledges with donor-imposed restrictions are recorded as revenue without donor restrictions if those restrictions are met in the same reporting period. Otherwise, gifts and pledges with donor-imposed restrictions are recorded as increases in net assets with donor restrictions.

Conditional promises (primarily bequest intentions) are not recorded until donor conditions are substantially met.

Gifts and pledges recorded as donor-restricted net assets are released from restrictions and recognized as net assets without restrictions after any donor stipulations are met. Gifts and pledges for equipment are released from restrictions and recognized as an operating item only after resources are expended for the applicable equipment. Gifts and pledges for buildings are released from restrictions and recognized as an operating item over time only after the building is brought into service.

5. Pledges Receivable

Pledges receivable as of June 30 are expected to be realized as follows (in thousands):

	 2023	2022		
In one year or less	\$ 42,435 \$	37,888		
Between one year and five years	36,562	49,535		
More than five years	7,230	6,060		
Less present value discount	(3,571)	(1,716)		
Total	\$ 82,656 \$	91,767		

Notes to Consolidated Financial Statements (continued)

6. Investments

Investments (including amounts for self-insurance) held by the College at June 30 are as follows (in thousands):

	2023			2022		
Pooled investments:						
U.S. equities	\$	352,221	\$	368,018		
Fixed income		77,092		134,203		
Cash and cash equivalents		163,736		43,253		
International equities		323,181		363,520		
Private equity securities		556,537		564,545		
Total pooled investments		1,472,767		1,473,539		
Other stocks		1,957		1,964		
Real estate, at cost		2,656		2,656		
Assets held in trust and other		11,112		10,933		
Total investments	\$	1,488,492	\$	1,489,092		

In fiscal year 2000, the College received \$25.0 million to establish a fund for investing a portion of receipts paid to the state of Texas under a judgment rendered in the tobacco settlement (the tobacco funds). The College is responsible for the administration of the tobacco funds, which are invested along with the College's pooled investments; however, the College does not have title to the assets. As of June 30, 2023 and 2022, the value of the tobacco funds is included in pooled investments and a corresponding liability has been recorded in assets held on behalf of others to reflect that the College does not currently have an ownership interest.

The earnings of the tobacco funds are required to be remitted to the state of Texas, which, in turn, appropriates the earnings to the College to benefit programs in medical research, health education, and treatment. The distributions in the years ended June 30, 2023 and 2022 of \$3.3 million and \$3.5 million, respectively, are included in state appropriations on the consolidated statements of activities.

The U.S. and international financial markets have experienced significant volatility that has resulted in substantial fluctuations in equity markets in which the College invests. Market volatility can affect the value the College receives for its investments in future periods.

Notes to Consolidated Financial Statements (continued)

6. Investments (continued)

Investment performance for the years ended June 30 is summarized as follows (in thousands):

	2023						
Operating		Noi	noperating	With Donor Restrictions			
Distribution of endowment	¢	((01	\$		¢ 10	\$	(701
earnings and other Investment income	\$	6,691	Э	 19,227	\$ 10	Э	6,701 19,227
Net realized (losses) gains		(1)		58,785	3,480		62,264
Net unrealized losses		(1)		(9,344)	21,709		12,365
Total investment return		6,690		68,668	25,199		12,505
Investment return, designated		0,070		00,000	23,177		100,557
for current operations		63,796		(64,004)	208		_
Investment management fees		(4,532)		(4,661)			(9,193)
Total investment return, net of		(1,22_)		(1,000)			(; ;=; =)
distributions and expenses	\$	65,954	\$	3	\$ 25,407	\$	91,364
				202	22 With Donor		
	0	Operating	Noi	noperating	Restrictions		Total
Distribution of endowment							
earnings and other	\$	3,511	\$		\$ 3	\$	3,514
earnings and other Investment income	\$	-	\$	18,477	855	\$	19,332
earnings and other Investment income Net realized (losses) gains	\$	3,511 (1,549)	\$		855 4,317		19,332 115,318
earnings and other Investment income Net realized (losses) gains Net unrealized losses	\$	(1,549)	\$	18,477	855		19,332 115,318
earnings and other Investment income Net realized (losses) gains Net unrealized losses Total investment return	\$	-	\$	18,477 112,550	855 4,317		19,332 115,318
earnings and other Investment income Net realized (losses) gains Net unrealized losses Total investment return Investment return, designated	\$	(1,549) 	\$	18,477 112,550 (139,428) (8,401)	855 4,317 (144,586) (139,411)		19,332 115,318 (284,014)
earnings and other Investment income Net realized (losses) gains Net unrealized losses Total investment return Investment return, designated for current operations	\$	(1,549) 	\$	18,477 112,550 (139,428) (8,401) (60,151)	855 4,317 (144,586)		19,332 115,318 (284,014) (145,850)
earnings and other Investment income Net realized (losses) gains Net unrealized losses Total investment return Investment return, designated	\$	(1,549) 	\$	18,477 112,550 (139,428) (8,401)	855 4,317 (144,586) (139,411)		19,332 115,318 (284,014)

Notes to Consolidated Financial Statements (continued)

7. Endowment Funds

The College's endowment consists of approximately 800 individual funds established for a variety of purposes. Its endowment includes both donor-restricted endowment funds and funds designated by the College to function as endowments. As required by U.S. GAAP, net assets associated with endowment funds, including funds designated by the College to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

ASC 958-205-45-28, Not-for-Profit Entities – Presentation of Financial Statements – Other Presentation Matters – Classification of Donor-Restricted Endowment Funds Subject to UPMIFA, provides guidance on the net asset classification of donor-restricted endowment funds for a not-for-profit organization that is subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act of 2006 (UPMIFA) and improves disclosures about an organization's endowment funds (both donor-restricted and College-designated endowment funds).

Interpretation of relevant law – The College has established a policy consistent with UPMIFA as adopted by the state of Texas. The College seeks to preserve the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. Accordingly, the College classified as net assets with donor restrictions: (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified as permanent endowment is available for appropriation for expenditure by the College in a manner consistent with the standard of prudence prescribed by UPMIFA.

Notes to Consolidated Financial Statements (continued)

7. Endowment Funds (continued)

In accordance with UPMIFA, the College considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- (1) The duration and preservation of the fund
- (2) The purposes of the College and the donor-restricted endowment fund
- (3) General economic conditions
- (4) The possible effects of inflation and deflation
- (5) The expected total return from income and the appreciation of investments
- (6) Other resources of the College
- (7) The investment policies of the College

The College's endowment consists of the following net asset types at June 30 (in thousands):

	Without			With		
	Donor Restrictions		Donor Destrictions			Total
2022	Kes	strictions	R	estrictions		Total
2023	•		•	052 022	•	052 022
Donor-restricted endowment funds	\$	-	\$	872,823	\$	872,823
Board-designated endowment funds		572,690		20,883		593,573
Total endowments at June 30, 2023	\$	572,690	\$	893,706	\$	1,466,396
	V	Vithout		With		
	_	Vithout Donor		With Donor		
]	_	R			Total
2022]	Donor	R	Donor		Total
2022 Donor-restricted endowment funds]	Donor	<u>R</u> \$	Donor	\$	Total 835,267
-	Res	Donor		Donor estrictions	\$	_

Notes to Consolidated Financial Statements (continued)

7. Endowment Funds (continued)

Funds with deficiencies – From time to time, the fair value of the assets associated with the individual donor-restricted endowment funds may fall below the level that the donor or UPMIFA requires the College to retain as a fund of perpetual duration. As of June 30, 2023, the College had deficiencies of this nature in 28 donor-restricted endowment funds, which together have an original gift value of \$18.5 million, a current fair value of \$17.5 million, and a deficiency of \$1.0 million. As of June 30, 2022, the College had deficiencies of this nature in 29 donor-restricted endowment funds, which together have an original gift value of \$19.1 million, a current fair value of \$17.8 million, a current fair value of \$13.1 million. The College maintains policies that permit spending from underwater endowment funds depending on the degree to which the fund is underwater, unless otherwise precluded by donor intent or relevant laws and regulations.

Return objectives and risk parameters – The College recognizes that the goals of endowment management are preserving the purchasing power of the assets and providing stable support for current programs. The primary focus of the College's endowment investment policy is structuring both the endowment's investment portfolio and its annual spending in order to balance the needs of current and future generations of scholars, scientists, patients, and teachers. Current annual spending from the endowment plus inflation combines to create a minimum target total return for the portfolio. The College expects its endowment funds, over time, to provide an average rate of return at least equal to the spending policy requirements plus the rate of inflation. Actual rates of return in any given year may vary from this amount.

Strategies employed for achieving objectives – The College employs strategies of investing in equity assets and some illiquid assets, broadly diversifying, and investing in assets that are out of favor. The College believes that these strategies will help achieve the total return target over the long term.

Spending policy and how the investment objectives relate to spending policy – The College's board-approved endowment earnings distribution policy, as permitted by UPMIFA, is based on a 5% distribution applied to a trailing 28-quarter average market value of the endowment assets for both fiscal years. In establishing this spending policy, the College considered the long-term expected return on its endowment assets and expects the current spending policy to preserve the real purchasing power of the endowment assets, while helping to maintain intergenerational value of the assets, as well as to provide additional real growth through new gifts and pledges and investment return. The Board of Trustees may, in its discretion, designate additional funds to be used for operating purposes.

Notes to Consolidated Financial Statements (continued)

7. Endowment Funds (continued)

The following endowment-related activities occurred during the years ended June 30 (in thousands):

	Without Donor Restrictions		With Donor Restrictions		Total
Endowment net assets at June 30, 2022	\$	615,334	\$	851,866	\$ 1,467,200
Investment income, net of expense		19,417		1,095	20,512
Gifts and pledges		10		13,247	13,257
Realized and unrealized gains, net		49,852		23,994	73,846
Appropriation of endowment assets					
for expenditure		(64,669)		_	(64,669)
Other changes:					
Transfer to/from board-designated endowments					
within net assets without donor restrictions		(47,254)		3,504	(43,750)
Endowment net assets at June 30, 2023	\$	572,690	\$	893,706	\$ 1,466,396

During the fiscal year 2023, the College redeemed \$48.4 million of board-designated endowment units for the construction of research facilities.

	 thout Donor With Donor estrictions Restrictions				
Endowment net assets at June 30, 2021	\$ 687,309	\$	980,353	\$	1,667,662
Investment income, net of expense	16,827		924		17,751
Gifts and pledges	27		10,474		10,501
Realized and unrealized losses, net	(28,569)		(140,438)		(169,007)
Appropriation of endowment assets					
for expenditure	(60,151)		_		(60,151)
Other changes:					
Transfer to/from board-designated endowments					
within net assets without donor restrictions	 (109)		553		444
Endowment net assets at June 30, 2022	\$ 615,334	\$	851,866	\$	1,467,200

Notes to Consolidated Financial Statements (continued)

8. Financial Assets and Liquidity Resources

The table below represents financial assets and liquidity resources available for general expenditures within one year (in thousands). The College defines general expenditures as the normal expenditures related to operations, excluding capital expenditures.

	20	23	2022
Financial assets:			
Cash and cash equivalents	\$ 8	39,109	\$ 49,548
Accounts receivable	33	85,113	312,011
Pledges receivable	8	32,656	91,767
Notes receivable	1	6,585	15,708
Investments, including securities loaned of \$80,610			
and \$88,153 for 2023 and 2022, respectively	1,48	38,492	1,489,092
Total financial assets	2,01	1,955	1,958,126
Liquidity resource:			
Unused bank line of credit	14	12,500	199,500
Less those unavailable for general expenditures within			
one year due to:			
Contractual or donor-imposed restrictions	(89	93,706)	(851,866)
Investments with liquidity restrictions		(2,934)	(2,934)
Investments held in trust	(1	1,112)	(10,933)
Pledges receivable	(4	10,221)	(53,879)
Notes receivable	(1	16,585)	(15,708)
Assets held on behalf of others	(4	19,081)	(48,752)
Financial assets not available for use within one year	(1,01	3,639)	(984,072)
Financial assets and liquidity resources available for			
general expenditures within one year	\$ 1,14	40,816	\$ 1,173,554

Notes to Consolidated Financial Statements (continued)

8. Financial Assets and Liquidity Resources (continued)

The College's endowment funds consist of donor-restricted endowments and funds designated by the board as endowment. Income from endowments is restricted for specific purposes. The College has a spending policy and \$65.5 million of appropriation from the endowments will be available in the next 12 months. As part of a liquidity management plan, the College has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. In the event of an unanticipated liquidity need, the College maintains a four-year, \$150.0 million line of credit available for working capital purposes that is scheduled to expire on June 30, 2024. During fiscal year 2023, the College secured a supplemental line of credit of \$100.0 million that expires on June 30, 2026 that is intended to replace a 364-day \$100.0 million line of credit that the College originally negotiated in April 2020 and that expires in October 2023 (see Note 10).

9. Property and Equipment

Property and equipment consist of the following at June 30 (in thousands):

	Useful Life (Years)		2023	2022
Land		¢	5 260	¢ 5.260
	_	\$	5,269	
Buildings	16–28		754,466	741,080
Land improvements	15–20		17,499	17,499
Leasehold improvements	5–15		104,414	98,523
Furniture and equipment	5-10		376,283	374,352
Computer software	3–5		110,012	113,639
			1,367,943	1,350,362
Less accumulated depreciation			(1,040,803)	(1,008,995)
			327,140	341,367
Construction-in-progress			57,790	36,827
Leased right-of-use assets –				
financing			418	796
		\$	385,348	\$ 378,990

Notes to Consolidated Financial Statements (continued)

9. Property and Equipment (continued)

In accordance with ASC 360, *Property, Plant, and Equipment*, when events or changes in circumstances indicate the carrying amount of property and equipment, and intangible or other long-lived assets, related to specifically acquired assets may not be recoverable, an evaluation of the recoverability of currently recorded costs is performed. When an evaluation is performed, the estimated value of undiscounted future net cash flows associated with the asset is compared with the asset's carrying value to determine whether a write-down to fair value is required. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. No impairments were recognized for the years ended June 30, 2023 or 2022.

10. Bonds and Notes Payable

A summary of bonds and notes payable at June 30 is as follows (in thousands):

		2023		2022
2012 Bond Series				
In September 2012, the College issued \$109.1 million of taxable				
fixed rate bonds. The interest rate is 5.26%, payable				
semiannually. Mandatory annual redemption before maturity				
is required between November 15, 2038 and 2045, with final	.		.	100.101
maturity on November 15, 2046.	\$	109,121	\$	109,121
2016 Bond Series				
In May 2016, the Harris County Cultural Education Facilities				
Finance Corp. issued for the College \$142.7 million of tax-				
exempt fixed rate bonds with multiple maturities. The interest				
rates range from 3.00% to 5.00%, payable semiannually.				
Beginning in November 2018, principal installments are due				
annually with final maturity at November 15, 2032. A				
majority of the outstanding bonds are callable beginning in				
May 2026.		106,510		114,220

Notes to Consolidated Financial Statements (continued)

10. Bonds and Notes Payable (continued)

	 2023	2022
2019A Bond Series In May 2019, the College retired \$75.0 million of tax-exempt floating rate notes with the Harris County Cultural Education Facilities Finance Corp. The Harris County Cultural Education Facilities Finance Corp. simultaneously issued \$75.0 million of		
tax-exempt floating rate notes. The interest rate resets monthly at a spread of 0.65% over the one-month London Interbank Offered Rate (LIBOR). The interest rate at June 30, 2023 was 4.55%. From July 3, 2023 and thereafter LIBOR will be replaced with the sum of the Secured Overnight Financing Rate (SOFR) plus 0.11448%.These bonds mature on November 15, 2046, but have an initial mandatory repurchase in July 2024.	\$ 75,000 \$	75,000
2020 Bond Series		
In November 2020, the Harris County Cultural Education Facilities Finance Corp. issued for the College the Taxable Medical		
Facilities Mortgage Revenue Refunding Bonds for		
\$208.02 million. The interest rates, payable semiannually, range		
from 1.4% to 3.9%. Principal installments are due annually beginning in 2022 and through 2030, with additional maturities		
due in 2037 and 2046. The proceeds from this issuance were used to advance refund the Bonds Series 2012A.	201,345	208,020
2022A Bond Series		
In January 2022, the Harris County Cultural Education Facilities Finance Corp. issued for the College \$75.0 million of tax-exempt floating rate notes. The proceeds from this issuance were used to advance refund the Bonds Series 2019B. The interest rate resets monthly at a spread of 0.52% over the Securities Industry and Financial Markets Association (SIFMA) rate. The interest rate at June 30, 2023 was 4.25%. These bonds mature on November 15,		
2046, but have an initial mandatory repurchase in February 2025.	 75,000	75,000
Total outstanding	566,976	581,361
Less deferred issuance costs	(4,052)	(4,278)
Plus original issue premium – 2016 Bond Series	 6,905	7,679
	\$ 569,829 \$	584,762

Notes to Consolidated Financial Statements (continued)

10. Bonds and Notes Payable (continued)

The aggregate annual scheduled maturities of long-term debt as of June 30, 2023 for the next five fiscal years and thereafter are as follows (in thousands):

2024	\$ 14,880
2025	15,410
2026	15,980
2027	16,585
2028	17,235
Thereafter	 486,886
	\$ 566,976

In addition, the College must purchase a portion of its debt within these fiscal years unless remarketed, as described above.

Advance refunding tax-exempt debt is subject to arbitrage rules under Code Section 103(c) and related regulations that, in general, prohibit the yield realized from the investment of the proceeds of the new debt from exceeding the yield on the debt itself. Compliance with those rules is necessary for the interest on the debt to be exempt from federal income tax, and the College believes that it is in compliance with those rules.

As of June 30, 2023, all bonds outstanding have been issued under terms of the Second Amended and Restated Master Trust Indenture, dated November 1, 2020, between the Master Trustee and the College. The Master Trustee has a secured interest in all gross receipts and substantially all College land, including all improvements, appurtenances, personal property, and proceeds now or hereafter placed, acquired, or arising from the land.

Bond Compliance

As of June 30, 2023, the College is in compliance with financial covenants per the Second Amended and Restated Master Trust Indenture, dated November 1, 2020.

Notes to Consolidated Financial Statements (continued)

10. Bonds and Notes Payable (continued)

Revolving Credit Line

The College maintains a \$150.0 million revolving line of credit that is scheduled to expire on June 30, 2024. The College had drawn \$107.5 million and \$50.5 million from this line of credit for working capital purposes as of June 30, 2023 and 2022, respectively. During fiscal year 2023, the College secured a supplemental line of credit of \$100.0 million that expires on June 30, 2026 that is intended to replace a 364-day \$100.0 million line of credit that the College originally negotiated in April 2020 and that expires in October 2023. There were no amounts outstanding on these supplemental lines of credit at June 30, 2023.

11. Derivative and Other Financial Instruments

The College has derivative financial instruments, as allowed by its Debt and Swap Policies' Guidelines, both of which specifically preclude their use for speculation. The College has three fixed payor swaps outstanding at June 30, 2023 and 2022. The College has not elected hedge treatment of these swap agreements; as such, the change in the fair value of interest rate swaps is recorded in nonoperating unrealized gain on interest rate swaps on the consolidated statements of activities and as an adjustment to reconcile operating activities on the consolidated statements of cash flows. These long-dated swaps have a predetermined annual notional amortization or accretion that occurs in November of each year.

Notes to Consolidated Financial Statements (continued)

11. Derivative and Other Financial Instruments (continued)

The following table summarizes the fair value from the College's perspective at June 30, and the income (loss) recorded related to the interest rate swap agreements as of and for the years ended June 30 (dollars in thousands):

	v								
Bank PLC PNC Bank		NC Bank	Mei	rill Lynch	Total				
Fi	xed rate	F	ixed rate	F	ixed rate				
Febi	uary 2032	Feb	ruary 2020	Jar	uary 2012				
Nove	mber 2045	Feb	ruary 2032	Nov	ember 2047				
\$	_	\$	103,295	\$	40,505	\$	143,800		
	4.274%		4.542%		4.554%				
\$	(13,180)	\$	(14,458)	\$	(9,534)	\$	(37,172)		
	(14,841)		(21,086)		(12,549)		(48,476)		
			. ,						
\$	_	\$	_	\$	_	\$	_		
	_		_		_		_		
\$	1,661	\$	6,628	\$	3,015	\$	11,304		
	11,082		16,308		9,393		36,783		
	Ba Fi Febr Nove \$ \$	4.274% (13,180) (14,841) (14,841) (14,841) (14,841) (14,841) (14,841)	Bank PLC PM Fixed rate F February 2032 Feb November 2045 Feb \$ 4.274% \$ (13,180) \$ (14,841) \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	Bank PLC PNC Bank Fixed rate Fixed rate February 2032 February 2020 November 2045 February 2020 \$ - 103,295 4.274% 4.542% \$ (13,180) \$ (14,458) (14,841) (21,086) \$ - - \$ 1,661 \$ 6,628	Bank PLC PNC Bank Mer Fixed rate Fixed rate F February 2032 February 2020 Jan November 2045 February 2032 Nov \$ - \$ 103,295 \$ 4.274% 4.542% \$ \$ (13,180) \$ (14,458) \$ (14,841) (21,086) \$ \$ - - - \$ \$ 1,661 \$ 6,628 \$	Bank PLC PNC Bank Merrill Lynch Fixed rate Fixed rate Fixed rate Fixed rate February 2032 February 2020 February 2020 November 2047 \$	Bank PLC PNC Bank Merrill Lynch Fixed rate Fixed rate Fixed rate February 2032 February 2020 January 2012 November 2045 February 2032 November 2047 \$ \$ 103,295 \$ 40,505 \$ 4.274% 4.542% \$ 40,505 \$ \$ (13,180) \$ (14,458) \$ (9,534) \$ \$ (14,841) (21,086) \$ (12,549) \$ \$ - \$ - \$ \$ - \$ \$ - \$ \$ - \$ - \$ - \$ \$ - - - - \$ - \$ \$ - \$		

12. Fair Value of Assets and Liabilities

The estimated fair values of all significant financial instrument amounts have been determined by the College using available market information and appropriate valuation methodologies. The estimates are not necessarily indicative of the amounts the College could realize in a current market exchange.

The carrying amounts of cash and cash equivalents, accounts receivable, patient accounts receivable, accounts payable, and short-term line of credit approximate fair value because of their short maturity.

The College's bonds payable are reported at carrying value (par) net of unamortized premiums/ discounts.

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

The College records investments, investments loaned under its security lending agreements, the related payable under security lending agreements, and its bond interest rate swap instruments at fair value in accordance with ASC 820.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The statement establishes consistency and comparability by providing a fair value hierarchy that prioritizes the inputs to valuation techniques into three broad levels, which are described below.

Level 1 – Inputs are quoted market prices in active markets for identical assets or liabilities (these are observable market inputs) that the College has the ability to access at the reporting date.

Level 2 – Inputs are other than quoted prices included within Level 1 that are either directly or indirectly observable for the asset or liability, including quoted market prices for similar assets in active markets, quoted prices for identical or similar assets in markets in which there are few transactions, inputs other than quoted prices that are observable for the asset, and inputs that are derived from observable market data by correlation or other means.

Level 3 – Inputs are generally unobservable market inputs that typically reflect the entity's estimate of assumptions that market participants would use in pricing the asset or liability (used when little or no market data is available).

ASC 820 requires the use of observable market inputs (quoted market prices) when measuring fair value whenever possible and requires Level 1 quoted prices to be used to measure fair value whenever possible.

ASC 820 provides guidance for estimating the fair value of investments in certain entities that calculate net asset value per share (or its equivalent). As such, the College utilizes net asset value as a practical expedient of fair value and other available information to determine fair value for investments meeting the prescribed requirements.

Level 1 investments are able to be liquidated as of the reporting date at published market values. Level 2 and 3 investments may contain restrictions on the ability to liquidate assets at the reporting date. Investments that can be liquidated within 90 days of the reporting date at net asset value or

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

its equivalent are classified as Level 2 investments. Investments classified as Level 3 have significant liquidity restrictions that would prevent redemption within 90 days of the reporting date, if at all. Private equity investments are measured at fair value using net asset value as a practical expedient as of the measurement date.

Financial assets and liabilities included in the College's consolidated financial statements and measured at fair value on a recurring basis as of June 30 are classified based on the applicable valuation technique level in the following tables (in thousands). Private equity investments and other financial assets are not categorized in the fair value hierarchy but are presented for reconciliation purposes:

		Total 2023		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant nobservable Inputs (Level 3)
Assets: Cash and cash equivalents	\$	163,736	\$	163,736	\$	_	\$	_
U.S. equities	Φ	358,799	φ	316,964	φ	41,835	Φ	_
International equities		323,181		206,647		116,534		_
Fixed income		77,092		37,146		39,946		-
Security lending collateral		84,259		_		84,259		
		1,007,067		724,493		282,574		-
Investments measured at NAV Assets held in trust and other		556,537 5,335		-		-		-
Real assets		2,656		-		-		-
Direct equity investments	Ø	1,157	¢		Ø		ſ	
Total assets	\$	1,572,752	\$		\$		\$	
Liabilities: Interest rate swap liability	\$	37,172	\$	_	\$	37,172	\$	_
Payable under security lending agreements Assets held on behalf of		84,259		-		84,259		_
others (state tobacco funds)		38,440		38,440		-		_
Total liabilities	\$	159,871	\$	38,440	\$	121,431	\$	_

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

	Total 2022	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant nobservable Inputs (Level 3)
Assets:				
Cash and cash equivalents	\$ 43,253	\$ 43,253	\$ _	\$ —
U.S. equities	374,427	318,708	55,719	—
International equities	363,520	247,710	115,810	—
Fixed income	134,203	29,996	104,207	—
Security lending collateral	 92,630	_	92,630	
	1,008,033	639,667	368,366	_
Investments measured at NAV	564,545	_	-	_
Assets held in trust and other	5,094	_	—	_
Real assets	2,656	—	-	—
Direct equity investments	 1,395	_	_	—
Total assets	\$ 1,581,723	\$ _	\$ _	\$
Liabilities:				
Interest rate swap liability Payable under security	\$ 48,476	\$ _	\$ 48,476	\$ _
lending agreements Assets held on behalf of	92,630	-	92,630	_
others (state tobacco funds)	38,127	38,127	_	_
Total liabilities	\$ 179,233	\$ 38,127	\$ 141,106	\$ _

Cash and cash equivalents and U.S. and international equities included in Level 1 are measured using quoted market prices in active markets for the identical equities. U.S. and international equities and fixed-income investments, included in Level 2, are measured using quoted market prices for similar assets and use the net asset value per share.

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

Private equity investments consist of leveraged buy-outs, venture capital, distressed debt, and real assets and real estate investments. Capital is allocated to domestic and international markets in various investment vehicles, primarily limited partnerships, but also includes private real estate investment trusts. Most of the underlying assets in the private equity partnerships are not immediately liquid. All private equity investments are held as long-term investments. Leveraged buy-outs, venture capital, and distressed debt investments are structured as closed-end, commitment-based investment funds where the investor commits a specified amount of capital upon inception of the fund, which is then drawn down over a specified period of the fund's life. These funds generally cannot be withdrawn or redeemed prior to the specified termination date and will only receive distributions upon a disposition of the underlying assets in the portfolio. As a limited partner, the College will not generally have any influence over the amount or timing of capital contributions and distributions. As of June 30, 2023, the remaining specified term of the leveraged buy-outs, venture capital, and distressed debt partnerships ranged from 1 to 12 years. However, a partnership's life may be (and normally is) extended beyond the original specified term by approval of the limited partners. Some of the College's real estate investments are different from the other private equity partnerships, as they are structured as open-ended, commingled investment vehicles. The underlying investments consist of large, diversified portfolios of existing real properties, primarily income-producing assets, such as office buildings, apartments, retail, and industrial properties, located across the United States. Subject to certain restrictions, redemptions of all or part of the College's investments in private equity real estate may be requested each quarter, and such redemptions will be made at the net asset value for the fund. Private equity investment valuation is determined by the private equity general partner using proprietary information that is unobservable to a market participant.

Interest rate swap liability (see Note 11) valuation is determined using market valuation techniques, including discounted cash flow analysis on the expected cash flow of each agreement. This analysis reflects the contractual terms of the agreement, including the period to maturity, and uses observable market-based inputs, including forward interest rate curves. These observable (Level 2) inputs are available to a market participant.

The securities lending collateral (see Note 2) consists of U.S. and non-U.S. obligations, government agency obligations, corporate debt securities, equities from indexes as approved by the securities lending agent's risk committee, and exchange-traded funds. The collateral and associated liability, included in Level 2, are determined using a mark-to-market valuation that is performed each business day.

Notes to Consolidated Financial Statements (continued)

13. Functional Expenses

The College's expenses relate principally to providing education, research, and clinical services. The functional expenses for these services are recorded directly or are allocated. Operation and maintenance of plant expense, depreciation expense, and interest expense are allocated to the various functional areas of the College based on the square footage of space occupied by each program and supporting service.

For the years ended June 30, expenses related to providing these services are as follows (in thousands):

								2023																																														
				Program	Act	tivities				Supportin	g Ac	tivities																																										
	In	Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Instruction		Research		Research		Medical Services	r		Management and General Fundraising		To	tal Expenses
Direct Salaries, wages, and benefits Services, supplies, and others	\$	148,878 19,747	\$	421,945 235,215	\$	355,706 134,702	\$	965,848 48,838	\$	59,986 28,149	\$	7,446 2,703	\$	1,959,809 469,354																																								
Allocated Operations and maintenance of plant Depreciation and interest		7,473 7,512		44,554 63,459		1,645 12,168		- 66				-		53,672 83,205																																								
Allocated expenses by functional area	\$	183,610	\$	765,173	\$	504,221	\$	1,014,752	\$	88,135	\$	10,149	\$	2,566,040																																								
								2022																																														
				Program	Act	tivities				Supportin	g Ac	tivities																																										
	In	struction	1	Research	Medical		Affiliated Medical Hospital Services Programs		Management and General Fundraising			ndraising	To	tal Expenses																																								
Direct								8						•																																								
Salaries, wages, and benefits Services, supplies, and others	\$	127,122 16,900	\$	401,854 221,948	\$	321,068 96,391	\$	917,243 42,457	\$	49,258 28,348	\$	5,329 2,239	\$	1,821,874 408,283																																								
Allocated Operations and maintenance																																																						
of plant		6,856		44,649		1,855		-		-		-		53,360																																								
Depreciation and interest		7,765		65,681		10,415		58		_		_		83,919																																								
Allocated expenses by		7,705		00,001										05,717																																								

Notes to Consolidated Financial Statements (continued)

14. Employee Benefits

Retirement Plan

Substantially all faculty and staff participate in the College's defined contribution retirement plan (the Plan). The Plan is a core benefit, and contributions are made by the College based on a formula using the employee's base annual salary. During the 2022 fiscal year, the College increased its contribution from 5% to 8%, the contribution level before the COVID-19 pandemic. The College's contribution to the Plan in the years ended June 30, 2023 and 2022 was \$94.9 million and \$81.2 million, respectively. The assets of the Plan are administered by third parties.

15. Leases

The components of lease cost for the fiscal years ended June 30 were as follows (in thousands):

	2023	2022
Finance lease expense:		
Amortization of right-of-use assets	\$ - \$	455
Interest on lease liabilities	_	14
Operating lease expense	14,024	13,233
Total lease cost	\$ 14,024 \$	13,702
Other information:		
Cash paid for amounts included in the measurement of lease		
liabilities:		
Operating cash flows from finance leases	\$ - \$	14
Operating cash flows from operating leases	14,133	12,890
Financing cash flows from finance leases	_	464
Right-of-use assets obtained in exchange for new operating		
lease liabilities	2,867	3,597
Weighted average remaining lease term – finance leases (in		
years)	-	1.75
Weighted average remaining lease term – operating leases		
(in years)	2.59	3.4
Weighted discount rate – finance leases	-%	2.28%
Weighted discount rate – operating leases	2.32%	2.15%

The annual payments based on maturities are reported under commitments and contingencies (see Note 16).

Notes to Consolidated Financial Statements (continued)

16. Commitments and Contingencies

Leases

Annual payments based on maturities of the College's leases as of June 30, 2023 are as follows (in thousands):

	perating Leases
2024	\$ 12,405
2025	9,471
2026	4,356
2027	1,656
2028	587
Thereafter	_
Total undiscounted lease payments	28,475
Less present value adjustment	851
Total discounted lease payments	\$ 27,624

Private Investments

The College has committed to invest in certain private investments over a period of time. The remaining private investment commitment as of June 30, 2023 and 2022 is \$254.9 million and \$299.6 million, respectively. Based on historical patterns, the College expects those amounts will be called into the partnerships for investment over the next three to five years and will be funded by assets of the endowment.

Self-Insurance Program for Professional Liability

Medical malpractice and other actions alleging wrongful conduct and seeking punitive damages are sometimes filed against physicians and the College's affiliated institutions. Since 1977, the College has maintained a medical malpractice self-insurance program (the Program) that, until July 1, 2003, had been supplemented by reinsurance or excess insurance agreements with private insurance companies. Due to sharply increased costs, the College's favorable loss experience, and the positive effects of tort reform legislation, the College, effective July 1, 2003, elected not to

Notes to Consolidated Financial Statements (continued)

16. Commitments and Contingencies (continued)

purchase excess insurance coverage. To date, there has not been a settlement or jury verdict on a case that exceeded the self-insurance retention level that would have been required by the insurance market had the College decided to purchase coverage. The College continued to monitor the insurance market, and during fiscal year 2011, the College started purchasing reinsurance above a \$15.0 million self-insured retention. For the year ended June 30, 2023, the College purchased \$50.0 million in reinsurance above the \$15.0 million per occurrence and \$35.0 million aggregate self-insurance retention. For the year ended June 30, 2022, the College purchased \$50.0 million in reinsurance above the \$15.0 million per occurrence and \$35.0 million aggregate self-insurance retention.

The Program's dedicated account is funded on a quasi-occurrence basis, meaning it is designed to cover the health care provider for an incident that happened while he or she was a participant no matter when the claim or lawsuit was filed, but if the incident upon which the claim or lawsuit is based was not reported to the College's Risk Management office, the matter would be asserted against the coverage in the fiscal year in which reporting occurred. Settlements, judgments, and costs of defense are paid from a pool of a self-insured retention, depending on the year the claim occurred or was filed; several layers of excess coverage are available to respond to them. Funding for the Program has been actuarially determined to the level of \$35.0 million per occurrence and \$70.0 million aggregate for payment of medical malpractice losses and related expenses. For the period from July 1, 2003 through September 1, 2010, all risk of loss is borne by the College.

The College has been named as a defendant in various claims for damages resulting from alleged medical malpractice. The malpractice reserve, which includes reserves for incurred but not reported claims, is \$53.2 million and \$53.9 million as of June 30, 2023 and 2022, respectively.

This liability was determined on a discounted basis without consideration of any insurance recoveries. The discount rate used in calculating the actuarial present value at June 30, 2023 and 2022 was 4%.

Notes to Consolidated Financial Statements (continued)

17. Transactions With Affiliates

Included among the College's Board of Trustees are members from the banking, insurance, and legal communities who provide assistance in the development of policies and programs for the College. Also, certain trustees, faculty, and staff of the College participate in the management of affiliated hospitals with which the College has contracts to provide services. During fiscal years 2023 and 2022, the College paid legal and other professional fees of approximately \$1.9 million and \$2.6 million, respectively, to law firms and other organizations with which several board members are affiliated. A portion of the College's pooled investments with a market value of \$71.6 million and \$77.7 million for fiscal years 2023 and 2022, respectively, was managed by an investment firm affiliated with a trustee. Also, the College has received, from time to time, significant contributions from various board members and corporations with which board members are affiliated. These transactions have been entered into in the normal course of business. The College also enters into transactions in the normal course of business with BSLMC and Baylor Genetics.

18. Financial Responsibility Standards

The Financial Responsibility Standards issued by the United States Department of Education (Department) require an institution to be financially responsible to participate in any Title IV, Higher Education Act program. In February 2020, the Department issued a revised financial responsibility rule that adopts new accounting standards and revises definitions and terminology to calculate the composite score ratios. The regulation is effective for financial statement filings that are submitted to the Department after July 1, 2020.

The notes supporting the Financial Responsibility Supplemental Schedule are presented below:

Note A

Net assets with donor restrictions, as reported on the consolidated balance sheets, are presented below (in thousands):

Temporarily restricted net assets	\$ 623,733
Permanently restricted net assets	 495,143
Total net assets with donor restrictions	\$ 1,118,876

Notes to Consolidated Financial Statements (continued)

18. Financial Responsibility Standards (continued)

Note **B**

Endowments with donor restrictions, as reported in Footnote 7: Endowment Funds, are presented below (in thousands):

Temporarily restricted endowment	\$ 411,388
Permanently restricted endowment	482,318
Total endowments with donor restrictions	\$ 893,706

Note C

All debt obtained for long-term purposes, as reported on the consolidated balance sheets, is limited to the total net property, plant, and equipment for the expendable net assets calculation. The details are presented below (in thousands):

Footnote 10: Bonds and Notes Payable		
Total outstanding balance of bonds and notes payable	\$	566,976
Less deferred issuance costs		(4,052)
Plus original issue premium – 2016 Bond Series		6,905
Total bonds and notes payable		569,829
Footnote 16: Commitments and Contingencies		
Lease liability – operating		27,624
Lease liability – financing		
Total lease liability		27,624
All debt obtained for long-term purposes	\$	597,453
Balance Sheet: Property, plant, and equipment, net		
Property and equipment, net	\$	385,348
Plus leased right-to-use assets – operating	_	25,951
Total property, plant, and equipment, net	\$	411,299

All debt obtained for long-term purposes reported for the expendable net assets calculation is limited to \$411.3 million.

Notes to Consolidated Financial Statements (continued)

18. Financial Responsibility Standards (continued)

Note D

Unsecured related-party receivables are a component of pledges receivable, as reported on the consolidated balance sheets (in thousands):

Unsecured related-party receivables	\$ 15,228
Other pledges receivable	 67,428
Total pledges receivable	\$ 82,656

Note E

For the purpose of calculating the total revenue without donor restrictions and gains without donor restrictions, the investment returns reported under both operating and nonoperating activities on the consolidated statements of activities are aggregated with total revenue and gains without donor restrictions (in thousands):

Operating – investment income, net of expenses	\$ 65,954
Nonoperating – investment income, net of distribution	3
Net investment income	\$ 65,957

Note F

The College's postretirement benefit obligation at June 30, 2023 is \$5.6 million and is recorded in accounts payable and other liabilities of \$245.0 million.

Supplementary Information

Financial Responsibility Supplemental Schedule (In Thousands)

Primary Reserve Ratio

Expendable net assets:

Financial Statement/ Note Footnote Disclosure		Line Item Description	Amount		
	Consolidated balance sheets	Net assets without donor restrictions	\$	408,443	
	Consolidated balance sheets	Net assets with donor restrictions		1,118,876	
Note A	See Note 18	Net assets with donor restrictions: restricted			
		in perpetuity		(495,143)	
Note B	See Note 18	Annuities, term endowments, and life income			
		funds with donor restrictions		(411,388)	
	Not applicable	Intangible assets		_	
	Consolidated balance sheets	Property, plant, and equipment, net		(385,348)	
	Consolidated balance sheets	Leased right-to-use assets – operating		(25,951)	
Note F	See Note 18	Post-employment and defined benefit pension			
		liabilities		5,628	
Note C	See Note 18	All debt obtained for long-term purposes, not			
		to exceed total net property, plant, and			
		equipment		411,299	
Note D	See Note 18	Unsecured related-party receivables		(15,228)	
		Expendable net assets	\$	611,188	

Total expenses without donor restrictions and losses without donor restrictions:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount		
	Consolidated statement of activities	Total operating expenses	\$	2,566,040	
	Consolidated statement of activities	Nonoperating losses without donor restrictions: Other nonoperating activities		90	
		Total expenses without donor restrictions and losses without donor restrictions	\$	2,566,130	

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

Equity Ratio

Modified net assets:

	Financial Statement /				
Note	Footnote Disclosure	Line Item Description	Amount		
	Consolidated balance sheets	Net assets without donor restrictions	\$	408,443	
	Consolidated balance sheets	Net assets with donor restrictions		1,118,876	
	Not applicable	Intangible assets		_	
Note D	See Note 18	Unsecured related-party receivables		(15,228)	
		Modified net assets	\$	1,512,091	

Modified assets:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount		
	Consolidated balance sheets Not applicable	Total assets Intangible assets	\$	2,815,716	
Note D	See Note 18	Unsecured related-party receivables Modified assets	\$	(15,228) 2,800,488	

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

Net Income Ratio

Change in net assets without donor restrictions:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated statement of activities	Change in net assets without donor restrictions	\$ (28,807)
		Change in net assets without donor restrictions	\$ (28,807)

Total revenue without donor restrictions and gains without donor restrictions:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount		
	Consolidated statement of activities	Total operating revenue	\$	2,524,260	
	Consolidated statement of activities			368	
	Consolidated statement of activities	Nonoperating – unrealized gain on interest rate swaps		11,304	
	Consolidated statement of activities	Non-operating – equity in earnings of unconsolidated affiliates – nonoperating		1,388	
Note E	See Note 18	Nonoperating – investment income, net of distribution		3	
		Total revenue without donor restrictions and gains without donor restrictions	\$	2,537,323	

Reports and Schedules Required by the Uniform Guidance



Ernst & Young LLP 1401 McKinney Street Suite 2400 Houston, TX 77010 Tel: +1 713 750 1500 Fax: +1 713 750 1501 ey.com

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Management and The Board of Trustees Baylor College of Medicine

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the consolidated financial statements of Baylor College of Medicine, which comprise the consolidated balance sheet as of June 30, 2023 and the related consolidated statements of activities, and cash flows for the year then ended, and the related notes (collectively referred to as the "financial statements"), and have issued our report thereon dated November 21, 2023.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered Baylor College of Medicine's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Baylor College of Medicine's internal control. Accordingly, we do not express an opinion on the effectiveness of Baylor College of Medicine's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements, on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.



Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Baylor College of Medicine's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

November 21, 2023



Ernst & Young LLP 1401 McKinney Street Suite 2400 Houston, TX 77010 Tel: +1 713 750 1500 Fax: +1 713 750 1501 ey.com

Report of Independent Auditors on Compliance for Each Major Federal and State Program and Report on Internal Control Over Compliance

The Management and the Board of Trustees Baylor College of Medicine

Report of Independent Auditors on Compliance for Each Major Federal and State Program

Opinion on Each Major Federal and State Program

We have audited Baylor College of Medicine's compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on each of BCM's major federal programs for the year ended June 30, 2023 and the types of compliance requirements identified as subject to audit in the Texas Grant Management Standards (TxGMS) that could have a material effect on Baylor College of Medicine's major state programs for the year ended June 30, 2023. Baylor College of Medicine's major federal programs and state programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, Baylor College of Medicine complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal and state programs for the year ended June 30, 2023.

Basis for Opinion on Each Major Federal and State Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) and TxGMS. Our responsibilities under those standards and the Uniform Guidance and TxGMS are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Baylor College of Medicine and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for each major federal and state program. Our audit does not provide a legal determination of Baylor College of Medicine's compliance with the compliance requirements referred to above.



Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to BCM's federal and state programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Baylor College of Medicine's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, Uniform Guidance or TxGMS will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Baylor College of Medicine's compliance with the requirements of each major federal and state program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance and TxGMS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding Baylor College of Medicine's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of Baylor College of Medicine's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance and TxGMS, but not for the purpose of expressing an opinion on the effectiveness of Baylor College of Medicine's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.



Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal and state program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance requirement of a federal and state program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiencies, in internal control over compliance requirement of a federal and state program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* with a type of compliance requirement of a federal and state program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations during our audit, we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance that weaknesses or significant deficiencies in internal control over compliance.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance and TxGMS. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

March 22, 2024

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2023

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF AGRICULTURE AGRICULTURAL RESEARCH-BASIC AND APPLIED RESEARCH		10.001		\$ 16,794,618 \$	_	\$ -	\$ 16,794,618	\$ 69,982
PASS THROUGH AWARD FROM: <i>PRAIRIE VIEW A&M</i> 1890 INSTITUTION CAPACITY BUILDING GRANTS		10.216	2018-38821-27766	32,786	_	_	32,786	_
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI) PASS THROUGH AWARD FROM:		10.310		340,596	-	-	340,596	41,881
TEXAS A&M UNIVERSITY AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	Total ALN 10.310	10.310	M2201139	<u>35,551</u> 376,147			35,551 376,147	41,881
PASS THROUGH AWARD FROM: PRAIRIE VIEW A&M STATE ADMINISTRATIVE MATCHING GRANTS FOR THE SUPPLEMENTAL NUTRITIONAL ASSISTANCE PROGRAM TOTAL DEPARTMENT OF AGRICULTURE		10.561	HHS001018600002	17,203,551		100,734 100,734	100,734 17,304,285	111,863
DEPARTMENT OF COMMERCE MEASUREMENT AND ENGINEERING RESEARCH AND STANDARDS TOTAL DEPARTMENT OF COMMERCE		11.609		4,254 4,254			<u>4,254</u> 4,254	
DEPARTMENT OF DEFENSE PASS THROUGH AWARD FROM: NATIONAL MARROW DONOR PROGRAM BASIC AND APPLIED SCIENTIFIC RESEARCH NATIONAL MARROW DONOR PROGRAM BASIC AND APPLIED SCIENTIFIC RESEARCH	Total ALN 12.300	12.300 12.300	1702 1904	12,518 	-	- -	12,518 5,149 17,667	- - -
MILITARY MEDICAL RESEARCH AND DEVELOPMENT PASS THROUGH AWARD FROM:		12.420		14,952,434	_	-	14,952,434	842,199
CEDARS-SINAI MEDICAL CENTER MILITARY MEDICAL RESEARCH AND DEVELOPMENT CHILDRENS HOSPITAL MEDICAL CENTER, CINCINNATI MILITARY MEDICAL RESEARCH AND DEVELOPMENT		12.420 12.420	W81XWH2110222 W81XWH-20-1-0689	52,140 (4,825)	-	-	52,140 (4,825)	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF DEFENSE (continued)							
PASS THROUGH AWARD FROM (continued):							
GEORGE WASHINGTON UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0672	\$ 50,025 \$	-	\$ –	\$ 50,025	\$ –
THE METHODIST HOSPITAL RESEARCH INSTITUTE							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0285	106,076	_	-	106,076	_
JOHNS HOPKINS UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	DARPA 175076	90,827	-	-	90,827	_
JOHNS HOPKINS UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1910292	27,666	-	-	27,666	-
JOHNS HOPKINS UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W911QY-20-9-12	4,742	-	-	4,742	_
LOYOLA UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0108	3,931	-	-	3,931	-
MOFFITT CANCER CENTER	12.420		1.454			1.456	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0921	1,456	-	-	1,456	_
NOVA SOUTHEASTERN UNIVERSITY	12 420	W01XWII 19 2 00/2	52 502			52 502	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT RESEARCH TRIANGLE INSTITUTE	12.420	W81XWH-18-2-0062	52,592	-	_	52,592	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0077	240,392		_	240,392	
RESEARCH TRIANGLE INSTITUTE	12.420	W81XWH-15-2-0077	240,392	_	-	240,392	_
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-2-0044	414,443			414,443	
RICE UNIVERSITY	12.420	workwii-10-2-00-44	-11,115			+1+,++5	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-09-0016	231,984	_	_	231,984	_
RICE UNIVERSITY	12.120		201,701			201,001	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	DARPA N6001-19-C-4020	643,771	_	_	643,771	_
RICE UNIVERSITY			/· ·			,	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W911NF-23-0017	26,578	_	_	26,578	_
STATE UNIVERSITY OF NEW YORK							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-2-0012	41,759	-	_	41,759	_
STATE UNIVERSITY OF NEW YORK							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-1089	1,134	-	-	1,134	_
TULANE UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0026	125,782	-	-	125,782	-
UNIVERSITY OF ALABAMA AT BIRMINGHAM							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0135	109,179	-	-	109,179	-
UNIVERSITY OF CALIFORNIA, BERKELEY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0586	982	-	-	982	-

DEPARTMENT OF DEPENSIVE (continued) PASS THROUGH AWARD ROM (continued): UNITERATIVE OF DEPENSIVE (continued): UNITERATIVE OF CLIPPENSI AN FEARCESCO MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 WRIXWH-18-2.0442 \$ 22,275 \$ - \$ 22,275 \$ - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 WRIXWH-18-2.0442 \$ 22,275 \$ - \$ 22,275	Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
PASS THROUGH 4WARD FROM (continued): UNITEARY MEDICAL RESEARCH AND DEVELOYMENT 12.420 WSI XWH-16-2.0042 \$ 2.5 s - \$ 2.227 \$ - MILTARY MEDICAL RESEARCH AND DEVELOYMENT 12.420 WSI XWH-16-2.0042 \$ 22.20 - - 25.20 - MILTARY MEDICAL RESEARCH AND DEVELOYMENT 12.420 WSI XWH-16-2.0401 199.162 - - 2.629 - MILTARY MEDICAL RESEARCH AND DEVELOYMENT 12.420 WSI XWH-16-0461 6.291 - - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.291 - 6.391 - 6.301 - - 9.813 19.964 - - 9.900 -	rederal Grantor/Pass-Through Grantor/Program Title	(ALN)	Identifying Number	Cluster	Cluster	Expenditures	Expenditures	Subrecipients
UNITERSITY OF CLUPCONE, SAN PERICENCE 12.420 WS1XW1-18-2-0442 \$ 22.275 \$ - \$ 25.250	DEPARTMENT OF DEFENSE (continued)							
MILTRAY MERICAL RISEARCH AND DEVELOPMENT 12.420 W81XWH-18-2-042 \$ 2.275 \$ -\$ \$ 2.2275 \$ - \$ 2.2275 \$ - \$ 2.2275 \$ - \$ 2.2275 \$ - \$ 2.2275 \$ - \$ 2.2275 \$ - \$ 2.2275 \$ - \$ 2.2520	PASS THROUGH AWARD FROM (continued):							
IDMPERSITY OF CLUPONIA, S.M.FERANCISCO NELLIPONIA, S.M.FERANCISCO Second Sec	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-21-1-0417 25.250 - - 25.250 - DINFERSITY OF CALLFORMAS, AS MF RAVISTOO 199,162 - - 199,162 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0861 6.291 - - 6.291 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0861 6.291 - - 6.291 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-10-0024 95,813 - - 95,813 19,964 MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-10-1-0243 34,156 - - 34,156 - - 34,156 - - 34,156 - - 34,156 - - 34,156 - - 34,156 - - 34,156 - - 34,156 - - 34,156 - - 34,156 - - 34,156 - - 34,156 - - 34,156 - - 34,156 - -	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-2-0042	\$ 22,275 \$	- 5	s –	\$ 22,275	\$ –
UNITERSITY OF CALIFORNIA SAMPRANCISCO UNITERSITY OF CALIFORNIA SAMPRANCISCO UNITERSITY OF PRONSILANA IN DEVELOPMENT 12.420 W81XWH-159-0001 199,162 - - 62.91 - UNITERSITY OF PRONSILANA INITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-10661 6.291 - 62.91 - 62.91 - 62.91 - 62.91 - 62.91 - 62.91 - 62.91 - 62.91 - 62.91 - 62.91 - 62.91 - 62.91 - 62.91 - 62.91 - 62.91 - 95.813 - - 62.91 - 95.813 19.964 19.962 19.962 19.962 </td <td>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-15-90001 199,162 - - 199,162 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-14861 6.291 - 6.291 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-16-0.024 95,813 - - 95,813 19,964 MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-121-0243 34,156 - - 34,156 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-14410 500 - - 500 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-14410 500 - - 6,391 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-21-0187 6,391 - 6,391 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-9021 5,530 - 5,530 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-9021 5,530 - 17,732,549 <td>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</td> <td>12.420</td> <td>W81XWH-21-1-0417</td> <td>25,250</td> <td>_</td> <td>-</td> <td>25,250</td> <td>_</td>	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0417	25,250	_	-	25,250	_
UNITERSTIT OF PENNSTLANA UNITERSTIT OF PAINSTLANA UNITERSTIT OF AND DEVELOPMENT 12 420 W81XWH-19-14861 6.291 - - 6.291 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12 420 W81XWH-16-D-0024 95.813 - - 95.813 19.964 MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-10-D024 95.813 - - 95.813 19.964 MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-10-10243 34,156 - - 95.00 - - 14,156 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1.0410 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - <t< td=""><td>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0861 6,291 - 6,291 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-16-D-0024 95,813 - - 95,813 19,964 THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON 12.420 W81XWH-19-1-043 34,156 - - 43,156 - - 45,07 MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0443 34,156 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 500 - - 530 - - 530 - - 530 - - 10,329 - - 10,329	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-9-0001	199,162	_	-	199,162	_
UNITERSITY OF PITTSRURGH UNITERSITY OF PITTSRURGH UNIT UNI	UNIVERSITY OF PENNSYLVANIA							
MILTARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-16-D-0024 95.813 - - 95.813 19.964 THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON 12.420 W81XWH-11-0-243 34,156 - - 34,156 - MILTARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0410 500 - - 500 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-22-1-0187 6.391 - - 7.424 - - 7.424 <td>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</td> <td>12.420</td> <td>W81XWH-19-1-0861</td> <td>6,291</td> <td>_</td> <td>-</td> <td>6,291</td> <td>_</td>	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0861	6,291	_	-	6,291	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-21-1-0243 34,156 - - 34,156 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0410 500 - - 500 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-22-1-0187 6,391 - - 6,391 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-22-1-0187 6,391 - - 6,391 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-22-1-0187 6,391 - - 23,424 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-9-0021 5,830 - - 23,424 - WASHINGTON (NUTERSITY 12.420 W81XWH-12-1-0288 140,389 - - 140,389 - - 16,2169 862,163 MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0288 140,389 - - 17,732,549 862,163 MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420	UNIVERSITY OF PITTSBURGH							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-12-1-0243 34,156 - - 34,156 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0410 500 - - 500 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0410 500 - - 6.391 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-22-1-0187 6.391 - - 6.391 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 PROPOSAL 67637 23,424 - - 23,424 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-90021 5,830 - - 5,830 - - 140,389 - - 140,389 - - 140,389 - - 17,732,549 862,163 - - 17,732,549 862,163 - - 140,389 - - 140,389 - - 160,389 - - 17,732,549 862,163 - - 17,732,549 862,163 - - 140,389 <td>MILITARY MEDICAL RESEARCH AND DEVELOPMENT</td> <td>12.420</td> <td>W81XWH-16-D-0024</td> <td>95,813</td> <td>_</td> <td>-</td> <td>95,813</td> <td>19,964</td>	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024	95,813	_	-	95,813	19,964
THE UNITERSITY OF TEXAS MD ANDERSON CANCER CENTER 12.420 W81XWH-19-10410 500 - - 500 - THE UNITERSITY OF TEXAS MD ANDERSON CANCER CENTER 12.420 W81XWH-19-10410 500 - - 500 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-22-10187 6.391 - - 6.391 - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 6.391 - - 12.420 W81XWH-20-9021 5.830 - - 18.383 - - 18.383 - - 18.383 - - 17.732,549 862.163 - - 17.732,549 862.163 - - 17.732,549 862.163	THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0410 500 - - 500 - THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 12.420 W81XWH-22-1-0187 6,391 - - 6,391 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-22-1-0187 23,424 - - 23,424 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 PROPOSAL 67637 23,424 - - 23,424 - WASHINGTON UNIVERSITY MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-90021 5,830 - - 140,389 - - 140,389 - - 140,389 - - 140,389 - - 17,732,549 862,163 - - 17,732,549 862,163 - - 17,732,549 862,163 - - 140,389 - - 140,389 - - 17,732,549 862,163 - - 17,732,549 862,163 - - 17,732,549 862,163 - - 140,389 - - 140,389	MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0243	34,156	_	-	34,156	-
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-22-1-0187 6.391 - - 6.391 - THE UNIVERSITY OF TEXAS HAALTIN SCIENCE CENTER AT SAN ANTONIO 12.420 PROPOSAL 67637 23,424 - - 23,424 - WASHINGTON UNIVERSITY OF MALKARESARCH AND DEVELOPMENT 12.420 W81XWH-20-9.0021 5,830 - - 5,830 - WILLITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1.0288 140,389 - - 140,389 - - 140,389 - - 17,732,549 - - 17,732,549 - - 17,732,549 - - 17,732,549 - - 17,732,549 - - 17,732,549 - - 17,732,549 - - 17,732,549 - - 17,732,549 - - 17,732,549 - - 17,732,549 - - 16,901 - - 16,901 - - 16,901 - - 16,901 - - 16,901 - - -								
MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-22-1-0187 6,391 - - 6,391 - THE UNIVERSITY OF TEXAS MEALTH SCIENCE CENTER AT SAN ANTONIO 12.420 PROPOSAL 67637 23,424 - - 23,424 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-9-0021 5,830 - - 5,830 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-9-0021 5,830 - - 5,830 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-9-0021 5,830 - - 140,389 - - 140,389 - - 17,732,549 862,163 MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0288 140,389 - - 17,732,549 862,163 MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-0023 128,341 - - 17,732,549 862,163 PASS THROUGH AWARD FROM: 12.500 HU001-17-2-0023 128,341 - - 128,341 - AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM 12.800		12.420	W81XWH-19-1-0410	500	-	-	500	-
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 PROPOSAL 67637 23,424 - - 23,424 - WASHINGTON UNIVERSITY MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-9-0021 5,830 - - 5,830 - WILLIARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0288 140,389 - - 140,389 - - 140,389 - - 140,389 - - 140,389 - - 140,389 - - 17,732,549 862,163 PASS THROUGH AWARD FROM: - - - 140,389 - - 17,732,549 862,163 NUTFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS 12.750 HU001-17-2-0023 128,341 - - 128,341 - AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM 12.800 158,190 - - 158,190 56,900 PASS THROUGH AWARD FROM: - - 128,100 158,190 - - 158,190 56,900 PASS THROUGH AWARD FROM:								
MILITARY MEDICAL RESEARCH AND DEVELOPMENT12.420PROPOSAL 6763723,42423,424-WASHINGTON UNIVERSITYMILITARY MEDICAL RESEARCH AND DEVELOPMENT12.420W81XWH-20-9-00215,8305,830-MILITARY MEDICAL RESEARCH INSTITUTE12.420W81XWH-19-1-0288140,389140,389-MILITARY MEDICAL RESEARCH AND DEVELOPMENT12.420W81XWH-19-1-0288140,389140,389-MILITARY MEDICAL RESEARCH AND DEVELOPMENT12.420W81XWH-19-1-0288140,389140,389-PASS THROUGH AWARD FROM: HENRY JACKSON FOUNDATION UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS12.750HU001-17-2-0023128,341128,341-AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM12.800158,190158,19056,900PASS THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT12.910N66001-17-C-4002(50,238)(50,238)-		12.420	W81XWH-22-1-0187	6,391	-	-	6,391	-
WASHINGTON UNIVERSITY MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-9-0021 5,830 - - 5,830 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0288 140,389 - - 140,389 - MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-19-1-0288 140,389 - - 140,389 - PASS THROUGH AWARD FROM: HENRY JACKSON FOUNDATION UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS 12.750 HU001-17-2-0023 128,341 - - 128,341 - AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM 12.800 158,190 - - 158,190 56,900 PASS THROUGH AWARD FROM: HENRY JACKSON FOUNDATION UNIFORMED SERVICES UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 N66001-17-C-4002 (50,238) - - 158,190 - - 56,900								
MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH-20-9-0021 5,830 - - 5,830 - MILITARY MEDICAL RESEARCH INSTITUTE 12.420 W81XWH-19-10288 140,389 - - 140,389 - - 140,389 - - 140,389 - - 140,389 - - 140,389 - - 140,389 - - 17,732,549 862,163 PASS THROUGH AWARD FROM: HENRY JACKSON FOUNDATION UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS 12.750 HU001-17-2-0023 128,341 - - - 128,341 - AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM 12.800 158,190 - - 158,190 56,900 PASS THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 N66001-17-C-4002 (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - -		12.420	PROPOSAL 67637	23,424	-	-	23,424	-
WILLIAM BEAUMONT HOSPITAL RESEARCH INSTITUTE MILITARY MEDICAL RESEARCH AND DEVELOPMENT12.420W81XWH-19-1-0288140,389140,389-PASS THROUGH AWARD FROM: HENRY JACKSON FOUNDATION UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS12.750HU001-17-2-0023128,341128,341-AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM12.800158,190158,19056,900PASS THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT12.910N66001-17-C-4002(50,238)(50,238)-								
MILITARY MEDICAL RESEARCH AND DEVELOPMENT12.420W81XWH-19-1-0288140,389140,389-PASS THROUGH AWARD FROM: HENRY JACKSON FOUNDATION UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS12.750HU001-17-2-0023128,341128,341-AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM12.800158,190158,19056,900PASS THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT12.910N66001-17-C-4002(50,238)(50,238)-		12.420	W81XWH-20-9-0021	5,830	_	-	5,830	_
Total ALN 12.42017,732,54917,732,549862,163PASS THROUGH AWARD FROM: HENRY JACKSON FOUNDATION UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS12.750HU001-17-2-0023128,341128,341-AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM12.800158,190158,19056,900PASS THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT12.910N66001-17-C-4002(50,238)(50,238)-								
PASS THROUGH AWARD FROM: HENRY JACKSON FOUNDATION UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS 12.750 HU001-17-2-0023 128,341 - - 128,341 - AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM 12.800 158,190 - - 158,190 56,900 PASS THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 N66001-17-C-4002 (50,238) - - (50,238) -	MILITARY MEDICAL RESEARCH AND DEVELOPMENT		W81XWH-19-1-0288		-	_		-
HENRY JACKSON FOUNDATION UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS12.750HU001-17-2-0023128,341-128,341-AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM12.800158,190158,19056,900PASS THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT12.910N66001-17C-4002(50,238)(50,238)-		Total ALN 12.420		17,732,549	-	_	17,732,549	862,163
HENRY JACKSON FOUNDATION UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS12.750HU001-17-2-0023128,341-128,341-AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM12.800158,190158,19056,900PASS THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT12.910N66001-17C-4002(50,238)(50,238)-	PASS THROUGH AWARD FROM							
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS12.750HU001-17-2-0023128,341-128,341-AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM12.800158,190158,19056,900PASS THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT12.910N66001-17-C-4002(50,238)(50,238)-								
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM 12.800 – – – 158,190 56,900 PASS THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 N66001-17-C-4002 (50,238) – – (50,238) –		12 750	HU001-17-2-0023	128 341	_	_	128 341	_
PASS THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 N66001-17-C-4002 (50,238) (50,238) -		12.750	110001 17 2 0025	120,511			120,511	
THE TRUSTEES OF COLUMBLA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 N66001-17-C-4002 (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - - (50,238) - - - (50,238) -	AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800		158,190	_	_	158,190	56,900
THE TRUSTEES OF COLUMBLA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 N66001-17-C-4002 (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - (50,238) - - - (50,238) - - - (50,238) -				,			,	,
RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 N66001-17-C-4002 (50,238) (50,238) -	PASS THROUGH AWARD FROM:							
	THE TRUSTEES OF COLUMBIA UNIVERSITY							
TOTAL DEPADTMENT OF DEFENSE 17.096 500 010.062	RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	N66001-17-C-4002		-	_	<u> </u>	-
17,200,507 17,200,507 17,200,507 17,200,507	TOTAL DEPARTMENT OF DEFENSE			17,986,509	-	-	17,986,509	919,063

Federal Grantor/Pass-Through Grantor/Program Title	Assista Listin Numb (ALN	ng er Pass-Through Entity/Other	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT LEAD-BASED PAINT HAZARD CONTROL IN PRIVATELY-OWNED HOUSING TOTAL DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT	14.90	00	<u>\$ 16,685</u> 16,685	<u>s –</u> –	<u>\$ </u>	\$ 16,685 16,685	\$
DEPARTMENT OF JUSTICE PASS THROUGH AWARD FROM: <i>CATHOLIC HEALTH INITIATIVES NATIONAL FOUNDATION</i> SERVICES FOR TRAFFICKING VICTIMS	16.32	2019-VT-BX0091	-	-	67,448	67,448	_
PASS THROUGH AWARD FROM: UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER – NORTH TEXAS NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION AND DEVELOPMENT PROJECT GRANTS T	16.56 otal ALN 16.560	60 2022-GG-04414-MUMU	<u>2,496</u> 2,496			<u>2,496</u> 2,496	
PASS THROUGH AWARD FROM: <i>SANTA MARIA HOSTEL</i> SECOND CHANCE ACT REENTRY INITIATIVE TOTAL DEPARTMENT OF JUSTICE	16.81	2 15PBJA-22-GG-01768-SCAX	2,496		11,968 79,416	11,968 81,912	
OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION OCCUPATIONAL SAFETY AND HEALTH SUSAN HARWOOD TRAINING GRANTS TOTAL OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION	17.50	12	14,565 14,565	-	-	14,565 14,565	
DEPARTMENT OF THE TREASURY PASS THROUGH AWARD FROM: SANTA MARIA HOSTEL COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY	21.02	7 ARPA-LFRF			95,637	95.637	
THE UNIVERSITY OF TEXAS AT AUSTIN COVID-19 CORONA VIRUS STATE AND LOCAL FISCAL RECOVERY THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	21.02	2021-CS-21027	_	_	3,202,450	3,202,450	_
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY DEPARTMENT OF THE TREASURY	21.02	OOG 4546301			576,489 3,874,576	576,489 3,874,576	

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION PASS THROUGH AWARD FROM: TEXAS TECH UNIVERSITY								
SCIENCE EXPLORATION PASS THROUGH AWARD FROM:		43.001 43.003	80NSSC22K0250	\$ 209,435 14,944,044	\$	\$ -	\$ 209,435 14,944,044	\$
MASSACHUSETTS GENERAL HOSPITAL EXPLORATION UNIVERSITY OF WASHINGTON		43.003	80NSSC20K0841	26,284	_	_	26,284	-
EXPLORATION	Total ALN 43.003	43.003	NNX16AE78G	55,273 15,025,601	-	-	55,273 15,025,601	8,379,584
PASS THROUGH AWARD FROM: CENTER FOR ADVANCEMENT OF SCIENCE IN SPACE SPACE OPERATIONS		43.007	GA-2018-270	25,794	-	-	25,794	-
PASS THROUGH AWARD FROM: MEDICAL UNIVERSITY OF SOUTH CAROLINA OFFICE OF STEM ENGAGEMENT TOTAL NATIONAL AERONAUTICS AND SPACE ADMINISTRATION		43.008	80NSSC21M0149	8,759 15,269,589			8,759 15,269,589	8,379,584
NATIONAL ENDOWMENT FOR THE HUMANITIES PASS THROUGH AWARD FROM: ASSOCIATION OF AMERICAN MEDICAL COLLEGES PROMOTION OF THE HUMANITIES TEACHING AND LEARNING RESOURCES AND CURRICULUM DEVELOPMENT TOTAL NATIONAL ENDOWMENT FOR THE HUMANITIES		45.162	AH-268665			2,482 2,482	2,482 2,482	
NATIONAL SCIENCE FOUNDATION ENGINEERING GRANTS PASS THROUGH AWARD FROM:		47.041		128,610	_	-	128,610	-
NORTHWESTERN UNIVERSITY ENGINEERING GRANTS TEXAS A&M UNIVERSITY		47.041	NSF-1830961	57,396	-	-	57,396	_
ENGINEERING GRANTS THE UNIVERSITY OF TEXAS AT AUSTIN		47.041	NSF-2037383	18,097	-	-	18,097	-
ENGINEERING GRANTS	Total ALN 47.041	47.041	NSF-00000183	20,693 224,796	-		20,693 224,796	

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
NATIONAL SCIENCE FOUNDATION (continued) MATHEMATICAL AND PHYSICAL SCIENCES PASS THROUGH AWARD FROM: RICE UNIVERSITY		47.049		\$ 2,633,544 \$	-	\$ –	\$ 2,633,544	\$ 1,316,770
MATHEMATICAL AND PHYSICAL SCIENCES UNIVERSITY OF HOUSTON		47.049	PHY-2019745	726,234	-	-	726,234	-
MATHEMATICAL AND PHYSICAL SCIENCES WASHINGTON UNIVERSITY		47.049	DBI-1707400	555,529	-	-	555,529	84,947
MATHEMATICAL AND PHYSICAL SCIENCES		47.049	DGE-1745038	42,999	_	-	42,999	_
	Total ALN 47.049			3,958,306	-	-	3,958,306	1,401,717
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING PASS THROUGH AWARD FROM: <i>RICE UNIVERSITY</i>		47.070		324,996	_	-	324,996	-
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Total ALN 47.070	47.070	CNS-1801865	10,274 335,270			10,274 335,270	
BIOLOGICAL SCIENCES PASS THROUGH AWARD FROM: CARNEGIE INSTITUTE OF WASHINGTON		47.074		490,550	-	-	490,550	50,309
BIOLOGICAL SCIENCES RICE UNIVERSITY		47.074	DBI-2213983	33,539	-	-	33,539	-
BIOLOGICAL SCIENCES UNIVERSITY OF ILLINOIS AT CHICAGO		47.074	IOS-1856742	(136)	-	-	(136)	-
BIOLOGICAL SCIENCES UNIVERSITY OF MICHIGAN		47.074	NSF 2107527	10,492	-	-	10,492	-
BIOLOGICAL SCIENCES		47.074	NSF 1935265	131,530	_	-	131,530	_
	Total ALN 47.074			665,975	-	-	665,975	50,309
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES		47.075		149,540	-	-	149,540	-
EDUCATION AND HUMAN RESOURCES		47.076		164,738	_	-	164,738	_
TOTAL NATIONAL SCIENCE FOUNDATION				5,498,625	-	-	5,498,625	1,452,026

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF EDUCATION FEDERAL WORK-STUDY PROGRAM		84.033		\$ –	\$ 64,591	\$ -	\$ 64,591	\$
FEDERAL PERKINS LOANS		84.038		_	1,010,256	-	1,010,256	_
PASS THROUGH AWARD FROM: HOUSTON INDEPENDENT SCHOOL DISTRICT		04.175				20 102	20,102	
MAGNET SCHOOLS ASSISTANCE MAGNET SCHOOLS ASSISTANCE Te	otal ALN 84.165	84.165 84.165	Rusk Academy Ryan Academy			28,193 38,896 67,089	28,193 38,896 67,089	
FEDERAL DIRECT STUDENT LOANS		84.268		-	22,564,693	-	22,564,693	-
EDUCATION STABILIZATION FUND GOVERNOR'S EMERGENCY EDUCATION RELIEF (GEER) FUND GOVERNOR'S EMERGENCY EDUCATION RELIEF (GEER II) FUND		84.425C 84.425C			-	47,138 134,361	47,138 134,361	
TOTAL DEPARTMENT OF EDUCATION	otal ALN 84.425				23,639,540	181,499 248,588	181,499 23,888,128	
DEPARTMENT OF HEALTH AND HUMAN SERVICES PASS THROUGH AWARD FROM: ARKANSAS CHILDREN'S HOSPITAL BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES – PREVENTION AND SURVEILLANCE		93.073	DD001285	29,746			29,746	
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES – PREVENTION		95.075	DD001285	29,740	_	_	29,740	_
AND SURVEILLANCE To	otal ALN 93.073	93.073	HHS000962600001	13,908 43,654	-	-	13,908 43,654	
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH		93.077		84,440	-	_	84,440	-
PASS THROUGH AWARD FROM: THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH		93.080	U27 DD000020	35,794	_	_	35,794	_
PASS THROUGH AWARD FROM: UNIVERSITY OF MARYLAND PREVENTION OF DISEASE, DISABILITY AND DEATH BY INFECTIOUS DISEASES		93.084	CK000615-01-00	12,889	_	_	12,889	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
FOOD AND DRUG ADMINISTRATION-RESEARCH PASS THROUGH AWARD FROM:	93.103		\$ 1,336,757 \$	-	\$ -	\$ 1,336,757	\$ 558,107
DUKE UNIVERSITY							
FOOD AND DRUG ADMINISTRATION-RESEARCH	93.103	FD006298	(5,845)	_	_	(5,845)	_
UNIVERSITY OF FLORIDA							
FOOD AND DRUG ADMINISTRATION-RESEARCH	93.103	FD005407	26,961	-	-	26,961	_
Total ALN 93.10	13		1,357,873	-	—	1,357,873	558,107
PASS THROUGH AWARD FROM: CITY OF HOUSTON							
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SED	93.104	SM082256	760,853	-	-	760,853	274,485
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		_	_	1,008,276	1,008,276	31,871
PASS THROUGH AWARD FROM:							
ASSOCIATION OF UNIVERSITY CENTERS ON DISABILITIES	02.110	101 0000 22			1.050	1.050	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	93.110	#01-8800-23	-	-	1,950	1,950	-
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MC43532	_	_	343,592	343,592	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MC24051-PROGRAM INCOME	-	-	1,602,904	1,602,904	-
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS Total ALN 93.11	93.110	H30MC24051	_	-	31,198 2,987,920	31,198 2,987,920	31,871
Total ALN 93.11	.0		_	_	2,987,920	2,987,920	51,8/1
COVID-19 ENVIRONMENTAL HEALTH	93.113		179,433	_	_	179,433	_
ENVIRONMENTAL HEALTH	93.113		4,100,024	-	-	4,100,024	1,239,494
PASS THROUGH AWARD FROM:							
BOSTON CHILDREN'S HOSPITAL ENVIRONMENTAL HEALTH	93.113	ES034713	54,034			54,034	
COLORADO STATE UNIVERSITY	95.115	E3034715	54,054	_	_	54,054	_
ENVIRONMENTAL HEALTH	93.113	ES029766	674	_	_	674	_
THE METHODIST HOSPITAL RESEARCH INSTITUTE							
ENVIRONMENTAL HEALTH	93.113	ES031511	141,755	-	-	141,755	-
MAINE HEALTH ENVIRONMENTAL HEALTH	93.113	ES030101	2.017	_	_	2.017	_
			,,			,,-,	

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
SAM HOUSTON STATE UNIVERSITY							
ENVIRONMENTAL HEALTH	93.113	ES032149	\$ 3,856 \$	5 – 5	\$ –	\$ 3,856	\$ -
TEXAS A&M UNIVERSITY							
ENVIRONMENTAL HEALTH	93.113	ES033601	252,435	_	-	252,435	_
UNIVERSITY OF MASSACHUSETTS							
ENVIRONMENTAL HEALTH	93.113	ES032552	97,053	_	-	97,053	_
UNIVERSITY OF CHICAGO							
ENVIRONMENTAL HEALTH	93.113	ES028615	12,335	_	-	12,335	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
ENVIRONMENTAL HEALTH	93.113	ES031063	142,569	-	-	142,569	-
THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON							
ENVIRONMENTAL HEALTH	93.113	ES016302	15,673	-	-	15,673	_
	Total ALN 93.113		5,001,858	-	-	5,001,858	1,239,494
ORAL DISEASES AND DISORDERS RESEARCH	93,121		2,126,975			2,126,975	16,488
PASS THROUGH AWARD FROM:	95.121		2,120,975	_	-	2,120,975	10,488
THE METHODIST HOSPITAL RESEARCH INSTITUTE							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE021863	604			604	
UNIVERSITY OF NORTH CAROLINA	93.121	DE021805	004	—	-	004	_
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE029754	44,006			44,006	
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	95.121	DE029734	44,000	_	_	44,000	_
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE025248	7,238			7,238	
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	93.121	DE023248	7,238	_	_	7,238	_
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE030104	96,163	_	_	96,163	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	75.121	BE050101	50,105			90,105	
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE030140	1,986	_	_	1,986	_
UNIVERSITY OF UTAH	,,,,,,	DE050110	1,,,00			1,000	
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE027493	8,000	_	_	8,000	_
UNIVERSITY OF SOUTH FLORIDA			-,			-,	
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE026480	(6,356)	_	_	(6,356)	_
RICE UNIVERSITY			(-))			(-,)	
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE021798	31,831	_	_	31,831	_
FRED HUTCHINSON CANCER RESEARCH CENTER							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE027850	43,862	_	_	43,862	_
	Total ALN 93.121		2,354,309	_	_	2,354,309	16,488

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) EMERGENCY MEDICAL SERVICES FOR CHILDREN PASS THROUGH AWARD FROM:	93.127		\$ - \$	6 – 5	\$ 124,054	\$ 124,054	\$ -
COLUMBIA UNIVERSITY EMERGENCY MEDICAL SERVICES FOR CHILDREN UNIVERSITY OF BUFFALO	93.127	MC00007	-	_	164,184	164,184	-
EMERGENCY MEDICAL SERVICES FOR CHILDREN UNIVERSITY OF TEXAS DELL MEDICAL SCHOOL	93.127	MC33154	-	-	133,297	133,297	-
EMERGENCY MEDICAL SERVICES FOR CHILDREN Total ALN 93.127	93.127	MC37471			309,766 731,301	309,766 731,301	
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS PASS THROUGH AWARD FROM: HARRIS COUNTY	93.136		470,195	_	_	470,195	153,261
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS MICHIGAN PUBLIC HEALTH INSTITUTE	93.136	CE924976	40,299	_	_	40,299	_
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS Total ALN 93.136	93.136	NCFRP/CDC	17,412 527,906		-	17,412 527,906	153,261
NIEHS SUPERFUND HAZARDOUS SUBSTANCES - BASIC RESEARCH AND EDUCATION PASS THROUGH AWARD FROM: TEXAS A&M UNIVERSITY	93.143		1,865,581	-	-	1,865,581	673,236
NIEHS SUPERFUND HAZARDOUS SUBSTANCES - BASIC RESEARCH AND EDUCATION Total ALN 93.143	93.143	ES027704	(1,241) 1,864,340		_	(1,241) 1,864,340	673,236
HIV-RELATED TRAINING AND TECHNICAL ASSISTANCE PASS THROUGH AWARD FROM: UNIVERSITY OF NEW MEXICO	93.145	HA33225	378,242	_	_	378,242	4,823
CENTERS OF EXCELLENCE	93.157		17,598	_	_	17,598	-
HUMAN GENOME RESEARCH PASS THROUGH AWARD FROM:	93.172		16,417,957	-	-	16,417,957	3,496,452
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH HUMAN GENOME RESEARCH JOHNS HOPKINS UNIVERSITY	93.172	HG011711	221,513	_	_	221,513	_
HUMAN GENOME RESEARCH	93.172	HG006542	1	-	-	1	-

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
PASS THROUGH AWARD FROM (continued):								
RICE UNIVERSITY								
HUMAN GENOME RESEARCH		93.172	HG012206	\$ 38,344 \$		\$ –	\$ 38,344	\$ -
UNIVERSITY OF COLORADO BOULDER								
HUMAN GENOME RESEARCH		93.172	HG011774	17,067	_	-	17,067	-
UNIVERSITY OF FLORIDA HUMAN GENOME RESEARCH		93.172	HG010925	3,072			3,072	
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL		93.172	116010925	3,072		_	5,072	_
HUMAN GENOME RESEARCH		93.172	HG009650	108,591	_	_	108,591	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							,	
HUMAN GENOME RESEARCH		93.172	HG011803	176,962	_	-	176,962	-
HARVARD MEDICAL SCHOOL								
HUMAN GENOME RESEARCH		93.172	HG011016	467,813	-	-	467,813	-
YALE UNIVERSITY								
HUMAN GENOME RESEARCH	T (1 ALNI 02 172	93.172	HG012108	(15)	_	-	(15)	-
	Total ALN 93.172			17,451,305	-	_	17,451,305	3,496,452
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS		93.173		3,170,055	_	_	3,170,055	102,376
PASS THROUGH AWARD FROM:				-,,			-,-,-,	,
UNIVERSITY OF SOUTHERN CALIFORNIA								
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS		93.173	DC014450	23,163	_	-	23,163	_
UNIVERSITY OF COLORADO DENVER								
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS		93.173	DC019642	37,326	_	-	37,326	_
THE UNIVERSITY OF TEXAS AT AUSTIN		93.173	DC010570	29 (2)			20 (2)	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Total ALN 93.173	93.173	DC018579	38,636 3,269,180		_	38,636 3,269,180	102,376
	10tal ALIN 93.175			5,209,180		—	5,209,180	102,570
COVID-19 IMMUNIZATION RESEARCH. DEMONSTRATION. PUBLIC INFORMATION								
TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS		93.185		372,422	_	_	372,422	_
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION TRAINING								
AND CLINICAL SKILLS IMPROVEMENT PROJECTS		93.185		1,246,857	_	-	1,246,857	_
	Total ALN 93.185			1,619,279	-	-	1,619,279	_
		02.196		200.007			200.007	
NATIONAL RESEARCH SERVICE AWARD IN PRIMARY CARE MEDICINE		93.186		388,096	-	-	388,096	-

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH PASS THROUGH AWARD FROM:		93.213		\$ 68,816 \$	\$ - \$;	68,816	\$ –
TEXAS A&M HEALTH SCIENCE CENTER RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH UNIVERSITY OF ALABAMA AT BIRMINGHAM		93.213	AT011587	103,582	-	-	103,582	13,705
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	Total ALN 93.213	93.213	AT010517	7,225			7,225 179,623	13,705
NATIONAL RESEARCH SERVICE AWARDS HEALTH SERVICES RESEARCH TRAINING		93.225		73,819	-	-	73,819	-
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES PASS THROUGH AWARD FROM: MEDSTAR RESEARCH INSTITUTE		93.226		2,955,223	_	-	2,955,223	333,013
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES STANFORD UNIVERSITY		93.226	HS029356	38,970	-	-	38,970	-
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES UNIVERSITY OF MICHIGAN		93.226	HS027990	11,848	-	-	11,848	_
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES WASHINGTON UNIVERSITY		93.226 93.226	HS024953 HS026622	(15) 26,858	-	-	(15) 26,858	-
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	Total ALN 93.226	93.226	HS026742	3,721 3,036,605	-	-	3,721 3,036,605	333,013
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH		93.233		1,604,538	-	-	1,604,538	_
MENTAL HEALTH RESEARCH GRANTS PASS THROUGH AWARD FROM: ALLEN BRAIN INSTITUTE		93.242		10,397,739	-	-	10,397,739	2,120,539
MENTAL HEALTH RESEARCH GRANTS ALLEN BRAIN INSTITUTE		93.242	MH114830	316,840	-	-	316,840	130,948
MENTAL HEALTH RESEARCH GRANTS PENDLETON BRADLEY HOSPITAL		93.242	MH130981	460,151	-	-	460,151	-
MENTAL HEALTH RESEARCH GRANTS CHILDREN'S HOSPITAL OF PHILADELPHIA		93.242	MH128595	25,182	-	_	25,182	-
MENTAL HEALTH RESEARCH GRANTS UNIVERSITY OF COLORADO DENVER		93.242	MH125958	462,531	-	-	462,531	_
MENTAL HEALTH RESEARCH GRANTS		93.242	MH121362	116,541	-	-	116,541	-

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
PASS THROUGH AWARD FROM (continued):								
UNIVERSITY OF HOUSTON								
MENTAL HEALTH RESEARCH GRANTS		93.242	MH125039	\$ 12,574 \$	5 –	\$ -	\$ 12,574	\$ -
UNIVERSITY OF ILLINOIS								
MENTAL HEALTH RESEARCH GRANTS		93.242	MH131248	6,709	-	-	6,709	_
UNIVERSITY OF PENNSYLVANIA								
MENTAL HEALTH RESEARCH GRANTS		93.242	MH129439	92,501	-	-	92,501	-
THE UNIVERSITY OF TEXAS AT AUSTIN								
MENTAL HEALTH RESEARCH GRANTS		93.242	MH127842	43,875	_	-	43,875	-
THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON								
MENTAL HEALTH RESEARCH GRANTS		93.242	MH100930	107,921	-	-	107,921	-
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI								
MENTAL HEALTH RESEARCH GRANTS		93.242	MH111932	253,346	-	-	253,346	-
UNIVERSITY OF TENNESSEE		02.242		10.044			10.044	
MENTAL HEALTH RESEARCH GRANTS		93.242	MH112143	18,844	-	-	18,844	_
UNIVERSITY OF NORTH CAROLINA		02.242	NU120420	00.277			00.2/7	5.05/
MENTAL HEALTH RESEARCH GRANTS		93.242 93.242	MH128439 MH118249	89,367	-	-	89,367	5,856
MENTAL HEALTH RESEARCH GRANTS		93.242 93.242	MH118249 MH124526	14,402	-	-	14,402	-
MENTAL HEALTH RESEARCH GRANTS		93.242	MH124526	31,177	-	-	31,177	-
UNIVERSITY OF WISCONSIN MENTAL HEALTH RESEARCH GRANTS		93.242	MH123422	182,519			182,519	
MENTAL HEALTH RESEARCH GRANTS	Total ALN 93.242	93.242	MH123422	12.632.219	-		12,632,219	2,257,343
	10tal ALN 95.242			12,032,219	_	_	12,032,219	2,237,343
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES – PROJECTS OF REGIONAL &								
NATIONAL SIGNIFICANCE		93.243		_	_	664,527	664,527	177,185
PASS THROUGH AWARD FROM:		JJ.24J				004,527	004,527	177,105
AMERICAN ACADEMY OF ADDICTION PSYCHIATRY								
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &								
NATIONAL SIGNIFICANCE		93.243	T1081358	_	_	24,399	24,399	_
BEHAVIORAL HEALTH SOLUTIONS						,	,	
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &								
NATIONAL SIGNIFICANCE		93.243	SP082149	_	_	29,829	29,829	_
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &						- ,		
NATIONAL SIGNIFICANCE		93.243	TI080684	_	_	39,962	39,962	_
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &								
NATIONAL SIGNIFICANCE		93.243	TI085219	_	_	60,829	60,829	_
							,	

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) PASS THROUGH AWARD FROM (continued): CENTER FOR RECOVERY AND WELLNESS RESOURCES SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE THE UNIVERSITY OF TEXAS AT SAN ANTONIO		93.243	T1080624	S –	\$ –	\$ 142,175	\$ 142,175	\$
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE CITY OF HOUSTON NATIONAL SIGNIFICANCE		93.243	TI026787	-	_	14,633	14,633	_
WATOWAL SIGNIFICATEL	Total ALN 93.243	93.243	SP080300		-	90,093 1,066,447	90,093 1,066,447	177,185
OCCUPATIONAL SAFETY AND HEALTH PROGRAM PASS THROUGH AWARD FROM: NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION		93.262		246,311	-	-	246,311	-
OCCUPATIONAL SAFETY AND HEALTH PROGRAM UNIVERSITY OF PITTSBURGH		93.262	OH012201	2,536	-	-	2,536	-
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	Total ALN 93.262	93.262	OH009077	119,439 368,286	-		119,439 368,286	
ALCOHOL RESEARCH PROGRAMS PASS THROUGH AWARD FROM: <i>YALE UNIVERSITY</i>		93.273		768,836	-	-	768,836	218,253
ALCOHOL RESEARCH PROGRAMS VANDERBILT UNIVERSITY		93.273	AA020790	(169)	-	-	(169)	_
ALCOHOL RESEARCH PROGRAMS UNIVERSITY OF LOUISVILLE		93.273	AA029542	21,982	-	-	21,982	-
ALCOHOL RESEARCH PROGRAMS SCRIPPS RESEARCH INSTITUTE		93.273	AA026225	38,073	-	-	38,073	-
ALCOHOL RESEARCH PROGRAMS	Total ALN 93.273	93.273	AA021667	55,197 883,919	-	-	55,197 883,919	218,253

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster E	Other Federal xpenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		\$ 556,604 \$	- \$		\$ 556,604	\$ -
PASS THROUGH AWARD FROM:							
MASSACHUSETTS GENERAL HOSPITAL							
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA047933	214,969	_	_	214,969	-
SCRIPPS RESEARCH INSTITUTE							
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA046170	64,216	-	-	64,216	_
UNIVERSITY OF ALABAMA AT BIRMINGHAM							
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA056673	104,797	-	-	104,797	-
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA053241	64,787	-	-	64,787	-
UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON							
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA040621	47,733	-	-	47,733	-
Total ALN 93	.279		1,053,106	_	-	1,053,106	_
CENTERS FOR DISEASE CONTROL AND PREVENTION INVESTIGATIONS AND TECHNICAL ASSISTANCE	93.283		106,206	_	_	106,206	_
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE							
HUMAN HEALTH	93.286		1,061,786	_	_	1,061,786	251,156
PASS THROUGH AWARD FROM:							
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI							
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE							
HUMAN HEALTH	93.286	EB028520	730	_	_	730	-
JOHNS HOPKINS UNIVERSITY							
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE							
HUMAN HEALTH	93.286	EB028156	58,349	-	-	58,349	-
RICE UNIVERSITY							
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE							
HUMAN HEALTH	93.286	EB030772	18,709	-	-	18,709	-
TEXAS A&M UNIVERSITY							
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE	02.200	50000045	2.420				
HUMAN HEALTH	93.286	EB025945	3,428	_	-	3,428	-
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB029064	61,931			61,931	
	93.280	EB029004	01,931	-	-	01,931	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) PASS THROUGH AWARD FROM (continued): UNIVERSITY OF SOUTHERN CALIFORNIA							
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH WAYNE STATE UNIVERSITY	93.286	EB032169	\$ 92,888	§ – S	S –	\$ 92,888	\$ –
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH Total ALN 93	93.286 .286	E026453	<u>112,261</u> 1,410,082			112,261 1,410,082	251,156
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH PASS THROUGH AWARD FROM:	93.307		3,377,484	_	-	3,377,484	959,251
UNIVERSITY OF ARIZONA MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH HOWARD UNIVERSITY	93.307	MD014127	17,666	-	_	17,666	_
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH TEXAS SOUTHERN UNIVERSITY	93.307	MD007597	90,207	_	-	90,207	-
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH THE UNIVERSITY OF TEXAS AT AUSTIN	93.307	MD007605	7,493	-	-	7,493	-
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH Total ALN 93	93.307 .307	MD009675	16,985 3,509,835	-		16,985 3,509,835	959,251
COVID-19 TRANS-NIH RESEARCH SUPPORT TRANS-NIH RESEARCH SUPPORT PASS THROUGH AWARD FROM:	93.310 93.310		984,597 10,087,700	-	_	984,597 10,087,700	371,256 497,969
BETH ISRAEL DEACONESS MEDICAL CENTER TRANS-NIH RESEARCH SUPPORT HARVARD MEDICAL SCHOOL	93.310	TR002881	336,704	-	-	336,704	_
TRANS-NIH RESEARCH SUPPORT MASSACHUSETTS GENERAL HOSPITAL	93.310	HG007530	6,525	-	_	6,525	-
TRANS-NIH RESEARCH SUPPORT MEDICAL COLLEGE OF WISCONSIN	93.310	OD023253	166,804	-	-	166,804	-
TRANS-NIH RESEARCH SUPPORT RICE UNIVERSITY	93.310	HG010423	79,679	_	-	79,679	-
TRANS-NIH RESEARCH SUPPORT UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAGNE	93.310	HL151545	52,104	-	-	52,104	-
TRANS-NIH RESEARCH SUPPORT	93.310	OD023272	41,367	_	-	41,367	-

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) PASS THROUGH AWARD FROM (continued):								
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER TRANS-NIH RESEARCH SUPPORT WASHINGTON UNIVERSITY		93.310	OD032581	\$ 429,281 \$	5 – 5	-	\$ 429,281	\$ -
COVID-19 TRANS-NIH RESEARCH SUPPORT	Total ALN 93.310	93.310	HD091218	20,732			20,732 12,205,493	869,225
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	101111111111	93.315		119,209	_	_	119,209	
PASS THROUGH AWARD FROM: THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON								
COVID-19 EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASE EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASE	Total ALN 93.323	93.323 93.323	HHS001089700001 HHS001089700001		-	118,665 1,680,937 1,799,602	118,665 1,680,937 1,799,602	
COVID-19 STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION		93.326		534,000	_		534,000	_
STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION	Total ALN 93.326	93.326		742,802			742,802 1,276,802	
HEALTH PROFESSIONS STUDENT LOANS, INCLUDING PRIMARY CARE LOANS/LOANS FOR DISADVANTAGED STUDENTS		93.342		_	201,199	_	201,199	_
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES PASS THROUGH AWARD FROM:		93.350		729,843	-	-	729,843	202,224
THE BRIGHAM & WOMEN'S HOSPITAL, INC NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES DYSTONIA MEDICAL RESEARCH FOUNDATION		93.350	TR003201	87,515	-	_	87,515	-
DISTONA MEDICAL RESEARCH FOUNDATION NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES DUKE UNIVERSITY		93.350	TR001456	1,610	_	-	1,610	-
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES HUDSONALPHA FOUNDATION		93.350	TR001803	4,095	-	-	4,095	-
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES WASHINGTON UNIVERSITY		93.350	OD027070	1,536	-	-	1,536	-
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	Total ALN 93.350	93.350	TR002764	61,913 886,512		-	61,913 886,512	- 202,224

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
COVID-19 RESEARCH INFRASTRUCTURE PROGRAMS		93.351		\$ 252,539	\$ -	\$ –	\$ 252,539	\$ -
RESEARCH INFRASTRUCTURE PROGRAMS		93.351		6,568,875	_	-	6,568,875	297,299
PASS THROUGH AWARD FROM:								
UNIVERSITY OF CALIFORNIA, DAVIS								
RESEARCH INFRASTRUCTURE PROGRAMS		93.351	OD023221				-	
RESEARCH INFRASTRUCTURE PROGRAMS		93.351	OD011107	164,610	_	-	164,610	-
UNIVERSITY OF WISCONSIN								
RESEARCH INFRASTRUCTURE PROGRAMS		93.351	OD011106	53,320	_	_	53,320	—
HARVARD MEDICAL SCHOOL RESEARCH INFRASTRUCTURE PROGRAMS		93.351	OD026435	660			660	
RESEARCH INFRASTRUCTURE PROGRAMS	Total ALN 93.351	93.331	0D020435	7,040,004	_		7,040,004	297,299
	10tal ALIN 95.551			7,040,004	_	_	7,040,004	291,299
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT PASS THROUGH AWARD FROM:		93.353		1,762,380	-	-	1,762,380	219,173
CHILDREN'S HOSPITAL OF PHILADELPHIA								
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	CA23568	540,946	_	-	540,946	10,730
FRED HUTCHINSON CANCER RESEARCH CENTER								
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	CA154967	29,160	_	-	29,160	-
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER								
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	DE028233	246,001	-	-	246,001	-
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	CA274321	284,741	_	-	284,741	-
UNIVERSITY OF ALABAMA AT BIRMINGHAM 21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		02.252	Ch24(5(7	72 002			72.002	
2151 CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT UNIVERSITY OF TENNESSEE		93.353	CA246567	72,002	_	-	72,002	-
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	CA229164	34,994	_	_	34,994	_
UNIVERSITY OF UTAH		10.000	0/122/101	51,771			51,771	
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	CA224076	515,143	_	_	515,143	_
	Total ALN 93.353			3,485,367	_	_	3,485,367	229,903
NURSING RESEARCH		93.361		2,402,650	-	_	2,402,650	531,636
PASS THROUGH AWARD FROM:								
UNIVERSITY OF MICHIGAN								
NURSING RESEARCH		93.361	NR013658	134,855	_	-	134,855	83,179
UNIVERSITY OF IOWA								
NURSING RESEARCH		93.361	NR017610	291,750	-	-	291,750	-
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON		02.261	ND017927	EE 450			EE 450	
NURSING RESEARCH	Total ALN 93.361	93.361	NR017837	<u>55,450</u> 2,884,705	-	-	55,450 2,884,705	614,815
	10tal ALIN 93.361			2,884,705	—	-	2,884,705	014,813

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) 21ST CENTURY CURES ACT – PRECISION MEDICINE INITIATIVE	93,368		\$ 40.338.995 \$	6 –	\$ –	\$ 40.338.995	\$ 2,601,064
2131 CENTURT CURES ACT – PRECISION MEDICINE INTIATIVE	95.508		\$ 40,556,995 3		s –	\$ 40,558,995	\$ 2,001,004
CANCER CAUSE AND PREVENTION RESEARCH	93.393		10,085,784	_	_	10,085,784	2,529,225
PASS THROUGH AWARD FROM:							
OREGON HEALTH & SCIENCE UNIVERSITY							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217842	50,673	-	-	50,673	-
CITY OF HOPE RESEARCH INSTITUTE							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA242218	110,020	_	_	110,020	-
DARTMOUTH COLLEGE							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA243449	30,509	_	-	30,509	_
GEORGE WASHINGTON UNIVERSITY							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA181255	387,769	-	-	387,769	-
MOUNT SINAI MEDICAL CENTER							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA256660	27,493	_	-	27,493	-
NORTHWESTERN UNIVERSITY							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225002	44,661	-	-	44,661	-
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225478	15,952	-	-	15,952	-
TEXAS A&M HEALTH SCIENCE CENTER							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA262623	9,444	_	-	9,444	-
UNIVERSITY OF ALABAMA AT BIRMINGHAM							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA213140	42,140	-	-	42,140	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA220502	37,485	-	-	37,485	-
UNIVERSITY OF SOUTHERN CALIFORNIA							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA258808	103,072	-	-	103,072	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA214253	108,942	-	-	108,942	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA257328	27,713	-	-	27,713	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA262263	56,412	_	-	56,412	-
RUTGERS UNIVERSITY							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA277812	3,863	_	-	3,863	-
ST JUDE CHILDREN'S RESEARCH HOSPITAL							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA258856	8,986	_	-	8,986	-
VANDERBILT UNIVERSITY							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA275082	276,548	_	-	276,548	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225005	12,711	-	-	12,711	-
STANFORD UNIVERSITY							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217105	150,284	-	-	150,284	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA232754	205,998	_	-	205,998	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA239342	\$ 10,792 \$	- \$	_	\$ 10,792	\$ -
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA231141	120,719	_	_	120,719	_
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA260761	28,669	_	_	28,669	_
UNIVERSITY OF MINNESOTA							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA239701	7,127	_	_	7,127	_
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA212008	127,510	_	_	127,510	_
UNIVERSITY OF WISCONSIN							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA253911	57,823	_	_	57,823	_
ARIZONA STATE UNIVERSITY							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237118	308,862	-	-	308,862	
	Total ALN 93.393		12,457,961	-	-	12,457,961	2,529,225
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		3,830,088	_	_	3,830,088	1,082,413
PASS THROUGH AWARD FROM:	<u> </u>		5,650,000			5,650,000	1,002,415
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA200468	3,968	_	_	3,968	_
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214263	91,575	_	_	91,575	_
CANCER DETECTION AND DIAGNOSIS RESEARCH	93,394	CA271888	1,505	_	_	1,505	_
CANCER DETECTION AND DIAGNOSIS RESEARCH	93,394	CA280980	20,210	_	_	20,210	_
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA195524	30,694	_	_	30,694	_
CHILDREN'S HOSPITAL OF PHILADELPHIA	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	011/0021	50,051			50,051	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93,394	CA193776	5,166	_	_	5,166	176
DANA-FARBER CANCER INSTITUTE			- /			-,	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93,394	CA230503	12,153	_	_	12,153	_
FRED HUTCHINSON CANCER RESEARCH CENTER			,			,	
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214172	(1)	_	_	(1)	_
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA230144	11,331	_	_	11,331	_
NEW YORK UNIVERSITY							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214195	1,535	_	_	1,535	_
NORTHWESTERN UNIVERSITY							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA200064	29,303	_	_	29,303	_
RICE UNIVERSITY							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA249367	17,387	_	_	17,387	-
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA252245	283,237	_	_	283,237	-
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA255894	56,239	_	-	56,239	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
UNIVERSITY OF MARYLAND							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA255753	\$ 9,144 \$	- \$	-	\$ 9,144	\$ -
UNIVERSITY OF MICHIGAN							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214955	13,703	_	-	13,703	-
UNIVERSITY OF NORTH CAROLINA							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA259926	27,398	-	-	27,398	-
WASHINGTON UNIVERSITY							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	MC27865	72,751	-	-	72,751	-
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA273194	30,590	-	-	30,590	-
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA086368	6,713	-	-	6,713	-
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA271887	52,104	-	-	52,104	-
NSABP							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA196067	182,967	_	-	182,967	-
	Total ALN 93.394		4,789,760	_	-	4,789,760	1,082,589
CANCER TREATMENT RESEARCH	93.395		8,616,050	_	_	8,616,050	1,935,322
PASS THROUGH AWARD FROM:							
CHILDREN'S HOSPITAL OF LOS ANGELES							
CANCER TREATMENT RESEARCH	93.395	CA252236	156	_	-	156	_
EMORY UNIVERSITY							
CANCER TREATMENT RESEARCH	93.395	CA277686	35,898	_	-	35,898	_
FRED HUTCHINSON CANCER RESEARCH CENTER							
CANCER TREATMENT RESEARCH	93.395	CA227092	3,042	_	-	3,042	_
GEORGE WASHINGTON UNIVERSITY							
CANCER TREATMENT RESEARCH	93.395	CA181255	3,840	-	-	3,840	-
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI							
CANCER TREATMENT RESEARCH	93.395	CA039542	111,238	-	-	111,238	-
JACKSON LABORATORY							
CANCER TREATMENT RESEARCH	93.395	CA237307	329,267	-	-	329,267	-
KAISER PERMANENTE							
CANCER TREATMENT RESEARCH	93.395	CA260689	43,915	_	-	43,915	-
MASSACHUSETTS GENERAL HOSPITAL							
CANCER TREATMENT RESEARCH	93.395	CA261669	93,113	-	-	93,113	-
NORTHWESTERN UNIVERSITY							
CANCER TREATMENT RESEARCH	93.395	CA120813	188,792	-	-	188,792	-
CANCER TREATMENT RESEARCH	93.395	CA228272	129,668	_	-	129,668	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
ST JUDE CHILDREN'S RESEARCH HOSPITAL							
CANCER TREATMENT RESEARCH	93.395	CA81457	\$ 78,816	5 –	s –	\$ 78,816	\$ -
UNIVERSITY OF MINNESOTA							
CANCER TREATMENT RESEARCH	93.395	CA239701	42,276	_	_	42,276	_
TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER							
CANCER TREATMENT RESEARCH	93.395	CA221957	60,204	_	_	60,204	_
CANCER TREATMENT RESEARCH	93.395	CA263988	99,915	_	_	99,915	_
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
CANCER TREATMENT RESEARCH	93.395	CA208535	1,657	_	_	1,657	_
CANCER TREATMENT RESEARCH	93.395	CA255596	41,767	_	_	41,767	_
CANCER TREATMENT RESEARCH	93.395	CA235620	230,006	_	_	230,006	_
NRG ONCOLOGY FOUNDATION, INC							
CANCER TREATMENT RESEARCH	93.395	CA180868	6,029	_	_	6,029	_
OREGON HEALTH & SCIENCE UNIVERSITY							
CANCER TREATMENT RESEARCH	93.395	CA180888	9,821	_	_	9,821	_
PUBLIC HEALTH INSTITUTE							
CANCER TREATMENT RESEARCH	93.395	CA180886	383,484	_	_	383,484	_
CANCER TREATMENT RESEARCH	93.395	CA189955	45,491	_	_	45,491	_
CANCER TREATMENT RESEARCH	93.395	CA228823	182,396	_	_	182,396	_
CANCER TREATMENT RESEARCH	93.395	CA233249	76,273	_	_	76,273	_
CANCER TREATMENT RESEARCH	93.395	CA180886	33,143	_	_	33,143	_
CANCER TREATMENT RESEARCH	93.395	CA233249	60,062	_	_	60,062	_
SEATTLE CHILDREN'S RESEARCH INSTITUTE							
CANCER TREATMENT RESEARCH	93.395	CA222486	8,958	_	_	8,958	_
UNIVERSITY OF NORTH CAROLINA							
CANCER TREATMENT RESEARCH	93.395	CA148761	163,190	_	_	163,190	_
CHILDREN'S HOSPITAL OF PHILADELPHIA							
CANCER TREATMENT RESEARCH	93.395	CA180886	194,909	_	_	194,909	38,705
CANCER TREATMENT RESEARCH	93.395	CA212190	563	_	_	563	_
CANCER TREATMENT RESEARCH	93.395	ADVL1515				_	
CANCER TREATMENT RESEARCH	93.395	CA228823	41,968	_	_	41,968	_
CANCER TREATMENT RESEARCH	93.395	CA233249	(302)	_	_	(302)	_
	Total ALN 93.395		11,315,605	-	-	11,315,605	1,974,027

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
CANCER BIOLOGY RESEARCH	93.396		\$ 13,919,511	s –	s –	\$ 13,919,511	\$ 1,248,839
PASS THROUGH AWARD FROM:	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		• 10,010,011	~	Ŷ	• 10,717,011	• 1,210,000
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
CANCER BIOLOGY RESEARCH	93.396	CA255080	29,532	_	_	29,532	_
CANCER BIOLOGY RESEARCH	93.396	CA240526	6,631	_	_	6,631	_
CANCER BIOLOGY RESEARCH	93,396	CA248731	76.899	_	_	76,899	_
CANCER BIOLOGY RESEARCH	93.396	CA236781	16,906	_	_	16,906	_
CANCER BIOLOGY RESEARCH	93.396	CA266187	8,794	_	_	8,794	_
DARTMOUTH COLLEGE							
CANCER BIOLOGY RESEARCH	93.396	CA225028	5,123	_	_	5,123	_
GEORGIA TECH UNIVERSITY			-, -			- / -	
CANCER BIOLOGY RESEARCH	93.396	CA218664	10,648	_	_	10,648	_
HEALTH RESEARCH. INC.							
CANCER BIOLOGY RESEARCH	93.396	CA251545	196,037	_	_	196,037	_
LURIE CHILDREN'S HOSPITAL OF CHICAGO			,			, i i i i i i i i i i i i i i i i i i i	
CANCER BIOLOGY RESEARCH	93.396	CA217613	39,165	_	_	39,165	_
THE METHODIST HOSPITAL RESEARCH INSTITUTE			,			,	
CANCER BIOLOGY RESEARCH	93.396	CA253553	259,247	_	_	259,247	_
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI							
CANCER BIOLOGY RESEARCH	93.396	CA154947	145,523	_	_	145,523	_
RICE UNIVERSITY			,			, i i i i i i i i i i i i i i i i i i i	
CANCER BIOLOGY RESEARCH	93.396	CA258512	40,185	_	_	40,185	_
UNIVERSITY OF CALIFORNIA, BERKELEY							
CANCER BIOLOGY RESEARCH	93.396	CA260205	277,700	_	_	277,700	_
UNIVERSITY OF CALIFORNIA, IRVINE							
CANCER BIOLOGY RESEARCH	93.396	CA228140	41,283	_	_	41,283	_
UNIVERSITY OF COLORADO DENVER							
CANCER BIOLOGY RESEARCH	93.396	CA224867	275,015	-	-	275,015	-
UNIVERSITY OF FLORIDA							
CANCER BIOLOGY RESEARCH	93.396	CA263574	136,602	-	-	136,602	-
UNIVERSITY OF HOUSTON							
CANCER BIOLOGY RESEARCH	93.396	CA256543	73,231	_	_	73,231	-
UNIVERSITY OF NORTH CAROLINA							
CANCER BIOLOGY RESEARCH	93.396	CA148761	(874)	-	-	(874)	-
UNIVERSITY OF NEW MEXICO							
CANCER BIOLOGY RESEARCH	93.396	CA206980	101,293	_	_	101,293	_
	Total ALN 93.396		15,658,451	-	-	15,658,451	1,248,839

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
COVID-19 CANCER CENTERS SUPPORT GRANTS		93.397		\$ (42,881) \$	-	s –	\$ (42,881)	s –
CANCER CENTERS SUPPORT GRANTS		93.397		8,689,353	_	-	8,689,353	573,102
PASS THROUGH AWARD FROM:		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		0,009,000			0,000,000	575,102
CASE WESTERN RESERVE UNIVERSITY								
CANCER CENTERS SUPPORT GRANTS		93.397	CA163060	3,826	_	_	3,826	2,435
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER				,			<i>.</i>	<i>,</i>
CANCER CENTERS SUPPORT GRANTS		93.397	CA127001	157,680	-	-	157,680	-
CANCER CENTERS SUPPORT GRANTS		93.397	CA221707	-	-	-	-	-
SOUTHWEST ONCOLOGY GROUP								
CANCER CENTERS SUPPORT GRANTS		93.397	CA180888	41,654	-	-	41,654	-
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER								
CANCER CENTERS SUPPORT GRANTS		93.397	CA217333	27	-	-	27	-
UNIVERSITY OF ALABAMA AT BIRMINGHAM								
CANCER CENTERS SUPPORT GRANTS		93.397	CA107399	37,837	_	-	37,837	-
	Total ALN 93.397			8,887,496	-	-	8,887,496	575,537
CANCER RESEARCH MANPOWER		93.398		1,842,840	_	_	1,842,840	_
PASS THROUGH AWARD FROM:				· · · ·			,- ,- ·	
RICE UNIVERSITY								
CANCER RESEARCH MANPOWER		93.398	HL146032	19,331	_	_	19,331	_
	Total ALN 93.398			1,862,171	-	-	1,862,171	_
CANCER CONTROL		93,399		1,002,079			1,002,079	342,088
PASS THROUGH AWARD FROM:		93.399		1,002,079	_	_	1,002,079	342,088
CHILDREN'S HOSPITAL OF PHILADELPHIA								
CANCER CONTROL		93.399	CA189955	30,369	_	_	30,369	_
NRG ONCOLOGY FOUNDATION. INC		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	01107700	20,203			20,209	
CANCER CONTROL		93.399	CA189867	194,865	_	_	194,865	_
NSABP								
CANCER CONTROL		93.399	FB-13	13	_	_	13	_
CANCER CONTROL		93.399	CA12027 #TFED41S2EXT-714	421	_	_	421	_
PUBLIC HEALTH INSTITUTE								
CANCER CONTROL		93.399	CA189955	41,817	_		41,817	-
	Total ALN 93.399			1,269,564	_	-	1,269,564	342,088

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM: AMERICAN PUBLIC HEALTH ASSOCIATION							
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL							
PARTNERSHIPS TO IMPROVE AND PROTECT THE NATION'S HEALTH	93.421	CDC OT000294	\$ 62,000 \$	- \$	_	\$ 62,000	\$ -
UNIVERSITY OF VERMONT							
COVID-19 STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATION'S HEALTH	93.421	NU38OT000280-04-02	51,398			51,398	
Total ALN 93.4		105001000200-04-02	113,398		_	113,398	
PASS THROUGH AWARD FROM: TIRR MEMORIAL HERMANN						-	
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING & REHABILITATION RESEARCH	93.433	90DPCP0010	32,277	_	_	32,277	_
UNIVERSITY OF HOUSTON			- ,			- ,	
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING & REHABILITATION RESEARCH		90IFST006	39,979	_	_	39,979	_
Total ALN 93.4	433		72,256	-	_	72,256	_
GLOBAL TUBERCULOSIS: DEVELOPING, EVALUATING, IMPLEMENTING EVIDENCE-BASED							
AND INNOVATIVE APPROACHES TO FIND, CURE, AND PREVENT TUBERCULOSIS GLOBALLY	93.494		-	-	1,188,565	1,188,565	468,500
COVID-19 PROVIDER RELIEF FUND AND AMERICAN RESCUE PLAN (ARP) RURAL DISTRIBUTION	93.498		-	_	6,636,839	6,636,839	-
PASS THROUGH AWARD FROM:							
TEXAS DEPARTMENT OF FAMILY AND PROTECTIVE SERVICES							
TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	93.558	HHS000791900013	-	-	768,944	768,944	_
PASS THROUGH AWARD FROM:							
TEXAS DEPARTMENT OF FAMILY AND PROTECTIVE SERVICES							
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	HHS000855300003	-	-	1,417,652	1,417,652	506,745
TEXAS COUNCIL FOR DEVELOPMENTAL DISABILITIES							
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	20212	_	_	_	_	_
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	21312	-	_	100	100	_
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	22411	-	-	153,382	153,382	47,498
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630 93.630	22412 23102	-	_	46,521 103,247	46,521 103,247	—
Develor mental disadilities dasic soft okt and advocact okants Total ALN 93.		25102		_	303,250	303,250	47,498
							*
PASS THROUGH AWARD FROM:							
HARRIS HEALTH SYSTEM MATERNAL OPIOID MISUSE MODEL	93.687	CMS331766	_	_	105,553	105,553	_
					,	,000	

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
¥ ¥ ¥					•	•	
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) MENTAL AND BEHAVIORAL HEALTH EDUCATION AND TRAINING GRANTS	93.732		\$ 104,843	s –	s –	\$ 104,843	¢
MENTAL AND BEHAVIORAL HEALTH EDUCATION AND TRAINING GRANTS	93.732		5 104,845	• -	5 –	\$ 104,843	» –
PASS THROUGH AWARD FROM:							
UNIVERSITY OF HOUSTON							
CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) RESEARCH,							
DEMONSTRATIONS AND EVALUATIONS	93.779	CMS331751	10	_	_	10	_
CARDIOVASCULAR DISEASES RESEARCH	93.837		14,368,840	_	-	14,368,840	1,230,392
PASS THROUGH AWARD FROM:							
THE BRIGHAM & WOMEN'S HOSPITAL, INC							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135008	360,661	-	-	360,661	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148218	169,647	_	-	169,647	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL150311	8,181	_	-	8,181	_
DUKE UNIVERSITY							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134510	153	-	-	153	-
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL088942	6,366	-	-	6,366	-
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL152108	24,427	_	-	24,427	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL156059	14,618	_	-	14,618	_
UNIVERSITY OF COLORADO							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL147064	9,605	-	-	9,605	-
EAST CAROLINA UNIVERSITY							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142544	105,695	-	-	105,695	-
JOHNS HOPKINS UNIVERSITY							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL096812	387,945	_	-	387,945	_
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146907	144,592	_	-	144,592	_
MASSACHUSETTS GENERAL HOSPITAL	02.027	LH 10000	7.002			7.002	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL123336	7,093	-	—	7,093	-
PENNSYLVANIA STATE UNIVERSITY	02.027	HI 1277(2	72 750			72 750	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL137763	73,759	_	-	73,759	_
UNIVERSITY OF HOUSTON	02 827	III 146745	249 107			249 107	
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	HL146745 HL126145	248,197 4,049	-	_	248,197 4,049	-
UNIVERSITY OF BUFFALO	95.837	HL120143	4,049	-	_	4,049	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL137558	23,120		_	23,120	
CARDIO VASCULAR DISEASES RESEARCH	75.63/	FIL13/338	25,120	_	_	25,120	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistanc Listing Number (ALN)	e Pass-Through Entity/O Identifying Number		Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
UNIVERSITY OF PENNSYLVANIA							
COVID-19 CARDIOVASCULAR DISEASES RESEARCH	93.837	HL141736	\$ 375	\$ -	\$ -	\$ 375	\$ -
TEXAS A&M UNIVERSITY							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134780	53,909	_	_	53,909	_
TEXAS A&M HEALTH SCIENCE CENTER							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146852	143,214	-	-	143,214	-
EMORY UNIVERSITY							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL157323	15,877	-	-	15,877	-
STANFORD UNIVERSITY							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL159176	32,643	_	_	32,643	_
UNIVERSITY OF ALABAMA AT BIRMINGHAM							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL120338	68,514	-	-	68,514	-
UNIVERSITY OF MINNESOTA							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL059367	8,579	_	-	8,579	_
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155509	30,722	_	-	30,722	_
UNIVERSITY OF NORTH CAROLINA							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL152034	29,569	-	-	29,569	-
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL159960	11,912	-	-	11,912	-
UNIVERSITY OF WISCONSIN							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL149404	38,532	_	-	38,532	-
THE UNIVERSITY OF TEXAS AT SAN ANTONIO							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL157810	3,277	_	-	3,277	-
RICE UNIVERSITY							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140305	252,096	-	-	252,096	-
WASHINGTON UNIVERSITY	02.025	111 105 100	1.42			1.10	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL105400	142	_	-	142	_
YALE UNIVERSITY	02.025	W 1 (200 /	20.576			20.574	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL163984	28,576	_		28,576	-
	Total ALN 93.837		16,674,885	-	_	16,674,885	1,230,392
LUNG DISEASES RESEARCH	93.838		1,939,227			1,939,227	(36,224)
PASS THROUGH AWARD FROM:	93.838		1,939,227	—	-	1,939,227	(30,224)
THE BRIGHAM & WOMEN'S HOSPITAL, INC							
LUNG DISEASES RESEARCH	93.838	HL130974	288,754	_	_	288,754	_
CHILDRENS HOSPITAL MEDICAL CENTER, CINCINNATI	95.656	112130974	200,754	_		200,754	_
LUNG DISEASES RESEARCH	93.838	HL157392	25,368	_	_	25,368	_
20.10 Dibli Abbi Abbi Abbi Abbi Abbi	25.050	112137372	25,500	_	_	25,500	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
CHILDREN'S HOSPITAL OF PHILADELPHIA							
LUNG DISEASES RESEARCH	93.838	HL146395	\$ 17,147 \$	- \$	-	\$ 17,147	\$ -
JOHNS HOPKINS UNIVERSITY							
LUNG DISEASES RESEARCH	93.838	HL151458	660	-	-	660	-
NATIONAL JEWISH MEDICAL AND RESEARCH CENTER							
LUNG DISEASES RESEARCH	93.838	HL156812	5,707	-	-	5,707	-
LUNG DISEASES RESEARCH	93.838	HL089897	16,159	-	-	16,159	-
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER							
COVID-19 LUNG DISEASES RESEARCH	93.838	6922-03-COVID-S012	22,897	_	_	22,897	-
COVID-19 LUNG DISEASES RESEARCH	93.838	20-312-0217571-66102L	(279)	_	_	(279)	-
LUNG DISEASES RESEARCH	93.838	6793-02-S012	1,425	_	_	1,425	955
UNIVERSITY OF ALABAMA AT BIRMINGHAM							
LUNG DISEASES RESEARCH	93.838	HL133232	3,597	_	_	3,597	-
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
LUNG DISEASES RESEARCH	93.838	HL157100	5,853	_	-	5,853	_
THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON							
LUNG DISEASES RESEARCH	93.838	HL145477	625,109	_	_	625,109	-
WAYNE STATE UNIVERSITY							
LUNG DISEASES RESEARCH	93.838	HL148247	58,438	_	_	58,438	-
YALE UNIVERSITY							
LUNG DISEASES RESEARCH	93.838	HL145567	6,411	_	_	6,411	-
	Total ALN 93.838		3,016,473	_	-	3,016,473	(35,269)
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		4,887,466	_	_	4,887,466	340,151
PASS THROUGH AWARD FROM:							
AUGUSTA UNIVERSITY							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL106365	14,331	_	_	14,331	-
CHILDRENS HOSPITAL MEDICAL CENTER, CINCINNATI							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133883	13,032	_	_	13,032	-
CHILDREN'S HOSPITAL OF PHILADELPHIA							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL148054	1,494	_	_	1,494	-
CLEVELAND CLINIC FOUNDATION							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL140097	9,908	_	-	9,908	-
EMORY UNIVERSITY							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL148560	83,517	-	-	83,517	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL124112	\$ 129,560 \$	s – s	- 5	6 129,560	¢
BLOOD DISEASES AND RESOURCES RESEARCH BLOOD WORKS NORTHWEST	95.839	HL124112	\$ 129,500 5	• - •		129,300	5 –
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL152200	22,902	_	_	22,902	_
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	25.057	111122200	22,902			22,702	
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL153963	406	_	_	406	_
RUTGERS UNIVERSITY							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133817	738	-	-	738	_
UNIVERSITY OF HOUSTON							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL151858	182,079	-	-	182,079	_
To	tal ALN 93.839		5,345,433	-	-	5,345,433	340,151
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		6,806,679			6,806,679	1,784,340
PASS THROUGH AWARD FROM:	75.040		0,000,075	_	_	0,000,077	1,764,540
LURIE CHILDREN'S HOSPITAL OF CHICAGO							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR079113	9,569	_	_	9,569	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR075380	10,681	-	-	10,681	_
TUFTS UNIVERSITY							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	AR076411	37,577	-	-	37,577	-
UNIVERSITY OF MICHIGAN							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR078073	61,598	-	-	61,598	-
UNIVERSITY OF MINNESOTA ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR042423	101,607			101,607	
	40 y3.846	AR042425	7,027,711	_	_	7.027.711	1,784,340
	All ALIV 75.640		7,027,711	_	_	7,027,711	1,764,540
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		30,751,834	_	_	30,751,834	6,384,350
PASS THROUGH AWARD FROM:							
UNIVERSITY OF IOWA							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118752	225	-	-	225	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108334	70,513	-	-	70,513	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116378	118,667	_	-	118,667	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	DK126042 DK122708	656,110 12,579	-	_	656,110 12,579	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMUKAL RESEARCH	93.847	DK122708	12,579	_	-	12,579	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
CHILDREN'S HOSPITAL OF CHICAGO							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118612	\$ 64,770 \$	- 5	s –	\$ 64,770	\$ –
CHILDREN'S HOSPITAL COLORADO							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK062453	_	_	-	-	_
CEDARS-SINAI MEDICAL CENTER							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK109588	122,610	-	-	122,610	-
CASE WESTERN RESERVE UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130931	133,321	-	-	133,321	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118290	131,879	-	-	131,879	-
COLUMBIA UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104309	11,836	-	-	11,836	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130517	(11,821)	-	-	(11,821)	-
DUKE UNIVERSITY			40.000			40.000	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121710	187,880	-	-	187,880	_
UNIVERSITY OF UTAH	02.047	DV114457	00.520			00.520	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114456	90,529	_	-	90,529	_
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	02.047	DK110200	22.000			22.000	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119200	22,989	-	-	22,989	-
UNIVERSITY OF COLORADO DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126710	46,428			46,428	
DIABETES, DIGESTIVE, AND KIDNET DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK072493	40,428	_	_	40,428	_
UNIVERSITY OF COLORADO DENVER	93.0 4 7	DR0/2495	550	_	_	550	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117001	37.346			37,346	
UNIVERSITY OF MICHIGAN	/5.04/	DK117001	57,540	_	_	57,540	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK081943	27,989	_	_	27,989	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK083912	610	_	_	610	_
JOHNS HOPKINS UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126825	65,781	_	_	65,781	_
GEORGE WASHINGTON UNIVERSITY			,			,	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK061230	55,315	_	_	55,315	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK098246	24,585	_	_	24,585	_
LURIE CHILDREN'S HOSPITAL OF CHICAGO							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127995	78,080	-	_	78,080	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK072493	44,787	_	-	44,787	-
NEW YORK UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130517	171,587	_	-	171,587	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
OREGON HEALTH & SCIENCE UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123115	\$ 10,482 \$	_	s –	\$ 10,482	\$ -
SAINT LOUIS UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK061718	187,754	_	_	187,754	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110406	(5,529)	_	_	(5,529)	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134531	92,539	_	_	92,539	_
RUTGERS UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK112365	(41)	_	_	(41)	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK062431	160	_	-	160	-
TEMPLE UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132642	67,086	_	-	67,086	_
SEATTLE CHILDREN'S RESEARCH INSTITUTE							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121224	284,790	_	-	284,790	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK113005	75,288	_	-	75,288	_
UNIVERSITY OF CALIFORNIA, LOS ANGELES							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122013	4,536	_	-	4,536	-
UNIVERSITY OF CALIFORNIA, SAN DIEGO							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK097771	172,842	_	-	172,842	-
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120886	10,926	-	-	10,926	-
UNIVERSITY OF SOUTHERN CALIFORNIA							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124789	32,256	-	-	32,256	-
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115761	167,633	_	-	167,633	-
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108328	102,782	_	-	102,782	-
VANDERBILT UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123895	13,252	_	-	13,252	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124845	22,739	_	-	22,739	-
CHILDREN'S HOSPITAL OF PHILADELPHIA							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK066174	635	-	-	635	-
CHILDRENS HOSPITAL MEDICAL CENTER, CINCINNATI							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK103117	46,061	-	-	46,061	-
UNIVERSITY OF KANSAS	00.045	DW100004					
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129234	799	-	-	799	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
UNIVERSITY OF WASHINGTON							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH UNIVERSITY OF HOUSTON	93.847	DK107436	\$ 15,883 \$	- 5		\$ 15,883	\$ –
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH UNIVERSITY OF KENTUCKY	93.847	DK117476	62,184	-	-	62,184	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK095662	49,253	_	_	49,253	_
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	201017	51107002	19,200			19,200	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH UNIVERSITY OF ROCHESTER	93.847	DK124614	32,474	-	-	32,474	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120680	17,822	_	_	17,822	_
AMERICAN PSYCHOLOGICAL ASSOCIATION							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH UNIVERSITY OF SOUTH FLORIDA	93.847	DK118763	20,904	-	-	20,904	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128847	245,006	_	_	245,006	_
Total ALN 93.			34,647,495	_	-	34,647,495	6,384,350
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS PASS THROUGH AWARD FROM:	93.853		31,209,472	-	-	31,209,472	5,729,106
THE BRIGHAM & WOMEN'S HOSPITAL, INC							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS113890	322,985	_	-	322,985	_
CHILDREN'S HOSPITAL OF PHILADELPHIA							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS115052	51,318	_	_	51,318	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	75.055	10115052	51,510			51,510	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS113329	6,626	_	-	6,626	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS113893	5,929	-	-	5,929	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS103592	49,954	_	_	49,954	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS110806	183,074	-	-	183,074	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster l	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS115886	\$ 33,971 \$	- \$	-	\$ 33,971	\$ -
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS128921	90,647	-	-	90,647	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS125487	30,863	-	-	30,863	-
COLUMBIA UNIVERSITY							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	00.050	10050050	(1.005			(1.005	
DISORDERS	93.853	NS078059	61,095	-	-	61,095	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	00.050	20110026	(2.00)			(2.00)	
DISORDERS	93.853	NS110826	63,886	-	-	63,886	-
HARVARD MEDICAL SCHOOL EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS118402	239,851			239,851	
JOHNS HOPKINS UNIVERSITY	75.855	113116402	239,631	_	_	259,651	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS102920	2,784	_	_	2,784	_
KENNEDY KRIEGER INSTITUTE	75.055	10102/20	2,701			2,701	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS098482	21,794	_	_	21,794	_
NORTHWESTERN UNIVERSITY			,,,,			,,,,	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS108874	101,423	_	_	101,423	_
TEXAS A&M UNIVERSITY							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS106907	37,562	_	-	37,562	_
UNIVERSITY OF MICHIGAN							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS099340	(9,251)	-	-	(9,251)	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS099046	149,291	-	-	149,291	-
DUKE UNIVERSITY							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS112917	414,173	—	-	414,173	_
MAYO CLINIC							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	93.853	NS115198	33,164			22.164	
DISORDERS	93.833	105115198	33,104	-	-	33,164	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
OREGON HEALTH & SCIENCE UNIVERSITY							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS120981	\$ 6,781 \$		\$ -	\$ 6,781	\$ -
RICE UNIVERSITY							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS109361	51,237	-	-	51,237	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS126063	120,058	-	_	120,058	-
RUSH UNIVERSITY MEDICAL CENTER							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	02.052	NG100271	14,502			14.502	
DISORDERS THE ROCKEFELLER UNIVERSITY	93.853	NS109361	14,583	-	-	14,583	-
THE ROCKEFELLER UNIVERSITY EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS126057	128,657			128,657	
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	95.855	N3120037	128,037	_	_	128,057	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS112280	8,470	_	_	8,470	_
UNIVERSITY OF ALABAMA AT BIRMINGHAM	75.655	105112200	0,470			0,470	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS124141	77,965	_	_	77,965	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS128600	12,931	_	_	12,931	_
UNIVERSITY OF CINCINNATI			,			<i></i>	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS095869	681	_	_	681	_
UNIVERSITY OF COLORADO DENVER							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	N2114312	39,006	_	-	39,006	_
UNIVERSITY OF HOUSTON							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS124650	7,781	-	-	7,781	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS112497	21,748	-	-	21,748	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS117944	14,688	_	-	14,688	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
UNIVERSITY OF LOUISVILLE							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	02.052	2011 4002				14.000	¢
DISORDERS	93.853	NS114982	\$ 14,003 \$	- \$		\$ 14,003	\$ -
UNIVERSITY OF PENNSYLVANIA EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS113339	14,751			14,751	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	75.855	103113337	14,751	_	_	14,751	_
DISORDERS	93.853	NS114140	59,770	_	_	59,770	_
UNIVERSITY OF ROCHESTER	/5.855	105114140	55,110			55,110	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS118246	75,058	_	_	75,058	_
UNIVERSITY OF UTAH			, = , = = =				
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS122184	22,128	_	-	22,128	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS107486	19,218	_	_	19,218	_
UNIVERSITY OF WISCONSIN							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS115102	94,657	-	-	94,657	-
WILLIAM BEAUMONT HOSPITAL RESEARCH INSTITUTE							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS110838	24,261	-	_	24,261	-
	Total ALN 93.853		33,929,043	_	-	33,929,043	5,729,106
COVID-19 ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		4,207,382	_	_	4,207,382	520,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		22,604,503	_	_	22,604,503	2,187,550
PASS THROUGH AWARD FROM:			,,			,,	,,
BENAROYA RESEARCH INSTITUTE							
COVID-19 ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI109565	3,748	_	-	3,748	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI109565	38,097	_	-	38,097	-
BOSTON CHILDREN'S HOSPITAL							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI125051	6,276	-	_	6,276	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI126614	202,527	-	_	202,527	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154470	39,165	-	-	39,165	-
THE BRIGHAM & WOMEN'S HOSPITAL, INC							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI165967	52,053	-	-	52,053	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
CREIGHTON UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148219	\$ 23,787 \$	_	\$ –	\$ 23,787	\$ –
EAST CAROLINA UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI146930	151,501	-	-	151,501	-
GEORGE WASHINGTON UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI129789	11,423	-	-	11,423	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI117970	64,817	-	-	64,817	-
WASHINGTON UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141716	103,303	-	-	103,303	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI159677	97,610	-	-	97,610	-
UNIVERSITY OF UTAH							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI125301	77,249	-	-	77,249	-
EMORY UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148684	35,861	_	_	35,861	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134940	166,083	_	_	166,083	_
THE METHODIST HOSPITAL RESEARCH INSTITUTE							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148559	(6,250)	_	_	(6,250)	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI152999	878,516	_	_	878,516	4,491
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI165372	5,137	_	_	5,137	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI120749	(211)	_	_	(211)	_
THE OHIO STATE UNIVERSITY			()			()	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI156732	5,818	_	_	5,818	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	201000	11100,02	5,010			5,010	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI055449	46,789	_	_	46,789	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI152999	(192,232)	_	_	(192,232)	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI161943	23,725		_	23,725	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141349	(26)		_	(26)	
COLUMBIA UNIVERSITY	75.855	AIITIST	(20)			(20)	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI067773	121,375		_	121,375	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI120989	79,003	_		79,003	_
GEORGIA STATE UNIVERSITY	95.855	AI120989	79,003	_	-	79,003	_
	02 955	41170014	0(5(7			0(5(7	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170014	96,567	-	_	96,567	-
UNIVERSITY OF ARKANSAS	02.855	4115(101	25.072			25.072	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI156101	35,962	_	_	35,962	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170892	122,084	-	_	122,084	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
UNIVERSITY OF CALIFORNIA, LOS ANGELES							
COVID-19 ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI159946	\$ 41,725 \$	-	\$ –	\$ 41,725	\$ –
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A1068636	56,571	-	-	56,571	-
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI66967	99,012	-	-	99,012	-
UNIVERSITY OF CALIFORNIA, SAN DIEGO							
COVID-19 ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI069536	6,381	-	-	6,381	-
UNIVERSITY OF NORTH CAROLINA							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI050410	5,176	-	-	5,176	5,176
UNIVERSITY OF SOUTH CAROLINA							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI165560	170,141	-	-	170,141	_
UNIVERSITY OF PITTSBURGH							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI032539	52,226	-	-	52,226	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI174526	61,840	-	-	61,840	_
TEXAS A&M HEALTH SCIENCE CENTER							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI144459	85,885	-	-	85,885	_
TEXAS TECH UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI135197	11,662	-	-	11,662	_
UNIVERSITY OF CALGARY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI165327	72,130	-	-	72,130	-
UNIVERSITY OF HOUSTON							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI133697	19,440	-	-	19,440	-
UNIVERSITY OF KENTUCKY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI169231	49,435	-	-	49,435	-
UNIVERSITY OF MINNESOTA							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI171954	812,014	-	-	812,014	-
UNIVERSITY OF WISCONSIN							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154597	105,461	-	-	105,461	-
JOHNS HOPKINS UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI068632	167,642	-	-	167,642	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI130836	705,484	-	-	705,484	-
NEW YORK UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	HD100929	495	-	-	495	-
NEW YORK BLOOD CENTER							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI078314	29,930	-	-	29,930	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI117804	\$ 24,263 \$	- \$		\$ 24,263	\$ -
NEW YORK STATE HEALTH							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AL144891	39,185	-	-	39,185	-
RICE UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI167037	17,883	-	-	17,883	-
TULANE UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI62907	1,742	-	-	1,742	-
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154597	(1,410)	_	-	(1,410)	-
Total ALN	93.855		31,735,955	_	-	31,735,955	2,717,919
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		14,864,006	_	_	14,864,006	434,002
PASS THROUGH AWARD FROM:							
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM120011	14,191	-	-	14,191	-
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM072804	38,722	-	-	38,722	-
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM139801	100,545	-	-	100,545	-
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM125640	10,050	_	_	10,050	-
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM127332	-	_	_	_	-
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM130838	7,475	-	-	7,475	-
PACIFIC NORTHWEST RESEARCH INSTITUTE							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132589	31,102	_	-	31,102	_
TEXAS A&M UNIVERSITY							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132436	425	_	_	425	-
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM145416	225,061	_	-	225,061	_
UNIVERSITY OF MICHIGAN							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	AI150470	24,684	_	_	24,684	-
UNIVERSITY OF ILLINOIS							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136384	41,270	_	-	41,270	_
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM140709	81,525	-	-	81,525	-
Total ALN	93.859		15,439,056	_	-	15,439,056	434,002

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
					•	•	
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)	02.945		\$ 24 640 095	¢	¢	© 04 (40 005	0 722 120
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		\$ 24,640,095	\$ -	\$ -	\$ 24,640,095	\$ 2,723,138
PASS THROUGH AWARD FROM: BOSTON UNIVERSITY							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD101421	87.060			87.060	
UNIVERSITY OF NORTH CAROLINA	95.805	HD101421	87,000	-	_	87,000	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD086139	2,388		_	2,388	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD080139	7,362	_	_	7.362	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMORAL RESEARCH	93.865	HD089881	276,035		_	276,035	
CHILDREN'S HOSPITAL OF PHILADELPHIA	75.005	112009001	270,055			270,055	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD093483	2,991	_	_	2,991	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD101528	48,169	_	_	48,169	_
CHILDREN'S NATIONAL MEDICAL CENTER			,			,	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD099131	54,383	_	_	54,383	_
CHILDREN'S RESEARCH INSTITUTE			· · · · · ·			,	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD061221	192,942	_	_	192,942	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD094213	34,114	_	_	34,114	_
COLUMBIA UNIVERSITY							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD055651	571,734	-	_	571,734	-
CORNELL UNIVERSITY							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD109392	13,169	-	_	13,169	-
INDIANA UNIVERSITY							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD090215	28,140	-	_	28,140	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD107120	4,988	-	-	4,988	-
THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD095976	610	-	-	610	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD091347	2,468	-	_	2,468	-
THE NEMOURS FOUNDATION							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD100985	80,451	-	-	80,451	-
PRESIDENT AND FELLOWS OF HARVARD COLLEGE ON BEHALF OF HARVARD MEDICAL SCHOOL							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103133	516,424	-	-	516,424	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD101351	57,036	-	-	57,036	-
WASHINGTON STATE UNIVERSITY							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD108198	20,101	-	_	20,101	-
WASHINGTON UNIVERSITY	02.965	1100(5425	(2.274)			(2.274)	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD065435	(3,374)	-	_	(3,374)	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD070855	4,104	-	_	4,104	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD091218	185,823	-	_	185,823	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
WEILL MEDICAL COLLEGE							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD067244	\$ 108,389 \$	- 5	-	\$ 108,389	\$ 100,225
UNIVERSITY OF CALIFORNIA, LOS ANGELES							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD092471	25,324	_	-	25,324	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD095548	31,398	-	-	31,398	-
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
COVID-19 CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD105618	311,906	-	-	311,906	_
ST JUDE CHILDREN'S RESEARCH HOSPITAL CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103908	1.727			1.727	
UNIVERSITY OF COLORADO DENVER	93.865	HD103908	1,/2/	_	-	1,/2/	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD098415	9.642			9.642	
UNIVERSITY OF HOUSTON	95.805	11D098415	9,042	_	_	9,042	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD095520	153.608	_	_	153,608	_
UNIVERSITY OF MISSOURI	75.005	110073520	155,000			155,000	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD108198	74,350	_	_	74,350	_
UNIVERSITY OF UTAH						,	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD105462	2,714	_	_	2,714	_
UNIVERSITY OF WISCONSIN							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	75N93021C00006	67,664	_	_	67,664	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD102172	(531)	_	-	(531)	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD093660	194,199	-	-	194,199	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD105173	18,657	_	-	18,657	_
THE BRIGHAM & WOMEN'S HOSPITAL, INC							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HG009922	(138)	-	-	(138)	_
	Total ALN 93.865		27,826,122	-	-	27,826,122	2,823,363
COVID-19 AGING RESEARCH	93.866		463	-	-	463	-
AGING RESEARCH	93.866		20,351,766	_	-	20,351,766	1,334,661
PASS THROUGH AWARD FROM: BAYLOR SCOTT AND WHITE RESEARCH INSTITUTE							
AGING RESEARCH	93.866	AG061973	125,939		_	125,939	
BOSTON UNIVERSITY	93.800	AG001973	125,959	-	-	125,959	_
AGING RESEARCH	93.866	AG058589	231,719	_	_	231,719	_
DUKE UNIVERSITY	23.800	AG030507	231,/19	_	_	251,/19	_
AGING RESEARCH	93.866	AG070149	1.632	_	_	1.632	_
	25.800	100/01/2	1,052			1,002	

<u>Federal Grantor/Pass-Through Grantor/Program Title</u>	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
EMORY UNIVERSITY							
AGING RESEARCH	93.866	AG061357	\$ 107.610 \$	_	\$ –	\$ 107,610	s –
AGING RESEARCH	93.866	AG065187	87,010	_	-	87,010	-
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI			,				
AGING RESEARCH	93,866	AG078755	61,958	_	_	61,958	_
STANFORD UNIVERSITY	221000	110070700	01,900			01,000	
AGING RESEARCH	93.866	AG036695	(166,990)	_	_	(166,990)	(131,562)
LOUISIANA STATE UNIVERSITY			()			(,)	()
AGING RESEARCH	93.866	AG073204	16,447	_	_	16,447	_
MASSACHUSETTS GENERAL HOSPITAL							
AGING RESEARCH	93.866	AG064413	12,094	_	_	12,094	_
OHIO STATE UNIVERSITY			,			,	
AGING RESEARCH	93.866	AG058822	9,266	_	_	9,266	_
RICE UNIVERSITY			- /			- ,	
AGING RESEARCH	93.866	AG061597	4,592	_	_	4,592	_
AGING RESEARCH	93.866	AG062690	20,718	_	_	20,718	_
AGING RESEARCH	93.866	AG074229	58,100	_	_	58,100	_
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE							
AGING RESEARCH	93.866	AG071464	63,499	_	_	63,499	_
WAKE FOREST UNIVERSITY HEALTH SCIENCES						,	
AGING RESEARCH	93.866	AG062689	943,486	_	_	943,486	229,775
AGING RESEARCH	93.866	AG063744	8,150	_	_	8,150	_
AGING RESEARCH	93.866	AG064440	28,977	_	_	28,977	_
UNIVERSITY OF ARIZONA			- /			- /	
AGING RESEARCH	93.866	AG065169	125,823	_	_	125,823	_
UNIVERSITY OF CALIFORNIA. LOS ANGELES							
AGING RESEARCH	93.866	AG036695	450,139	_	_	450,139	131,562
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
AGING RESEARCH	93.866	AG064025	58,370	_	_	58,370	_
UNIVERSITY OF HOUSTON			/				
AGING RESEARCH	93.866	AG065170	36,342	_	_	36,342	_
THE UNIVERSITY OF TEXAS AT SAN ANTONIO			· · · · · · · · · · · · · · · · · · ·			<i>,</i> -	
AGING RESEARCH	93.866	AG052409	4,196	_	_	4,196	_
			,			,	

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
UNIVERSITY OF SOUTHERN CALIFORNIA							
AGING RESEARCH	93.866	AG010483	\$ 40,853 \$	- 5	s –	\$ 40,853	\$ –
AGING RESEARCH	93.866	AG024904	23,211	_	-	23,211	_
AGING RESEARCH	93.866	AG063689	144,345	_	-	144,345	_
AGING RESEARCH	93.866	AG054029	77,786	_	-	77,786	-
AGING RESEARCH	93.866	AG061848	23,680	_	-	23,680	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
AGING RESEARCH	93.866	AG069466	37,060	_	-	37,060	_
AGING RESEARCH	93.866	AG058463	(75)	_	-	(75)	_
AGING RESEARCH	93.866	AG061901	67,498	_	-	67,498	_
AGING RESEARCH	93.866	AG074226	157,489	_	-	157,489	_
AGING RESEARCH	93.866	AG076144	20,126	_	-	20,126	_
AGING RESEARCH	93.866	AG057587	418,252	_	-	418,252	-
UNIVERSITY OF WISCONSIN							
AGING RESEARCH	93.866	AG068515	540	_	-	540	_
WASHINGTON UNIVERSITY							
AGING RESEARCH	93.866	AG052494	(2,141)	_	-	(2,141)	_
AGING RESEARCH	93.866	AG070436	78,955	_	-	78,955	_
AGING RESEARCH	93.866	AG064634	_	_	-	_	_
	Total ALN 93.866		23,728,885	-	-	23,728,885	1,564,436
VISION RESEARCH	93.867		13,575,293	_	_	13,575,293	2,515,617
PASS THROUGH AWARD FROM:							
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC							
VISION RESEARCH	93.867	EY11751	59,141	_	-	59,141	_
VISION RESEARCH	93.867	EY14231	24,440	_	-	24,440	_
VISION RESEARCH	93.867	EY030030	10,731	_	-	10,731	_
RICE UNIVERSITY							
VISION RESEARCH	93.867	EY032596	46,081	_	-	46,081	_
JOHNS HOPKINS UNIVERSITY							
VISION RESEARCH	93.867	EY033103	34,783	_	-	34,783	_
NEW YORK UNIVERSITY							
COVID-19 VISION RESEARCH	93.867	EY026869	(2,051)	_	_	(2,051)	_
VISION RESEARCH	93.867	EY026869	1,600	_	_	1,600	_
TEXAS A&M UNIVERSITY							
VISION RESEARCH	93.867	EY029695	31,602	-	-	31,602	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) PASS THROUGH AWARD FROM (continued): <i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i> VISION RESEARCH VISION RESEARCH Total ALN 93.867	93.867 93.867	EY032768 EY024376	\$ 41,871 5 65,119 13,888,610	S _ : 	\$	\$ 41,871 65,119 13,888,610	\$
PASS THROUGH AWARD FROM: <i>RICE UNIVERSITY</i> MEDICAL LIBRARY ASSISTANCE	93.879	LM007093	211,622	_	_	211,622	-
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889		_	_	693,567	693,567	118,936
PASS THROUGH AWARD FROM: <i>REACH UP, INC</i> HEALTHY START INITIATIVE	93.926	H49MC12793	23,318	-	-	23,318	_
PASS THROUGH AWARD FROM: TEXAS DEPARTMENT OF STATE HEALTH SERVICES HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED	93.940	HS000077800010	_	_	131,511	131,511	_
PASS THROUGH AWARD FROM: FLORIDA STATE UNIVERSITY HIV DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION PROJECTS	93.941	PS005246	13,630	_	_	13,630	_
PASS THROUGH AWARD FROM: <i>SANTA MARIA HOSTEL</i> BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE <i>THE UNIVERSITY OF TEXAS AT AUSTIN</i>	93.959	B08T1083545	-	-	79,269	79,269	-
BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE Total ALN 93.959	93.959	170334/42919			251,307 330,576	251,307 330,576	
PPHF GERIATRIC EDUCATION CENTERS	93.969		837,846	_	-	837,846	344,181
PRIMARY CARE MEDICINE AND DENTISTRY CLINICIAN EDUCATOR CAREER DEVELOPMENT AWARDS	93.976		7,334	-	-	7,334	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
COVID-19 INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		\$ 48,600 \$	\$ –	\$ -	\$ 48,600	\$ -
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		514,810	_	-	514,810	8,814
PASS THROUGH AWARD FROM:							
MAKERERE UNIVERSITY							
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	TW011898	38,826	-	-	38,826	-
UNIVERSITY OF MARYLAND							
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	TW012274	242,263	-	-	242,263	17,206
Total ALN 93.9	89		844,499	-	-	844,499	26,020
PASS THROUGH AWARD FROM:							
THE UNIVERSITY OF TEXAS AT AUSTIN (TEXAS DEPARTMENT OF STATE HEALTH SERVICES) MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	HHS001011000001			20,666	20,666	
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	HHS001011000001	_	_	20,000	20,000	_
	93RD	HHSN268201600015I	_	_	_	_	_
	93RD	COVID-19 CDC #75D30122C14673	140,063	_	_	140,063	_
	93RD	HHSN268201600033I	3,987,322	_	_	3,987,322	3,919,475
	93RD	HHSN27200009-15-0020	(11)	_	_	(11)	_
	93RD	HHSN27200012-16-0075	(4)	_	_	(4)	_
	93RD	HHSN27200015	9,669	_	_	9,669	_
	93RD	HHSN2720013-16-0057.C1D1.00 58	(11)	_	-	(11)	-
	93RD	NIH 75N93022P00692	232,581	_	-	232,581	-
	93RD	NIH 75N93022P00891	1,742,719	_	-	1,742,719	_
	93RD	NIH 75N95023P00006	18,074	-	-	18,074	_
	93RD	NIH 75N93021P01502	18,493	-	-	18,493	_
	93RD	75N93019F00132	14,061	-	-	14,061	-
PASS THROUGH AWARD FROM:							
ATLANTA RESEARCH AND EDUCATION FOUNDATION	93RD	CDC 75D30119C04211	761,144	-	-	761,144	-
COVID-19 BOSTON CHILDREN'S HOSPITAL	93RD	CDC 75D30120C07725	(8,792)	-	-	(8,792)	-
COVID-19 BOSTON CHILDREN'S HOSPITAL	93RD	CDC 75D30121C10297	26,217	-	-	26,217	-
COVID-19 BOSTON CHILDREN'S HOSPITAL	93RD	CDC 75D30122C1333	15,576	-	-	15,576	-
BOSTON CHILDREN'S HOSPITAL	93RD	CDC 75D30121C10297	19,687	-	-	19,687	-
DUKE UNIVERSITY	93RD 93RD	HHSN2752010000031	217,816	-	-	217,816 47,278	-
DUKE UNIVERSITY HENNEPIN RESEARCH INSTITUTE	93RD 93RD	HHSN-2752018000031 75N-94019C00006	47,278 9,001	-	_	47,278	-
HENNEPIN RESEARCH INSTITUTE MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH	93RD 93RD	#W19031	9,001 4,009	_	_	4,009	_
MASSACHOSETTS DEPARTMENT OF POBLIC HEALTH MEDSTAR RESEARCH INSTITUTE	93RD 93RD	#W19031 HHSP233201500022I	4,009 560,652	_	_	560,652	_
MEDSTAK KESEARCH INSTITUTE	93KD	ппэг2332013000221	500,052	-	-	500,052	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS THROUGH AWARD FROM (continued):							
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1703	\$ 12,058 \$	- \$	- 1	\$ 12,058	s –
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1704	2,346	_	_	2,346	-
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1705	7,696	_	_	7,696	_
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1802	3,283	_	_	3,283	_
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1903	5.032	_	_	5,032	_
NRG ONCOLOGY FOUNDATION. INC	93RD	NCORP	19	_	_	19	_
UNIVERSITY OF ALABAMA AT BIRMINGHAM	93RD	HHSN272201600018C	39,306	_	_	39,306	_
UNIVERSITY OF ALABAMA AT BIRMINGHAM	93RD	HHSN268201800005I	41,290	_	_	41,290	_
UNIVERSITY OF CHICAGO	93RD	75Q80120D00018	153,521	_	_	153,521	_
UNIVERSITY OF MICHIGAN	93RD	75N92023R0177	26,454	_	_	26,454	_
UNIVERSITY OF MICHIGAN	93RD	75N92022F00001	140,868	_	_	140,868	_
COVID-19 UNIVERSITY OF NEW MEXICO	93RD	HHSN75Q80120C00003	4,703	_	_	4,703	_
UNIVERSITY OF NORTH CAROLINA	93RD	75N92022F0001	361,644	_	_	361,644	_
UNIVERSITY OF SOUTH FLORIDA	93RD	NIDDK-TRIALNET	55	_	_	55	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	93RD	75D30118C02646	63,142	_	_	63,142	_
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES		,	408,669,334	201,199	18,182,393	427,052,926	54,247,096
NATIONAL SCIENCE FOUNDATION							
PASS THROUGH AWARD FROM:							
NSF TECHNOLOGY, INNOVATION, AND PARTNERSHIPS	93RD		28,511	_	_	28,511	_
TOTAL NATIONAL SCIENCE FOUNDATION			28,511	-	-	28,511	-
DEPARTMENT OF HOMELAND SECURITY PASS THROUGH AWARD FROM: HARRIS COUNTY							
COVID-19 DISASTER GRANTS – PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS)	97.036	SMARTPOD			172,854	172,854	
DECLARED DISASTERS) DISASTER GRANTS – PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS)	97.036	SMARTPOD	-	_	172,834	172,834	_
DISASTER GRANTS – PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS) Total ALN 97		SWARTFOD			17,937	190,811	
TOTAL DEPARTMENT OF HOMELAND SECURITY	.050				190,811 190,811	190,811 190,811	-
TOTAL EXPENDITURES OF FEDERAL AWARDS			\$ 464,694,119 \$	5 23,840,739 \$	22,679,000	\$ 511,213,858	\$ 65,109,632

Schedule of Expenditures of State Awards

Year Ended June 30, 2023

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through			
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS DIRECT AWARD:			
	PP170094	\$ 14,80	1 \$ 13,030
	PP190051	169,07	
	PP200068	430,112	
	PP210007	358,550	
	PP210031	129,93	
	PP210044	567,87	
	PP220017	293,532	
	PP220024	33,600	
	PP220038	110,78	
	RP150587	(6,62	
	RP150648	13	
	RP160022	622	2 –
	RP160771	65	
	RP160805	101,52	
	RP170005	(1,30	
	RP170169	50,052	
	RP170500	262	
	RP170691	320,15	1 –
	RP180177	7,61	
	RP180196	123,863	3 –
	RP180381	163,73	3 47,252
	RP180672	751,274	
	RP180674	1,133,264	
	RP180785	889,622	

Program Description	Pass-Through Entity/Other Identifying Number	Ex	Total penditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through (continued)				
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued) DIRECT AWARD (continued):				
	RP190002	\$	248,765	\$ 44,31
	RP190067	Ť	109,833	• • • • • • •
	RP190132		213,151	
	RP190160		691,447	77,86
	RP190279		164,851	102,05
	RP190398		57,515	
	RP190522		7,101	2
	RP190602		716,778	117,24
	RP190641		746,008	9,55
	RP200025		220,881	46,67
	RP200135		232,955	
	RP200402		266,006	53,71
	RP200439		233,241	· · · · · ·
	RP200443		217,868	
	RP200504		738,797	
	RP200537		368,914	94,20
	RP200584		241,584	· · · · · ·
	RP200620		131,180	
	RP200633		519,944	43,56
	RP210027		707,675	
	RP210037		578,686	
	RP210064		758,753	410,09
	RP210075		157,800	15,12
	RP210143		65,141	
	RP210158		64,086	

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditure	Amounts Provided to Subrecipients
state of Texas: Direct & Pass-through (continued)			
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued) DIRECT AWARD (continued):			
	RP210227	\$ 799,7	77 \$ -
	RP220050	239,0	
	RP220119	188,	
	RP220127	271,8	
	RP220218	316,8	
	RP220232	186,0	
	RP220332	308,	
	RP220468	342,2	
	RP220480	158,	
	RP220524	145,.	
	RP220532	25,3	
	RP220646	735,0	
	RP220666	35,4	
	RP230026	80,3	
	RP230120	51,0	
	RR160009	420,3	
	RR160027	116,8	
	RR170024	538,3	
	RR170036	52,4	
	RR170039	56,0	
	RR170048	943,4	
	RR180061	696,9	
	RR180072	363,0	
	RR190043	480,7	
	RR190054	372,4	

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
	* • • • *	•	
State of Texas: Direct & Pass-through (continued)			
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued)			
DIRECT AWARD (continued):			
	RR190104	\$ 354,233	
	RR200009	374,801	
	RR200040	250,890	
	RR200063	250,292	
	RR200065	330,464	-
	RR200076	191,993	
	RR200079	246,545	
	RR200080	411,331	
	RR210012	430,399	
	RR210013	385,466	
	RR210029	527,179	
	RR210031	507,621	
	RR210037	547,344	
	RR210040	497,558	
	RR210056	153,401	
	RR210066	493,625	
	RR210082	164,850	
	RR220012	216,001	
	RR220033	948,774	
	RR220035	216,238	
	RR220039	369,477	
	RR220051	161,746	
	RR220051 RR220069	458,325	
	RR220009	116,093	
	RP230391	55,932	
	NI 250571	30,688,779	

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amo Provic Subrec	ded to
State of Texas: Direct & Pass-through (continued) CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued) PASS THROUGH AWARD FROM:				
PERIMETER MEDICAL IMAGING	DP190087	\$ 111,7	06 \$	-
RICE UNIVERSITY	RP210205	15,5	77	_
TEXAS A&M UNIVERSITY HEALTH SCIENCE CENTER				
	RP170719	272,6	93	-
	RP180131	27,0	37	_
	RP210043	142,8	10	-
	RR200043	224,2	98	_
		666,8	38	_
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER				
	PR190192	68,5	01	_
	RP180166	2,2	91	_
	RP180712	95,6		_
	RP190252		98	_
	RP200369	77,6	89	_
	RP200383	8,1	38	_
	RP220208	70,3	33	_
		322,7	36	_
THE METHODIST HOSPITAL RESEARCH INSTITUTE				
	RP180394	(1	09)	_
	RP210144	56,0	92	_
		55,9		_

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through (continued)			
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued)			
PASS THROUGH AWARD FROM:	55100050		^
THE UNIVERSITY OF TEXAS AT AUSTIN	RP180073	\$ (208)	\$ -
THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON			
	PP190023	50,025	_
	PP200057	16,016	_
		66,041	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON			
	PP180089	7,170	_
	PP200017	29,503	_
	RP190019	77	
	RP210111	31,221	
		67,971	-
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER			
	RP200554	159,248	_
TOTAL CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS		32,154,671	1,657,993
TEXAS COUNCIL ON ALZHEIMER'S DISEASE AND RELATED DISORDERS			
	TX COUNCIL ALZHEIMER/DISORDERS	113,226	_
TOTAL TEXAS COUNCIL ON ALZHEIMER'S DISEASE AND RELATED DISORDERS		113,226	_
TOBACCO SETTLEMENT FUNDS			
	BCM TOBACCO ENDOWMENT	1,575,079	_
	STATE MANAGED TOBACCO FUNDS	1,695,468	_
TOTAL TOBACCO SETTLEMENT FUNDS		3,270,547	-

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
JOINT ADMISSIONS MEDICAL PROGRAM (JAMP) COUNCIL			
	MEDICAL SCHOOL PROGRAM	112,408	_
	SPECIAL PROJECTS FOR PROGRAM INITIATIVES	8,785	_
	SUMMER PROGRAM	20,051	-
TOTAL JOINT ADMISSIONS MEDICAL PROGRAM COUNCIL		141,244	-
TEXAS HIGHER EDUCATION COORDINATING BOARD			
FAMILY PRACTICE RESIDENCY PROGRAM	THE CB AGREEMENT NUMBER 25618	33,466	_
AMILY PRACTICE RESIDENCY PROGRAM	THE CB AGREEMENT NUMBER 28454	95,161	_
		128,627	_
RADUATE MEDICAL EDUCATION – RESIDENT SUPPORT			
	THE CB # 23757	1,043	_
	THE CB # 25463	1,706,999	-
	THE CB # 27872	7,085,788	-
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 22798	(48,613)	_
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 22851	(33,446)	-
ME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 22794	(31,232)	-
ME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 22866	4,756	-
ME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 22876	14,889	-
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26195	224,382	-
ME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26196	921,455	_
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26197	439,643	-
ME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26326	228,521	-
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26436	1,212,968	-
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26437	1,187,428	-
		12,914,581	-

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
TEXAS HIGHER EDUCATION COORDINATING BOARD (continued) UNDERGRADUATE MEDICAL EDUCATION PROGRAM			
	THE CB AGREEMENT NUMBER 28021 MISSION SUPPORT	\$ 23,940,191 (692,932) 23,247,259	\$
EMERGENCY AND TRAUMA CARE EDUCATION EMERGENCY AND TRAUMA CARE EDUCATION	THE CB AGREEMENT NUMBER 27763 THE CB AGREEMENT NUMBER 23991	161,407 (1,408)	-
AUTISM GRANT PROGRAM — INNOVATIVE TREATMENT MODELS AUTISM GRANT PROGRAM — PARENT DIRECTED TREATMENT	THE CB AGREEMENT NUMBER 22971 THE CB AGREEMENT NUMBER 27505	305,671 132,626	
PASS THROUGH AWARD FROM: THE UNIVERSITY OF TEXAS SYSTEM – TEXAS CHILD MENTAL HEALTH CARE CONSORTIUM			
TEXAS CHILD MENTAL HEALTH CARE CONSORTIUM TEXAS CHILD MENTAL HEALTH CARE CONSORTIUM	THE CB 24218 THE CB 25767	1,055,841 3,920,632	1,972 79,032
TOTAL TEXAS HIGHER EDUCATION COORDINATING BOARD		5,574,769 41,865,236	81,004 81,004
PASS-THROUGH FROM DEPARTMENT OF FAMILY & PROTECTIVE SERVICES THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER			
SAFE BABIES PROJECT RESEARCH AND EVALUATION SERVICES TOTAL TEXAS DEPARTMENT OF FAMILY & PROTECTIVE SERVICES	HHS000820100001 HHS000705200001	463,171 41,575 504,746	13,278

Program Description	Pass-Through Entity/Other Identifying Number	E	Total xpenditures	Amounts Provided to Subrecipients
TEXAS DEPARTMENT OF STATE HEALTH SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES	537-18-0098-00001	\$	824 \$	-
PASS-THROUGH FROM TEXAS DEPARTMENT OF STATE HEALTH SERVICES HARRIS HEALTH				
HIV/STD Program	HIV PERI-NATAL TRANSMISSION PREVENTION FY22		45,765	_
HIV/STD Program	HIV PERI-NATAL TRANSMISSION PREVENTION FY23		177,683	_
			223,448	-
THE UNIVERSITY OF TEXAS AT AUSTIN				
LONE STAR STROKE CLINICAL TRIAL NETWORK	LONE STAR STROKE CLINICAL TRIAL NETWORK		379,453	-
HHS001011000001 DSHS GENETIC SEMINARS	HHS001011000001 DSHS GENETIC SEMINARS		117,692 497,145	
UT HEALTH SCIENCE CENTER AT HOUSTON ZIKA VIRUS	HHS000427700001		83,598	-
UT HEALTH SCIENCE CENTER AT TYLER				
TEXAS COLLABORATIVE FOR HEALTHY MOTHERS AND BABIES	HHS00139600001		194,582	_
TOTAL TEXAS DEPARTMENT OF STATE HEALTH SERVICES			999,597	-
TEXAS HEALTH AND HUMAN SERVICES COMMISSION				
HEALTHY TEXAS WOMEN'S GRANT PROGRAM	529-16-0132-00020			
FAMILY PLANNING GRANT PROGRAM	HHS000073460036 / HHS000734600018	\$	3,272,082 \$	
FAMILY PLANNING GRANT PROGRAM	529-16-0102-00011		1,655	_
HOUSE BILL 1802 GRANT PROGRAM TOTAL TEXAS HEALTH AND HUMAN SERVICES COMMISSION	HHS001195400001		17,002 3,290,739	
TOTAL TEARS HEALTH AND HUMAN SERVICES COMMISSION			5,470,159	_
TOTAL EXPENDITURES OF STATE AWARDS		\$	82,340,006	5 1,752,275

Notes to Schedule of Expenditures of Federal and State Awards

Year Ended June 30, 2023

1. Basis of Presentation

The accompanying schedule of expenditures of federal awards and the schedule of expenditures of state awards (the Schedules) present a summary of the financial activities of Baylor College of Medicine (the College) for the year ended June 30, 2023, which have been funded by the federal and state governments. The information in the Schedules is presented in accordance with the requirements of the Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and the *State of Texas Single Audit Circular*. Because the Schedules present only federal and state expenditure activities of the College, they are not intended to and do not present the financial position, changes in net assets, or cash flows of the College as a whole.

2. Summary of Significant Accounting Policies

The Schedules have been prepared on a modified accrual basis of accounting and include all expenditures of federal and state awards, direct and pass-through, received by the College from federal and state grantor agencies. Direct costs are charged to sponsored agreements on a cash basis except for salaries and fringe benefits that are charged on an accrual basis. Indirect costs are expensed against sponsored agreements at the close of the month in which the direct costs are charged and, therefore, are a combination of modified accrual and cash basis accounting. Federal and state awards are deemed to be expended when the College incurs the expenses. Such expenditures are recognized following the cost principles contained in Uniform Guidance or the *Texas Grant Management Standards* (TxGMS), as applicable, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Federal and state direct programs and pass-through programs are presented by federal or state department and, where applicable, the funding agency within the department and the pass-through entity.

The College did not elect to use 10% de minimis indirect costs rate as allowed under the Uniform Guidance.

Notes to Schedule of Expenditures of Federal and State Awards (continued)

3. Administered Federal Loan Programs

Outstanding loans under administered federal loan programs as of June 30, 2023, were as follows:

	Assistance Listing Number	I	tstanding Balance le 30, 2023
Federal Perkins Loan Program Health Professions Student Loans, Including Primary	84.038	\$	630,976
Care Loans, Loans for Disadvantaged Students (Health Professions Student Loans)	93.342		183,497

4. Federal Direct Student Loans Program

The College participated in the Federal Direct Student Loans Program (CFDA 84.268), including Unsubsidized Stafford Loans and PLUS Loans. The College was not the recipient of the funds. The programs are considered as a component of the student financial assistance cluster. Loan disbursements under the programs for the year ended June 30, 2023, totaled \$22,564,693.

5. Provider Relief Fund

The amount presented on the SEFA for Assistance Listing Number 93.498, COVID-19 – Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution (PRF Funds), is for the year ended June 30, 2023.

Health and Human Services (HHS) has indicated the PRF funds on the SEFA be reported corresponding to reporting requirements of the HRSA PRF Reporting Portal. Payments from HHS for PRF are assigned to "Payment Received Periods" (each, a Period) based upon the date each payment from the PRF was received. Each period has a specified period of availability and timing of reporting requirements. Entities report into the HRSA PRF Reporting Portal after each period's deadline to use the funds (i.e., after the end of the Period of Availability).

The SEFA includes \$6,636,839 of PRF Funds received from HHS between July 1, 2021 through June 30, 2022. Such amounts were recognized as other revenue in the College's consolidated financial statements in the years ended June 30, 2023 and 2022.

Schedule of Findings and Questioned Costs

Year Ended June 30, 2023

Section I – Summary of Auditor's Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:	Unmodified
Internal control over financial reporting:	
Material weakness(es) identified?	Yes XNo
Significant deficiency(ies) identified?	Yes <u>X</u> None reported
Noncompliance material to financial statements noted?	Yes XNo
Federal Awards	
Internal control over major federal programs:	
Material weakness(es) identified?	Yes <u>X</u> No
Significant deficiency(ies) identified?	Yes <u>X</u> None reported
Type of auditor's report issued on compliance for major federal programs:	Unmodified
Any audit findings disclosed that are required to be reported in accordance with Section 2 CFR 200.516(a)?	Yes <u>X</u> No

Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditor's Results (continued)

State Awards

Internal control over major federal programs:	
Material weakness(es) identified?	Yes <u>X</u> No
Significant deficiency(ies) identified?	Yes X None reported
Type of auditor's report issued on compliance for major state programs:	Unmodified
Any audit findings disclosed that are required to be reported in accordance with <i>State of Texas Single</i> <i>Audit Circular</i>	Yes XNo
	Name of Federal/State
Assistance Listing Number(s)	Program or Cluster
	Program or Cluster
Assistance Listing Number(s) Identification of major federal programs: Various AL Numbers	
Identification of major federal programs:	Program or Cluster Research and Development Cluster COVID-19 Provider Relief Fund and
Identification of major federal programs: Various AL Numbers	Research and Development Cluster
Identification of major federal programs: Various AL Numbers	Research and Development Cluster COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution COVID-19 Coronavirus State and
Identification of major federal programs: Various AL Numbers 93.498	Research and Development Cluster COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution
Identification of major federal programs: Various AL Numbers 93.498 21.027	Research and Development Cluster COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution COVID-19 Coronavirus State and
Identification of major federal programs: Various AL Numbers 93.498	Research and Development Cluster COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution COVID-19 Coronavirus State and
Identification of major federal programs: Various AL Numbers 93.498 21.027 Identification of major state programs:	Research and Development Cluster COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution COVID-19 Coronavirus State and Local Fiscal Recovery Funds

Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditor's Results (continued)

Dollar threshold used to distinguish between Type A and Type B federal programs	\$3,000,000
Dollar threshold used to distinguish between Type A and Type B state programs	\$2,470,200
Auditee qualified as low-risk auditee?	X Yes No
Section II – Financial Statement Findings	
No findings were noted.	
Section III – Federal Award Findings and Questioned Costs	

No findings were noted.

Section III – State Award Findings and Questioned Costs

No findings were noted.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2024 Ernst & Young LLP. All Rights Reserved.

ey.com